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Summary 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are severe 
neurodegenerative diseases with overlapping clinical and pathological features. 
Recently, a GGGGCC hexanucleotide repeat expansion in the non-coding region of 
the C9orf72  gene was discovered to be the most frequent pathogenic mutation in 
both diseases. Although lacking an ATG start codon, the repeat is translated into 
poly-GA, poly-GR and poly-GP dipeptide repeat (DPR) proteins. These DPR 
proteins form insoluble p62-positive inclusions distinct from the co-occuring TDP-
43 positive inclusions that are also found in most other forms of ALS and FTD. It is 
unclear how DPR proteins are translated although the mutant allele is poorly 
expressed and, even more important,  how they contribute to FTD/ALS.  
My data shows that although the levels of the mature C9orf72  mRNA are reduced in 
mutation carriers, the repeat containing transcripts are stabilized. Additionally, I 
discovered the antisense transcription of the repeat expansion and following it could 
be shown that the antisense RNA is translated into poly-PA, poly-PR and additional 
poly-GP DPR proteins. 
To analyze the role of sense and antisense DPR proteins individually, I designed 
synthetic genes to express the DPR sequence with an ATG start codon but without  
GGGGCC repeats. Only poly-GA formed insoluble p62-positive aggregates similar 
to the neuropathological findings in patients . Additionally, aggregates in poly-GA 
transduced primary neurons had the same size and intensity as aggregates found in 
patients. Of the five DPR proteins, only poly-GA and poly-PR induced cell death in 
primary neurons. To elucidate the underlying toxicity mechanisms I used  a mass 
spectrometry approach to identify poly-GA co-aggregating proteins. Although the 
poly-GA interactome showed a significant enrichment of proteins of the ubiquitin-
proteasome system, I could not detect altered proteasome activity. Among the other 
interactors, Unc119, a factor controlling trafficking of l ipidated cargo proteins, has 
been previously linked to neuromuscular function and axon maintenance in C. 
elegans.  
Summary 
 
 
8 
 
Unc119 co-aggregates with poly-GA and the levels of soluble Unc119 were strongly 
reduced in neurons overexpressing poly-GA, indicating a loss of function. In 
patients, Unc119 is also partially sequestered into  poly-GA aggregates. Unc119 
knockdown in primary neurons inhibited dendritic branching and caused 
neurotoxicity similar to poly-GA overexpression. Importantly, Unc119 
overexpression partially rescued poly-GA toxicity. Together, these findings support 
the hypothesis that Unc119 loss of function contributes to poly-GA toxicity. Apart 
from DPR inclusions, patients with C9orf72 mutation show abundant aggregates of 
phosphorylated TDP-43, but TDP-43 and DPR inclusions rarely occur within the 
same cells. TDP-43 aggregation correlates with neurodegeneration, but it is unclear, 
how the C9orf72 repeat expansion triggers TDP-43 pathology. In the neuronal 
expression model, poly-GA induced partial mislocalization of TDP-43 into small 
cytoplasmic aggregates, thus directly links both pathologies for the first time. 
Taken together, I have established the first DPR protein cell culture system 
that replicates important features of C9orf72 pathology and enables the 
prediction of novel pathological findings in patients such as Unc119 co -
aggregation. The toxicity of poly-GA and poly-PR in primary neurons suggests 
that these proteins contribute to the pathogenesis of C9orf72 ALS/FTD. 
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Zusammenfassung 
Amyotrophe Lateralsklerose (ALS) und Frontotemporale Demenz (FTD) sind zwei 
schwerwiegende neurodegenerative Erkrankungen, welche überlappende klinische 
und pathologische Eigenschaften zeigen. Kürzlich  wurde eine GGGGCC 
Hexanukleotid-Wiederholung außerhalb der kodierenden Sequenz des C9orf72  Gens 
gefunden. Obwohl diese Wiederholungssequenz kein ATG Startcodon aufweist, 
wird sie in poly-GA, poly-GR und poly-GP Dipeptid Repeat (DPR) Proteine 
translatiert. Diese DPR Proteine bilden unlösliche p62 -positive Einschlüsse, welche 
sich klar von den ebenso auftretenden TDP-43-positiven Einschlüssen in Patienten 
unterscheiden. Es ist allerdings unklar, warum DPR Proteine translatiert werden, 
obwohl das mutierte Allel schwach expremiert ist und wie sie zu FTD/ALS 
beitragen. 
Die Daten meiner Arbeit zeigen, dass die Repeat-enthaltenden Transkripte 
stabilisiert sind, obwohl die gesplicte C9orf72 mRNA in Mutationträgern reduziert 
ist. Des Weiteren konnte ich zeigen, dass die Antisense-Transkription der 
verlängerten Repeat-Region stattfindet und dies führte später zu der Entdeckung der 
Antisense Proteine poly-PA, poly-PR und poly-GP. Um den genauen Einfluss der 
Sense und Antisense DPR Proteine zu untersuchen habe ich synthetische Gene 
konzipiert, welche die DPR Sequenz mit einem ATG Startcodon , aber ohne die 
originale Repeatsequenz GGGGCC expremieren. Nur poly-GA zeigte die typischen 
unlöslichen p62-positiven Aggregate. Außerdem zeigen Aggregate in poly-GA 
transduzierten primären Neuronen die gleiche Größe und Intensität wie Aggregate 
in Patienten. Von den fünf DPR Proteinen induzierten nur poly-GA und poly-PR 
Apoptose in primären Neuronen. Mit Hilfe eines massenspektrometrischen Ansatzes 
wurden poly-GA co-aggregierende Proteine identifiziert. Unter den angereicherten 
Proteinen fanden sich besonders  Proteine des Ubiquitin-Proteasom Systems und 
zusätzlich der Trafficking Faktor Unc119. Unc119 wurde bereits mit 
neuromuskulären Funktionen und der Instandhaltung von Axonen in Zusammenhang 
gebracht. Unc119 co-aggregiert mit poly-GA und die löslichen Level von Unc119 
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waren in meinem System stark reduziert und wiesen auf einen Verlust der Funktion 
hin. In Patienten, findet sich Unc119 ebenfalls in poly-GA Aggregaten, was zu 
einem Verlust des cytosolischen Unc119 führte. Unc119 Knockdown inhibiert die 
normale Verzweigung von Dendriten und verursacht Neurotoxizität, vergleichbar 
mit der Überexpression von poly-GA. Außerdem schwächt Unc119 Überexpression  
die poly-GA Toxizität deutlich ab. Zusammen unterstützen die Ergebnisse die 
Annahme, dass poly-GA die normale Unc119 Funktion stört. 
Neben den DPR Protein Einschlüssen, finden sich weitere krankheitsrelevante 
Einschlüsse aus phosporyliertem TDP-43, die mit Neurodegeneration korrelieren. 
Weil TDP-43 und DPR Einschlüsse selten in der gleichen Zelle auf treten, ist unklar 
wie TDP-43 Veränderungen durch die C9orf72 Mutation ausgelöst werden. In dem 
neuronalen Expressionssystem induziert poly-GA eine partielle Mislokalisation von 
TDP-43 in kleine cytoplasmatische Aggregate und verknüpft somit zum ersten Mal 
beide Arten von Pathologie. 
Zusammengefasst, habe ich in dieser Arbeit das erste DPR Protein 
Zellkulturmodel etabliert, das viele wichtige Merkmale der Patienten 
reproduziert und erfolgreich Befunde in Patienten voraussagt, wie die Ko-
Aggregation von poly-GA mit Unc119. Die Translation des C9orf72-Repeats in 
aggregierende DPR Proteine trägt höchstwahrscheinlich zur Pathogenese  von 
ALS/FTD bei, da poly-GA und poly-PR das Absterben von Nervenzellen 
verursachen. 
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1. Introduction 
1.1. Frontotemporal dementia/Amyotrophic lateral sclerosis 
Frontotemporal dementia (FTD) and amyotrophic lateral s clerosis (ALS) are two 
severe neurodegenerative diseases with no effective treatment so far. FTD is the 
second most common form of presenile dementia with a prevalence of 5 -15 % of all 
dementia (Rademakers et al., 2012). First reports of FTD-like cases were described 
in 1892 by the neuropsychiatrist Arnold Pick  (Pick, 1892). Especially during the 
last 20 years, a broader knowledge on genetic and molecular basics of the disease 
was gained and the link to another neurodegenerative disease, ALS, was described.  
ALS also termed Charcot’s disease or Lou Gehrig’s disease is the most frequent 
motor neuron disorder (MND) with a worldwide prevalence of 1-2 people affected 
per 100,000 (Bennion Callister and Pickering-Brown, 2014; Ferrari et al., 2011; 
Rademakers et al., 2012). It is characterized by a severe loss of motor neurons that 
leads to death due to respiratory paralysis within 1 -5 years after the onset of 
symptoms. As ALS and FTD share common genetic and pathological features they 
are classified as a spectrum of disease with ALS or FTD as the extreme ends of the 
spectrum (Bennion Callister and Pickering-Brown, 2014; Ferrari et al., 2011; Ng et 
al., 2015). 
1.1.1. Clinical features 
1.1.1.1. Frontotemporal Dementia (FTD) 
FTD is comprised of three different syndromes, behavioral variant frontotemporal 
dementia (bvFTD), semantic dementia (SD) and progressive non fluent aphasia 
(PNFA). It has an average age of onset of mid to late 50s and can be further 
distinguished in familial and sporadic cases that occur equally common in men and 
women. Interestingly, 40 % of all FTD cases are familial with a clear genetic 
background (Snowden et al., 2002).  
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The three clinical syndromes are usually overlapping but a clear dominant feature 
of one of the three is often present. All three are characterized by the loss of 
neurons in the frontotemporal lobe (Josephs et al., 2011). In contrast to Alzheimer’s 
disease (AD), memory and visuospatial abilities remain intact initially.   
Behavioral variant FTD (bvFTD) is the most frequent of the three subtypes 
(Bennion Callister and Pickering-Brown, 2014). It is mainly characterized by 
changes in personality, deterioration of behavior and social conduct that can show 
through disinhibition, binge eating, emotional blunting or loss of insight (Bennion 
Callister and Pickering-Brown, 2014; Ferrari et al., 2011; Ng et al., 2015) .  
In contrast, patients with semantic dementia have severe naming and word 
comprehension impairments while speech output in general is still fluent. 
Additionally, they often show loss of facial recognition (prosopagnosia). Dependent 
on the temporal lobe affected first, semantic dementia can be classified in right or 
left SD variant. Moreover, behavioral changes can be observed in these patients, 
however, they manifest differently than the classical bvFTD (Rosen et al., 2006). 
 
Figure 1: Typical hallmark of an FTD patient.  
18
FDG PET scans showing the brain activity of a control brain, an Alzheimer disease patient (AD) and a patient with 
frontotemporal dementia (FTD). Highly active areas are depicted in red, whereas areas of low activity are depicted 
in blue. In contrast to a healthy person and an AD patient, patients with FTD show remarkably reduced activity in 
the frontal temporal lobes of the brain. Figure adapted from Dementia Today (Project, 2006). 
Patients suffering from progressive non fluent aphasia show  non fluent speech 
production, phonologic and grammatical errors and most pronounced , word retrieval 
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difficulties as well as problems in reading and writing. Behavioral changes, 
however, are less common in this subtype (Rosen et al., 2006). 
The clinical diagnosis of the three different subtypes is obtained based on the 
observed clinical features and neuroimaging techniques. In magnetic resonance 
imaging (MRI) and computer tomography (CT) the atrophy of the frontal lobes can 
be detected. Additionally, positron emission tomography can be used to visualize 
glucose metabolism a direct measure for brain activity (Figure 1). Furthermore, it is 
important to exclude other types of dementia such as Alzheimer’s disease or 
psychiatric conditions resulting in similar abnormal behavior. However, a definite 
diagnosis can only be achieved post mortem through neuropathological findings or 
mutation analysis.  
Up until now there is no cure for FTD and treatment strategies are only 
symptomatic. Apart from serotonin reuptake inhibitors (SSRI) to reduce behavioral 
symptoms, memantine, an NMDA receptor antagonist, cholinesterase inhibitors or 
antidepressants are used. However, all of these drugs were originally developed for 
the application in other diseases such as AD and there is only minimal evidence for 
a beneficial effect in FTD.  
1.1.1.2. Amyotrophic lateral sclerosis (ALS) 
Amyotrophic lateral sclerosis is a disease of the upper and lower motor neurons and 
the corticospinal tract (Kiernan et al., 2011). So far it is not known why specifically 
these types of neurons are affected and whether upper or lower motor neurons are 
impaired first. While the upper motor neuron degeneration causes symptoms of 
hyperreflexia and spasticity, progressive muscle weakness and muscle wasting are a 
result of degeneration of the lower motor neurons (Van Damme and Robberecht, 
2009). Consequently, patients suffer from progressive paralysis and respirator y 
failure may occur 1-5 years after disease onset. ALS is the most frequent form of 
motor neuron disease. It was first described by Jean-Martin Charcot in 1869 (Ferrari 
et al., 2011; Kiernan et al., 2011). 
The average onset of ALS is 55 years of age but it can also occur quite early in life. 
Only 10 % of the cases are familial, whereas the rest is classified as sporadic with 
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unknown genetic predisposition (Ferrari et al., 2011; Ng et al., 2015) . However, not 
all familial cases might be classified as such, due to missing familial medical 
history or the occurrence of recessive inherited  
 
Figure 2: Characteristic features of ALS. 
ALS is a disease of the upper and lower motor neurons and typically manifests in the disproportionate wasting of 
muscles. (A) The 'split hand', is a typical symptom of ALS patients in which disproportionate wasting of the 
abductor pollicis brevis and the first dorsal interossei muscle of the hand is present. This type of wasting is 
consistent with a cortical, motor neuronal origin seen in ALS. (B) The image depicts a limb-onset ALS. The patient 
shows prominent bilateral wasting of the shoulder girdles, pectoral muscles and the proximal upper arms. Figure 
adapted from (Kiernan et al., 2011). 
mutations. Familial cases tend to show an earlier age of onset but are otherwise not 
distinguishable through symptoms or disease progression.  
The final diagnosis of ALS is achieved through a combination of physical 
examination and neurological tests such as electromyography (EMG) or nerve 
conduction velocity. Typical phenotypes are the split hand, a clear sign for 
disproportionate wasting of muscles consistent with a cortical, motor neuron origin 
of ALS (Figure 2A), or prominent bilateral wasting of shoulder and upper arm 
muscles (Figure 2B) (Kiernan et al., 2011). For a clear diagnosis of ALS, other 
muscle affecting diseases showing similar phenotypes for instance spinal muscular 
atrophy (SMA) or multiple sclerosis (MS) have to be excluded through differential 
diagnosis. 
Unfortunately, there is no effective treatment for ALS so far. The only Food and 
Drug Administration (FDA) approved drug is r iluzole that is thought to protect  
neurons from glutamate mediated excitotox icity (Miller et al., 2007). However, 
survival of patients can be only prolonged by few months. Otherwise only 
symptomatic treatment options are available to alleviate pain, cramps or dep ression 
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symptoms. Thus, there is a pressing need to develop new affective treatment 
alternatives and biomarker tools to increase survival and life quality for these 
patients. 
1.1.1.3. FTD/ALS 
As mentioned earlier, symptoms of ALS and FTD can be present in the same patient 
with one of the disease being diagnosed first and following, the patient develops 
additional symptoms of the other disease. Those types are classified as FTD with 
motor neuron disease (FTD-MND) if FTD is the disease diagnosed first or ALS with 
cognitive impairment (ALSci) if ALS symptoms are predominant. Typically , the 
mixed disease is more severe and has a considerable poorer prognosis (Ng et al., 
2015). Motor neuron disease is often associated with the behavioral variant FTD, 
but rarely with semantic dementia or progressive non fluent aphasia (Josephs et al., 
2005; Josephs, 2008). Approximately 15 % of FTD patients also develop motor 
neuron symptoms (Lomen-Hoerth et al., 2002). Moreover, the frequency of FTD 
symptoms in ALS patients is 5-50 % depending on the literature source (Lomen-
Hoerth et al., 2002; Strong, 2008) . 
Additional evidence for a connection is found in families where both diseases occur 
within the same family (Ferrari et al., 2011; Josephs, 2008). The strongest evidence, 
however, comes from a mutation in the C9orf72 gene that can cause both diseases 
depending on the circumstances.  
1.1.2. Neuropathology 
Beside clinical evidence for the connection between FTD and ALS, the pathology 
seen in the patients clearly shows that there is a li nk between the two diseases on a 
molecular level (Figure 3). Specifically, there are distinct neuronal protein 
inclusions that are associated with both diseases such as the Tar DNA binding 
protein (TDP-43) or the Fused in Sarcoma (FUS) protein inclusions (Chen-Plotkin 
et al., 2010; Ng et al., 2015). Additionally, there is evidence that both diseases 
share some affected brain regions (Ferrari et al., 2011). 
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Figure 3: Pathological classification of FTD and ALS. 
FTD (orange) and ALS (green) can be classified based on the protein inclusions found in the patients. 97 % of all 
ALS cases and nearly 50 % of all FTD cases show TDP-43 positive cytoplasmic and nuclear inclusion (FTLD-
TDP/ALS-TDP). Adapted from (Chen-Plotkin et al., 2010). 
1.1.2.1. Frontotemporal Lobar Degeneration (FTLD) 
Frontotemporal lobar degeneration (FTLD) is the underlying pathology occurring in 
patients with FTD and is describing the typical atrophy of the frontal and temporal 
lobes. Shrinkage and spongiform morphology of the affected brain regions are a 
result of the massive neuronal loss being present through the progression of disease.  
Pathologically, FTLD can be divided into two major subtypes based on the 
aggregating proteins found in patients. First, cases with inclusions of t he 
hyperphosphorylated protein Tau (FTLD-TAU) and second, cases showing 
ubiquitin-positive but tau negative inclusions (FTLD-U) (Mackenzie et al., 2010). 
Currently 1/3 of all FTD cases are FTLD-Tau associated, whereas 2/3 are FTLD-U 
cases.  
The FTLD-U cases can be further subdivided into 3 major categories FTLD-TDP, 
FTLD-FUS and FTLD-UPS (Figure 3) (Mackenzie et al., 2011; Mackenzie et al., 
2010). 
In 2006, TDP-43 was discovered as the main inclusion protein in both FTD and 
ALS in sporadic and familial cases. FTLD-TDP is the most common pathological 
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subtype. TDP-43 pathology is present in 90 % of all FTLD-U cases. Based on the 
inclusion types found in patients, TDP pathology can be divided into 4 major 
subtypes FTLD-TDP type A-D (Mackenzie et al., 2011). 
The second FTLD-U subtype, FTLD-FUS, is characterized by cytosolic inclusions 
of the normally nuclear protein Fus. Cases are characterized by  a young age of 
onset, and mostly present with bvFTD (Seelaar et al., 2010). Furthermore, a 
negative family history often exists and caudate atrophy is detected in MRI 
(Josephs, 2010). 
FTLD-UPS is the rarest of the three subtypes,  showing only ubiquitin and p62-
positive but TDP-43 and Tau negative inclusions. They are also classified as 
dementia lacking distinctive histopathology (DLDH) and many are associated with 
multivesicular body protein 2b (Chmb2b) mutations (Holm et al., 2009). 
1.1.2.2. Motor Neuron Disease (MND) 
In contrast to the frontotemporal degeneration of FTD, typical neuropathological 
hallmarks of ALS include the loss of anterior horn cells, degeneration of the brain 
stem motor nuclei as well as of the descending corticospinal tract (Strong et al., 
2009). Additionally, Bunina body like intracellular inclusions, hyaline 
conglomerates and ubiquitin positive intracellular inclusions are found (van Welsem 
et al., 2002). 97 % of all familial and sporadic ALS cases show TDP -43 pathology 
(ALS-TDP) and the regional spreading from spinal and  cortical motor neurons and 
glia to other cortical regions is used to stage ALS progression (Mackenzie et al., 
2007; Maekawa et al., 2009). Cases without TDP-43 pathology mostly show 
inclusions of misfolded SOD1 protein (ALS-SOD1) always related to a mutation in 
SOD1 (Maekawa et al., 2009). Additionally, very rare cases negative for TDP-43 
show inclusions of the Fus protein (ALS-FUS) (Vance et al., 2009). 
1.1.2.3. FTLD/MND 
Beside several clear FTD or ALS pathological characteristics, there are also 
pathological features that are associated with mixed forms of the two diseases. 
These cases are often accompanied by spongiform degeneration in frontal and 
Introduction 
 
 
28 
 
precentral gyrus (cortical layers II and III) and subcortical gliosis (Strong et al., 
2009; Yoshida, 2004). Neuronal loss is most pronounced in the anterior cingul ate 
gyrus, substantia nigra and amygdala (Strong et al., 2009). They are either 
classified as ALSci or, if the frontal cortex is majorly involved, as FTD-MND. 
Apart from typical TDP-43 positive inclusions, many cases with mixed clinical and 
pathological features show additional NCI and dystrophic neurites that are 
ubiquitin/p62-positive but TDP-43 negative (Ng et al., 2015). 
1.1.3. Genetics 
As the pathology, genetics of the disease spectrum FTD-ALS are highly complex. 
Whereas some mutations can be clearly associated with one disease and therefore 
can be found at the extreme ends of the FTD-ALS continuum, others can be the 
cause of either diseases, or even mixed forms. 
 
Figure 4: Summary of the main genes linked to ALS and FTD and their frequency. 
FTD (orange) and ALS (green) are depicted as extreme ends of a disease spectrum. Genes linked specific to FTD 
are illustrated in orange on the left with their frequency in familial cases. ALS related genes are shown in green on 
the right. Genes associated with both diseases can be found in the middle with mixed coloring and arranged based 
on their frequency. C9orf72 is the most common known cause for both FTD and ALS. Adapted from (Guerreiro et 
al., 2015) 
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Figure 4 illustrates the main known genes that are currently associated with the 
clinical FTD-ALS spectrum. 
1.1.3.1. C9orf72 
The newest addition to genes associated with both FTD and ALS came in 2006. Two 
groups independently reported a locus on chromosome 9 in the 9p21.2 -p13.3 region 
to be associated with a substantial amount of autosomal dominant FTD -ALS cases 
(Morita et al., 2006; Vance et al., 2006) . The following paragraph will discuss 
C9orf72 and its role in FTD/ALS in more detail.  
Identification as most common pathogenic mutation 
In 2011, 11 years after the initial discovery (Hosler et al., 2000), two research 
groups independently discovered C9orf72 on the locus of chromosome 9 to be the 
most common genetic cause of frontotemporal dementia and amyotrophic lateral 
sclerosis (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . The mutation was 
mapped to an intronic region of the gene and was identified to be a hexanucleotide 
repeat expansion (GGGGCC). Patients with the mutation have up to several 
thousand repetitions of the repeat sequence , whereas healthy controls show less 
than 30. However, the repeat length can vary among different tissues due to somatic 
mutations as a patient that showed only 90 repeats in blood cells had a much higher 
repeat length in the brain (Fratta et al., 2015). So far, it is also unknown which 
minimum repeat length is sufficient to cause disease.  
The frequency of the mutation in FTD is about 25 % in familial FTD and 6 % in 
sporadic cases, whereas C9orf72  mutation accounts for roughly 40 % of familial 
ALS (Majounie et al., 2012; Renton et al., 2011) . Although C9orf72  is the most 
frequent genetic cause for both ALS and FTD, there are particular geographical 
regions that have a high mutation frequency such as Finland. Furthermore, it has 
been debated whether all C9orf72  patients stem from one single founder 
disseminated in Northern Europe. However, since C9orf72 mutations are also rarely 
found in Asian and African populations, a second theory of a predisposing 
haplotype is more likely (van der Zee et al., 2013). Descriptions concerning repeat 
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expansions increasing from 100 to over 1000 within one generation and somatically 
in the CNS support this hypothesis  (Dols-Icardo et al., 2014). 
Function 
So far not much is known about the C9orf72 protein. There are 3 transcripts 
variants and two potential protein isoforms. Depending on the transcript, the 
hexanucleotide repeat expansion can be either found in the promo tor region or the 
first intron (DeJesus-Hernandez et al. , 2011; Renton et al., 2011). 
 
Figure 5: C9orf72 gene structure and transcription variants. 
Schematic overview of the C9orf72 gene and its three transcription variants. Variants two and three may lead to 
transcription of the hexanucleotide repeat expansion. The expansion is depicted as orange rhombus, whereas exons 
are shown as white boxes and untranslated regions as green boxes. The figure was adapted from (DeJesus-
Hernandez et al., 2011). 
The C9orf72 protein, also called DENNL72 is predominantly expressed in neuronal 
cell populations that are vulnerable to ALS and FTD such as hippocampus, dentate 
gyrus, striatum, thalamus, brain stem nucleus, cerebellum, the cortex and the spinal 
cord (Suzuki et al., 2013). Structurally, it has been found to be similar to 
Differentially Expressed in Normal and Neoplasia (DENN) family of guanidine 
nucleotide exchange factors that activate Rab-GTPases. These proteins are 
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important regulators of membrane traffic (Levine et al., 2013; Zhang et al., 2012) . 
In accordance to that, the yeast orthologous gene of C9orf72, Lst4p, has been found 
to prevent lysosomal delivery of cargo by redirecting endosome localized proteins 
to the cell surface (Rubio-Texeira and Kaiser, 2006). Therefore, loss of function 
might hamper with lysosomal degradation of particular cargos. However, this still 
needs to be proven experimentally in mammalian cells. 
Clinical phenotypes and pathology 
The mutation in C9orf72 is most commonly associated with bvFTD, ALS or a 
combination of both. These cases have a high frequency of psychosis especially 
hallucinations and delusions, which often leads to a wrong diagnosis of 
schizophrenia or bipolar disorder at the beginning (Galimberti et al., 2014; Meisler 
et al., 2013). Patients also often present with an impaired episodic memory which 
may correlate with brain atrophy of the post cingulate gyrus and the parietal lobes 
seen in those patients. In comparison to other mutations, progressive non fluent 
aphasia and semantic dementia are quite rare in C9orf72 mutation carriers and half 
of ALS patients with C9orf72 mutation also show cognitive and behavioral 
impairment, which is much more frequent than in other mutations (Millecamps et 
al., 2012; Montuschi et al., 2015). Additionally, Parkinsonism can sometimes be 
seen in patients with C9orf72  mutation that initially showed FTD symptoms (Lesage 
et al., 2013; O'Dowd et al., 2012). Also noticeable is that, compared to other FTD 
cases, C9orf72 patients show increased subcortical involvement, especially thalamic 
and cerebellar involvement (Mahoney et al., 2012a). The age of onset and disease 
duration, however, are highly variable, even in one family, and can vary from 27 to 
83 years and a duration ranging from 3 to 264 month (Majounie et al., 2012; 
Sabatelli et al., 2012; Stewart et al., 2012) . Current studies suggest that ALS 
patients with C9orf72  mutation have a shorter survival than sporadic ALS (Byrne et 
al., 2012; Cooper-Knock et al., 2012; García‐Redondo et al., 2013). 
Neuropathological analysis shows p-TDP-43-positive inclusions in almost all 
C9orf72 patients. Atrophy of the frontal and temporal cortex, hippocampus, 
pyramidal motor system, amygdala, striatum, thalamus and midbrain is 
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symmetrically (Mackenzie et al., 2013). However, C9orf72 patients tend to show 
less frontotemporal atrophy but rather increased parieto -occipital, thalamic and 
cerebellar atrophy compared to other genes (Mahoney et al., 2012a). Overall, the 
region specific neurodegeneration correlates with p-TDP-43 inclusion incidence and 
of the four TDP-43 pathological subtypes C9orf72 is associated with type A and B. 
In type A specifically compact or granular neuronal cytoplasmic inc lusions (NCI), 
dystrophic neurites and occasional neuronal intranuclear inclusions (NII) are found 
in layer 2 of the cortex and cortical white matter. In contrast, type B is classified 
through granular NCIs in all cortical layers with only a few dystrophic  neurites or 
NIIs. However, there are also cases reported without any TDP -43 pathology 
(Mackenzie et al., 2013; Mackenzie et al ., 2011).  
In addition to TDP-43, p62-positive characteristically star-shaped neuronal 
inclusions are reported, that are most dominant in hippocampus, cerebellu m and 
neocortical regions. These inclusions were reported to be the most defining 
characteristic of C9orf72 patients (Al-Sarraj et al., 2011). In 2013, the predominant 
proteins in these inclusions could be identified as dipeptide repeat proteins 
resulting from the unconventional translation of the hexanucleotide repeat 
expansion in the C9orf72 gene (Ash et al., 2013; Mori et al., 2013c) .  
Disease mechanisms 
Since the discovery of the C9orf72 mutation, there is a huge discussion in the field 
whether it results in a loss of function or a gain of toxic function. Three potential 
disease mechanisms are discussed. First, repeat expansion might lead to reduction 
in C9orf72 transcription and translation, therefore causing a loss of function of the 
C9orf72 protein. Several groups could find evidence that transcript variant 1  (see 
Figure 5) is decreased in blood, cortex, cerebellum and spinal cord of mutation 
carriers compared to controls (Belzil et al., 2013a; Donnelly et al., 2013; Mori et 
al., 2013c; Renton et al., 2011). There is also evidence of hypermethylation of a 
CpG island upstream of the repeat potentially responsible for the downregulation  of 
the gene (Belzil et al., 2014; Liu et al., 2014; Xi et al., 2013) . Furthermore, 
knockdown of C9orf72 in neuronal cell lines showed defects in endocytosis and 
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autophagy and knockdown or knockout in C. elegans and zebrafish lead to motor 
dysfunction and axonopathy (Ciura et al., 2013; Farg et al., 2014; Therrien et al.,  
2013). However, no phenotype could be found in knockout mouse models 
questioning the importance of the C9orf72 protein and its relevance in disease.  
 
 
Figure 6: Possible disease mechanisms of C9orf72 hexanucleotide repeat expansion mutation. 
Three potential disease mechanisms are discussed. (1) The expansion might lead to a reduction in C9orf72 
expression and, thus, to a loss of C9orf72 protein function. (2) The repeat RNA may cause toxicity through 
sequestering important RNA-binding proteins, resulting in a toxic gain of function or (3) the repeat is 
unconventionally translated into five potential dipeptide repeat proteins, poly-GA, poly-GR, poly-GP, poly-PA and 
poly-PR leading to a toxic protein gain of function. Adapted from (Rohrer et al., 2015a). 
As a second hypothesis, the repeat RNA might sequester RNA binding proteins and 
the loss of these proteins might cause disease. RNA foci containing sense and 
antisense repeat RNA can be found in patients in affected brain regions and the 
burden in these areas correlates with clinical phenotypes (Mizielinska et al., 2013). 
By now, several proteins have been identified to be sequestered by C9orf72 repeat 
RNA (Almeida et al., 2013; Gendron et al., 2013; Mizielinska et al., 2013; Mori et 
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al., 2013b). However, variable sequestration of some has been observed and the role 
of RNA-binding proteins in the disease needs to be further elucidated.  
Finally, the repeat is translated through unconventional translation into 5 potential 
dipeptide repeat (DPR) proteins, poly-glycine-alanine (GA), poly-glycine-arginine 
(GR), poly-glycine-proline (GP), poly-proline-alanine (PA) and poly-proline-
arginine (PR). In 2013, two groups could independently show that sense and later 
also antisense proteins can be found in neuronal cytoplasmic inclusions in the brain 
of C9orf72  mutation carriers (Ash et al., 2013; Gendron et al., 2013; Mori et al., 
2013a; Mori et al., 2013c). However, toxicity and their relative role are unclear.  
DPR proteins 
The role that DPR proteins might play in disease is still unclear. Nonetheless , their 
presence in C9orf72 mutation carriers is undisputed. Since the repeat is located in 
an intronic region of the C9orf72 gene and does not carry an ATG start codon, 
canonical translation should not occur. Two rare possibilities of non-ATG 
translation have been reported. First, there is evidence that alternative start codons 
with a good Kozak sequence can initiate transcription (Ivanov et al., 2011; Peabody, 
1989; Touriol et al., 2003). Second, repeat-associated non-ATG (RAN)-dependent 
translation has been shown to occur in other repeat expansion disorders with non -
coding expansions such as fragile X tremor ataxia syndrome (FXTAS) or myotonic 
dystrophy type 1 (MD-1) (Cleary and Ranum, 2013; Todd et al., 2013) . RAN 
translation was initially discovered in spinocerebellar ataxia type 8 (SCA8) by Zu 
and colleagues showing that CAG expansions lacking an ATG start codon are 
translated in all three reading frames, rendering this hypothesis for translation the 
most likely (Zu et al., 2011). The underlying machinery of RAN translation is so far 
unknown. At present, the mechanism of translation in C9orf72  is not elucidated. 
Apart from overall translation it is very interesting to analyze if and how DPR 
proteins contribute to disease. It is also an open question , whether one of the five 
proteins is more important than the other or if one protein is preferentially pr oduced 
in patients. So far, all  studies show that poly-GA is the most abundant species in 
patients, but if poly-GA is also the species underlying the disease mechanisms still 
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needs to be elucidated (Mackenzie et al., 2013; Mori et al., 2013c) . Additionally, it 
is very important to discriminate between RNA and protein disease mechanisms and 
to identify their individual contributions. Therefore, good cellular models are 
needed to help answering these questions.  
1.1.3.2. Other genetic causes for FTD/ALS 
As can be seen in Figure 4, many mutations have been already identified that can 
cause either FTD or ALS. In this part, I will focus on mutations that are potentially 
in the same pathway as the mutation in C9orf72. 
TARDBP 
The TAR DNA binding protein (TARDBP) gene encodes for the 414 amino acids 
long TDP-43 protein that is responsible for the primary pathology in both FTD and 
ALS. Mutations were first discovered in 2008 and have a prevalence of 4-6 % in 
familial ALS and 1 % in sporadic ALS (Andersen and Al-Chalabi, 2011). So far, 
only one FTD patient with a TARDBP mutation was identified, suggesting a mainly 
ALS-related role of the TARDBP mutations (Borroni et al., 2009). The 33 known 
pathogenic mutations are almost all missense substitutions affecting the last exon of 
TARDBP which encodes the Gly-rich low complexity (prion-like) domain. The 
pathogenic mutations lead to a redistribution of the protein to the cytosol and to the 
loss of its nuclear function (Neumann et al., 2006). Physiologically, TDP-43 is a 
ubiquitously expressed DNA-/RNA-binding protein which plays an important role 
in RNA splicing and microRNA biogenesis.  
SQSTM1 
Sequestosome 1 (SQSTM1), also known as p62, is a major component  of 
cytoplasmic neuronal inclusions in FTD and ALS. Mutations associated with the 
FTD-ALS continuum, however, were discovered relatively late. Currently, 20 
mutations are identified in FTD (Le Ber et al., 2013; Rubino et al., 2012) . The 
frequency is roughly 1-3 % in FTD and ALS. SQSTM1 is an important protein in 
the ubiquitin-proteasome system and autophagy (Bennion Callister and Pickering-
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Brown, 2014; Hardy and Rogaeva, 2014; Ng et al., 2015) . The mutations found in 
FTD are associated with TDP-43 pathology. In ALS, increased levels of p62 and 
TDP-43 can additionally be found in the spinal cord. ALS patients with SQSTM1 
mutation also frequently show atrophy of the frontal lobe  (Hardy and Rogaeva, 
2014). 
UBQLN2 
Ubiquilin 2 is a member of the ubiquitin-like protein family. However, it’s exact 
function is still unknown (Lee and Brown, 2012). It is an intronless gene on 
chromosome Xp11.21. Autosomal dominant missense mutations were identified in 
either ALS or FTD, however, there is a high phenotypic variability within the same 
family (Vengoechea et al., 2013). Most mutations affect the proline residues in the 
ProXX repeat region leading to deficient protein degradation  (Gellera et al., 2012; 
Synofzik et al., 2012). Regarding pathology, UBQLN2 mutations are associated 
with ubiquitin, p62, TDP-43, Fus and Optineurin inclusions (Hardy and Rogaeva, 
2014). Moreover, UBQLN2-positive inclusions are found in the hippocampus of 
ALS patients with dementia but are absent in ALS cases without dementia, 
suggesting a link to neurodegeneration (Deng et al., 2011). 
1.2. Protein aggregation in neurodegeneration 
The presence of aggregated protein species is a common feature of 
neurodegenerative diseases that often comes along with toxicity and cellular 
damage. The central nervous system (CNS) is particularly susceptible for  the 
misfolding of proteins. However, the reasons for the specific vulnerability of 
distinct neuronal populations still needs to be elucidated  (Saxena and Caroni, 2011). 
Although many diseases are classified by a specific aggregating protein , there is an 
overlap between diseases and most aggregates do contain components of the cellular 
protein quality control system such as ubiquitin or p62 (Swart et al., 2014). 
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1.2.1. Characteristics of protein aggregates 
Protein aggregates can be classified into two groups, amorphous  aggregates or 
structured amyloid fibrils. Whereas amorphous aggregates appear granular and 
mostly consist of disordered and unstructured polypeptide tangles, amyloids are 
highly ordered and repetitive assemblies that have a so called cross β structure 
(Swart et al., 2014). Amyloids or amyloidogenic proteins further have a high β 
sheet content and are resistant against most proteolytic and denaturing agents. 
Additionally, they are also known to be selftemplating meaning a pathogenic 
protein can transmit its misfolded state to the wildtype protein. In general, t he 
process of aggregate formation can be described as nucleation – elongation – 
polymerization, where fibrils can undergo continuous fragmentation and reassembly 
(Chiti and Dobson, 2006; Harper and Lansbury Jr, 1997; Jarrett and Lansbury, 
1993). This continuous process may affect turnover and recycling of aggregates, 
thus possibly adding to the toxic production line. Generally, it is very interesting 
that proteins forming aggregates in neurodegenerative diseases differ structurally 
and functionally, however, they all share the potential to form aggregates, 
suggesting that the formation of aggregates is unlikely to be random in these 
diseases. The inclusion bodies seen in patients, also called aggresomes are formed 
through the transport of cellular aggregates along dynein motors to the microtubule 
organization center where they are packaged into inclusion bodies. This is likely a 
response to proteostatic stress initiated to eliminate misfolded or toxic proteins to 
minimize obstruction of cellular processes and target them for macroautophagy 
(Fortun et al., 2003; Iwata et al., 2005; Rideout et al., 2004; Swart et al., 2014) . It 
is, however, still under discussion if the formation of aggregates is a protective 
action of the cell to hide the toxic species or if the aggregates themselves are toxic 
through various mechanisms.  
1.2.2. Toxicity of aggregating proteins 
Over the past decades evidence for the involvement of aggregated proteins in 
disease initiation and progression of neurodegenerative diseases has been 
accumulating. As a first hint, insoluble proteins accumulate in affected brain 
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regions and are described as hallmarks of the individual diseases. Furthermore , 
many mutations that are disease causing, such as mutations in TDP-43, SOD1 and 
MAPT increase the propensity for aggregation of the underlying proteins  (Li et al., 
2001). Experimental evidence has come from animal models overexpressing disease 
associated mutant proteins that mirror some disease characteristics . Moreover, in 
vitro produced aggregates have shown toxicity in numerous cell culture systems  
(Bucciantini et al., 2002; Price et al., 2000) . Following these lines of evidence, it is 
highly likely that protein aggregates either directly contribute to cell death or are a n 
epiphenomenon of an earlier pathologic event. Early studies in Alzheimer’s disease 
Amyloid β (Aβ) research showed that intracerebral microinjections  of old rhesus 
monkeys with Aβ fibrils but not soluble Aβ lead to neuronal loss and tau 
phosphorylation (Guela et al., 1998). Additionally, switching off expression of 
aggregating proteins can rescue the phenotypes in conditional mouse models of 
spinocerebellar ataxias type 1 and 7 (SCA1, SCA7) and Huntington’s disease  
(Ramachandran et al., 2014; Yamamoto et al., 2000; Zu et al., 2004). 
To fully elucidate whether the inclusion bodies, intermediate aggregates or  
oligomeric species confer toxicity it is very important to understand the underlying 
toxicity mechanisms. 
1.2.2.1. Mechanisms of toxicity 
For the development of potential therapeutic approaches it is crucial  to understand 
the exact molecular events leading to cell death. Increasing amounts of pathogenic 
proteins may cause toxicity through multiple mechanisms such as inhibition of the 
protein degradation machinery, mitochondrial dysfunction, oxidative stress o r 
sequestration of important proteins.  
Insoluble proteins may further interfere with microtubule transport, autophagic 
trafficking or impair cellular functions through the recruitment of essential 
functional components such as proteasomal  machinery, chaperones and transcription 
factors or cytoskeletal proteins (Cummings et al., 1998; Ii et al., 1997) . The 
depletion of these factors may, in combination, lead to a multiple-systems 
neurotoxicity. Additional, the propagation of aggregated protein material may 
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further enhance toxicity. Overall, many studies have already implicated some of the 
above mentioned mechanisms (Blokhuis et al., 2013; Chhangani and Mishra, 2013; 
Hara et al., 2006). 
Protein sequestration 
A mechanism of toxicity of aggregating proteins may be the sequestration of 
important proteins. First of all, the cytoplasmic aggregation of disease relevant 
proteins may prevent them to execute their normal funct ion. Knockout studies from 
zebrafish and drosophila indicate that the loss of TDP-43 and Fus may be toxic for 
neuronal cells (Feiguin et al., 2009; Kabashi et al., 2010; Lin et al., 2011;  Sasayama 
et al., 2012; Wang et al., 2011) . However, the more likely hypothesis is that the 
aggregated proteins may recruit other proteins like chaperones or RNAs to the 
inclusions and thus, lead to a loss of function of the respective proteins (Blokhuis et 
al., 2013). This entrapment may remove important proteins from critical cellular 
processes such as protein degradation or RNA metabolism.  In spinal and bulbar 
muscular atrophy (SBMA), caused by a CAG repeat expansion, polyglutamine 
protein aggregates sequester an important transcriptional activator CREB-binding 
protein (CBP) leading to loss of function and neuronal toxicity. Overexpressing 
CBP could rescue these phenotypes in neuronal cell culture, supporting 
sequestration as an important disease mechanism in proteinopathies (McCampbell et 
al., 2000). 
Impairment of protein degradation 
Impairment of the protein degradation system has been discussed in many 
neurodegenerative diseases. A lot of evidence exists, suggesting that this is the 
main disease mechanism in many of these diseases (Lim and Yue, 2015; Swart et 
al., 2014). One of the strongest arguments for this theory is the existence of 
ubiquitin-positive inclusion bodies in all of them. Specifically, the ubiquitin 
proteasome system has been found to be impaired through Huntingtin, A β oligomers 
and α-synuclein (Jana et al., 2001; Lindersson et al., 2004; Tseng et al., 2008) . 
Furthermore, the second protein degradation system, the autophagy-lysosome-
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pathway has also been found to be impaired in AD, Parkinson’s disease (PD) and 
Huntington’s disease (HD). Interestingly, impairment of the autophagic system in 
mice leads to neurodegeneration and the formation of ubiquitin-positive inclusions 
(Hara et al., 2006; Komatsu et al., 2006) . Further reports support that ubiquitin i s 
also a relevant protein in selective autophagy, as it is involved in the degradation of 
mitochondria and protein aggregates through signaling the initiation of 
autophagosome formation (Ishihara and Mizushima, 2009; Kirkin et al., 2009) . 
Thus, the clearance of protein aggregates may be a very important mechanism in the 
development of neurodegenerative diseases.  
Mitochondrial dysfunction 
Mitochondria have an essential role in cell viability, specifically in neurons as they 
have a high energy consumption. Impairments in the mitochondrial function have 
been found in several neurodegenerative diseases such as AD, HD and PD (Browne 
et al., 1997; Caspersen et al., 2005; Crouch et al., 2005; Gu et al., 1996; Mancza k et 
al., 2006; Nicklas et al., 1985; Schapira et al., 1990) . Mouse models, 
overexpressing α-synuclein, an aggregating protein in AD and specifically PD, 
support the involvement of mitochondrial dysfunction in neurodegenerative 
diseases, as they show degenerated mitochondria and reduction in complex IV 
activity of the respiratory chain (Martin et al., 2006; Song et al., 2004). 
Aggregate propagation 
The spreading of aggregated protein material in a stereotypical staging pattern  
along axonal connections is well documented for most neurodegenerative diseases 
(Braak and Braak, 1991; Braak et al., 2003; Deng et al., 2004; Guo and Lee, 2014; 
Holmes and Diamond, 2012). Furthermore, many proteins found in neuronal 
inclusions show prion-like properties in vitro and in vivo suggesting this to be a 
highly common feature of neurodegeneration. Prion-like domains have self-
aggregating properties and are able to convert native proteins into the toxic prion 
type. This recruitment of native protein and misfolding that would not tak e place 
otherwise, may be an important disease mechanism of  aggregating proteins and is 
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called the prion hypothesis (Jucker and Walker, 2013). Evidence has been found in 
several cell culture and animal models  (Holmes and Diamond, 2012). Moreover, in 
vivo seeding and spreading has been shown for aggregate prone proteins A β (Eisele 
et al., 2010; Meyer-Luehmann et al., 2006), Tau (Frost et al., 2009; Sanders et al., 
2014) and Huntington’s polyQ (Ren et al., 2009). The most striking evidence 
proceeds from PD patients that received striatal grafts of fetal neuronal tissue, 
where α-synuclein lewy body pathology was also present in the implanted grafts  
(Kordower et al., 2008; Li et al., 2008). Thus, propagation of proteins may be an 
important mechanism of toxicity in neurodegenerative diseases.  
1.2.3. Clearance of protein aggregates 
The clearance of aggregated protein species is typically executed through either the 
ubiquitin-proteasome system (UPS) or the autophagy-lysosome-pathway, which can 
be subdivided into macroautophagy (MA), microautophagy and chaperone-mediated 
autophagy (CMA). These mechanisms can also work hand in hand and even 
compensate for one another to a certain amount if one system fails.  For example, α-
synuclein is normally degraded via the UPS system, however , with increased 
burden, the autophagy machinery is recruited and supports the overstrained system 
(Ebrahimi-Fakhari et al., 2011). Additionally, chemicals inhibiting lysosomal 
degradation also compromise the UPS funct ion suggesting that autophagy may also 
be required for the proper function of the UPS (Korolchuk et al., 2009). Typically, 
the ubiquitin-proteasome system is responsible for the clearance of single 
monomeric proteins, whereas larger aggregates are cleared through bulk  autophagy. 
The ubiquitin-proteasome system consists of the core protease machinery, th e 26S 
proteasome and specific enzymes controlling substrate recognition, selection and 
targeting. In the initial step multiple ubiquitin proteins are covalently attached  to 
the substrate protein with the help of the ubiquitin activating enzyme (E1), the 
ubiquitin ligase (E3) and the ubiquitin conjugation enzyme (E2). In the next step, 
ubiquitin chains are recognized by the 26S proteasome, consisting of the 20S core 
machinery and the 19S regulatory particles.  The 26S proteasome degrades the poly-
ubiquitinated substrate protein through unfolding the protein and cleavage into 
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short peptides. Peptides are further processed into amino acids by cellular 
aminopeptidases and ubiquitin is released for further reuse (Dantuma and Bott, 
2014). 
As mentioned before, many proteins found in inclusion bod ies are ubiquitinated. 
For α-synuclein, Tau, SOD1 and Huntingtin it is known that they are degraded via 
the ubiquitin-proteasome system and inhibition of the system leads to their 
accumulation (Dantuma and Bott, 2014). 
In the autophagy-lysosomal-pathway both CMA and MA might help in the clearance 
of aggregated proteins. Whereas the chaperone-mediated autophagy rather targets 
polypeptides to the surface of lysosomes for the translocation through the 
membrane and subsequent degradation, MA is used to eliminate larger aggregates or 
inclusion bodies. Therefore, the selected cargo is engulfed into double membrane 
vesicles and subsequent fused with lysosomes or endosomes. These mechanisms 
clearly have an important role in neurodegeneration as increasing autophagy results 
in the enhanced clearance of disease related proteins and increased survival of 
neuronal cells (Caccamo et al., 2010; Ravikumar et al., 2004; Sarkar et al., 2007) . 
1.2.3.1. The ubiquitin-proteasome system (UPS) in neurodegeneration 
The proteasome plays a central role in neurodegeneration. A lot  of evidence has 
accumulated showing that the inhibition of the UPS can lead to neurodegenerative 
phenotypes. However, it still needs to be elucidated whether the UPS is really 
impaired in neurodegenerative diseases. It is known that the UPS is actively 
involved in maintaining and resolving inclusion bodies (Schipper-Krom et al., 
2014) and there is an ubiquitin-dependent transport of proteins to aggresomes 
(Kawaguchi et al., 2003). Therefore it may well be that the UPS is important in the 
development of neurodegenerative diseases but it may still be functional  in those 
diseases. Another important hint for  a role of the UPS in neurodegeneration came 
from the discovery of mutations in several genes with  a function in the UPS such as 
Parkin, Ubiquilin1 or VCP (Chan et al., 2011; Ju and Weihl, 2010; Zhang and 
Saunders, 2009). However, these proteins also have other important cel lular 
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functions apart from the UPS (Dantuma and Bott, 2014). Thus, further evidence is 
needed to link the dysfunction of those proteins to the UPS.  
To provide an hypothesis  on the UPS state in neurodegenerative disease, activity 
measurements of the three individual enzymatic activities of the proteasome, the 
trypsin-like, chymotrypsin-like and the caspase-like activity are necessary. These 
measurements can be difficult , as for example, the chymotrypsin-like activity needs 
to be reduced by 80 % before an effect on protein clearance can be detected. On the 
other hand, stress conditions may lead to an earlier effect (Dantuma et al., 2000). 
Initial studies on proteasome activity in human post mortem tissue showed a 
reduced proteasome activity in several neurodegenerative diseases (Keck et al., 
2003; Keller et al., 2000; McNaught and Jenner, 2001; Seo et al., 2004) . The 
following cell line and animal studies, unfortunately, were not very consistent. 
Whereas some studies could replicate the reduced activity , others did find no effect 
or even an increased proteasomal activity (Dantuma and Bott, 2014). Nonetheless, 
there is evidence directly linking aggregating proteins to a dysfunctional 
proteasome. Α-synuclein and the prion protein both directly bind to and inhibit the 
UPS function in vitro and in vivo (Chen et al., 2006; Kristiansen et al., 2007; 
Snyder et al., 2003). The polyQ protein can also inhibit the UPS in vitro and in vivo 
however the inhibitory activity does not compromise the UPS function in vivo as the 
26S proteasome is still able to degrade ubiquitinated substrates (Hipp et al., 2012). 
Mouse models, where the Huntingtin expression can be regulated via Doxycyclin 
show an effect on UPS activity, however, this effect is transient and UPS 
restoration coincides with inclusion body formation in these mice (Mitra et al., 
2009; Ortega et al., 2010). Thus, the formation of inclusion bodies may be a 
protective mechanism of neurons to secure general UPS function.  
To draw a conclusion from the results achieved so far, there is not enough evidence 
supporting the theory of a global inhibition of the ubiquitin -proteasome system as a 
universal feature in all neurodegenerative diseases in general. There is , however, 
evidence for the involvement of the UPS in several neurodegenerative diseases. 
Whether it is impaired or can be used as a possible therapeutic strategy needs 
further investigations.  
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1.2.4. Protein aggregation and degradation mechanisms in FTD/ALS 
There is explicit evidence that protein aggregation is central in the pathology of 
FTD and ALS. Several studies point to a clear involvement of protein aggregates in 
neurotoxicity. Expression of wildtype or mutant TDP-43 leads to mislocalization 
and aggregation in the cytosol and a toxic gain of function in primary neurons 
(Barmada et al., 2010; Fallini et al., 2012). Transgenic mouse lines with 
cytoplasmic TDP-43 show a motor phenotype and a reduced life span  (Guo et al., 
2011; Stallings et al., 2010; Xu et al., 2010) . Additionally, the distribution of TDP-
43 aggregates in patients correlates with neurodegeneration, as aggregates can be 
found in the motor neurons in ALS and more wide spread in the brains of FTD 
patients (Baloh, 2011; Mackenzie et al., 2013). 
Several potential toxicity mechanisms for the existing protein aggregates are 
discussed in the literature. As for several other neurodegenerative diseases, the 
involvement of the ubiquitin-proteasome system is considered. The UPS has been 
linked to FTD and ALS by several functional studies (Blokhuis et al., 2013), UPS 
impairment in SOD1 mutant mice being just one of them (Cheroni et al., 2009). 
Further evidence comes from disease causing mutations in the Ubiquilin -2 gene as 
the overexpression of mutant Ubqln2 results in the impairment of UPS function 
(Deng et al., 2011). Interestingly, Ubqln2 positive inclusions in the hippocampus 
are absent in ALS patients without dementia suggesting a link to neurodegeneration 
(Deng et al., 2011). More evidence for the impairment in proteasome function 
comes from mice with a motor neuron specific knockout of the proteasome subunit 
Regulatory Particle Triphosphatase (Rpt3), which results in the loss of spinal cord 
motor neurons and locomotor dysfunction. Additionally, those mice show inclusion 
bodies positive for TDP-43, Fus, Ubqln2 and Optineurin (Tashiro et al., 2012). 
Apart from the proteasome, the second protein degradation pathway, autophagy, 
might also be involved in the pathology of FTD and ALS. Heat shock proteins, p62 
and other chaperones are upregulated in the spinal cord and present in patient 
aggregates (Basso et al., 2009; Watanabe et al., 2001) . Furthermore, mice lacking 
the important autophagy proteins, Autophagy protein 5 and 7 (Atg5, Atg7) in the 
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CNS show movement disorders, neurodegeneration and p62 and ubiquitin-positive 
inclusions (Hara et al., 2006; Komatsu et al. , 2006).  
All of these results further strengthen the importance of protein aggregation as a 
central hallmark in FTD and ALS and establish the components of the protein 
degradation system as important modulators of protein aggregation and toxicity in 
FTD/ALS. Recent studies have enlarged the knowledge on the molecular 
composition of the aggregates and provided a starting point for future 
investigations. Although current available disease models confirm a role for 
aggregated proteins in the pathology of FTD and ALS, those models often do not 
fully recapitulate the disease. Thus, new models are a crucial tool to achieve a 
clearer picture. Novel mutations triggering protein aggregation such as the C9orf72 
mutation causing FTD/ALS may be the perfect opportunity to help further dissect 
the underlying effects and mechanisms of action of protein aggregation in ALS and 
FTD. 
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2. Aim of the study  
The massively expanded GGGGCC repeat in C9orf72 mutation carriers is translated 
in all three reading frames resulting in aggregating DPR proteins poly-GA, poly-GR 
and poly-GP, however the role of these proteins in the disease is still elusive (Ash 
et al., 2013; Mori et al., 2013c) . Based on these initial findings, the overall aim of 
my thesis was to evaluate the contribution of the different DP R proteins to the 
pathophysiology of ALS/FTD. 
As several other microsatellite expansion disorders are bidirectionally transcribed 
(Belzil et al., 2013b), I first aimed to investigate whether antisense transcripts of 
the C9orf72 repeat expansion are present in the cerebellum of mutation carriers  and 
how poor transcription of the mutant allele and abundant DPR expression can be 
reconciled. 
Second, I aimed to develop a cell culture system in HEK293 cells  and primary 
neurons to investigate the expression and toxicity of the five different proteins 
(poly-GA, poly-GR, poly-GP, poly-PA and poly-PR) and compare the results to  the 
known characteristics seen in FTD and ALS patients. 
Understanding the downstream mechanisms of potential DPR protein toxicity is 
crucial to elucidate the pathophysiology of ALS/FTD. Accordingly, the third aim of 
my study was to identify cellular proteins co-aggregating with DPR proteins by LC-
MS/MS, since loss of function of these proteins may contribute to toxicity 
mechanisms. Furthermore, I aimed to validate the role of these interactors in DPR 
toxicity and confirm co-aggregation in patient brain. 
Another important goal in understanding how DPR proteins contribute to disease 
progression is to uncover a potential connection of DPR and TDP-43 pathology. To 
this end, the final aim of my thesis was to analyze if DPR proteins can initiate TDP -
43 mislocalization in my cell culture model . 
Thus, the results of my thesis  may help to identify novel therapeutic strategies for 
the devastating symptoms of C9orf72 FTD/ALS.  
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3. Materials and Methods 
3.1. Materials 
3.1.1. Equipment and tools 
3.1.1.1. General equipment 
Name Company 
Analytical scale Mettler-Toledo 
Autoclave Systec 
Balance Mettler-Toledo 
Bunsen burner Heraeus 
CFX384 Real-Time System quantitative PCR Biorad 
CO2-incubator Thermo Scientific 
Cooling centrifuge 5417R Eppendorf 
DNA electrophoresis gel system Thermo Scientific 
Dynabeads magnet Life technologies 
Film cassette G. Kisker 
Film developer CaWo 
Filter trap slot blot Hoefer Scientific Instruments 
Freezer (-20 °C) Liebherr 
Freezer (-80 °C) Heraeus 
Fridge Liebherr 
Glassware VWR 
Incubator B. Braun Biotech International 
Lamina flow Heraeus 
Microsurgical instruments (Dumont forceps 
and scissors) 
Microwave 
Milli Q plus filtration system Merck Millipore 
N2-tank Messer Griesheim 
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Nano Drop Implen 
Oven Memmert 
PCR thermal cycler Eppendorf 
pH meter Thermo Scientific 
Pipette boy Brand 
Power suppliers Bio-Rad, Major Science 
Powerwave XS plate reader BioTek 
Protein electrophoresis gel system Bio-Rad 
Rotors (TLA-55, SW28) Beckmann Coulter 
Scanner Epson 
UV lamp Intas 
Vortexer Scientific Industries 
Water bath GFL 
3.1.1.2. Microscope equipment 
Name Company 
Confocal laser scanning microscope  
(LSM 710) 
Zeiss 
Epifluorescence microscope (Axiovert.A2) Zeiss 
Immersol 518 F Zeiss 
Light microscope (Wilovert S) Hund Wetzlar 
Microscope cover glasses (18 mm, 20 mm) VWR 
Microscope slides Superfrost plus Thermo Scientific 
Objective (Plan Apochromat, 20x/1 air DIC) Zeiss 
Objective (Plan Apochromat, 40x/1.4 oil DIC) Zeiss 
Objective (Plan Apochromat, 63x/1.4 oil DIC) Zeiss 
Phase contrast microscope (CKX41) Olympus 
Vectashield H-1000 mounting medium Vectorlabs 
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3.1.1.3. Mass spectrometry equipment 
Name Company 
Easy-nLC 1000 HPLC system Thermo Fisher Scientific 
Inhouse 1.9 µm C18 particle packed columns 
75 µm inner diameter, 20 cm length 
Dr. Maisch GmbH 
Orbitrap Elite Thermo Fisher Scientific 
3.1.2. Consumables 
Name Company 
Cell culture dish (3.5 cm, 6 cm, 10 cm) Nunc 
Cell culture plate (12 well, 96 well) Nunc 
Cell culture flask (75 cm
2
) Nunc 
Cell culture plate black (96 well) BD Falcon 
Cellulose acetate filter membrane 0.2 µm GE Healthcare 
Centrifuge tubes (1.5 ml for TLA-55) Beckmann Coulter 
Centrifuge tubes for rotor SW28 Beckmann Coulter 
Gloves (Latex) Semperit 
Gloves (Nitrile) Meditrade 
Hard shell PCR plates 384 well Bio-Rad 
Immobilon-P membrane, PVDF, 0.45 µm Merck Millipore 
Parafilm “M” Pechiney Plastic Packaging 
PCR tubes, strips, 96 well plates Sarstedt 
PES membrane filters, 0.45 µm VWR international 
pH indicator strips Merck Millipore 
Pipette tips (10 µl, 200 µl, 1000 µl) Sarstedt, VWR 
Pipettes Gilson, Raynon, Eppendorf 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
Tricine gels 10-20 % Invitrogen 
Tubes (1,5 ml, 2 ml) Sarstedt 
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Tubes (15 ml, 50 ml) Sarstedt 
Whatman paper Schleicher & Schüll 
X-ray films Fuji 
3.1.3. Software and online tools 
Name Company/Link 
Adobe Illustrator Adobe Systems 
APE Wayne Davis 
AxioVision Zeiss 
Bio-Rad CFX manager Bio-Rad 
BLAST NCBI, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web 
&PAGE_TYPE=BlastHome 
Ensembl EMBL-EBI, Sanger Centre 
http://www.ensembl.org/index.html 
GraphPad Prism GraphPad Software, Inc 
ImageJ NIH 
iScore designer KAKENHI, http://www.med.nagoyau. 
ac.jp/neurogenetics/i_Score/i_score.html 
LSM Zeiss 
MetaMorph Molecular Devices 
NCBI http://www.ncbi.nlm.nih.gov/ 
Primer3 Whitehead Institute for Biomedical Research, 
http://bioinfo.ut.ee/primer3/ 
Spidey NCBI, http://www.ncbi.nlm.nih.gov/spidey/ 
3.1.4. Services 
Name Company 
Antibody production Eurogentec 
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DNA sequencing GATC Biotech 
Oligonucleotide synthesis Sigma-Aldrich 
3.1.5. Chemicals 
Name Company 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Biomol 
Acrylamide (19:1 / 40 % (w/v)) Serva 
Agarose ultrapure Life technologies 
Ammonium persulfate (APS) Roche 
Ampicillin Boehringer Mannheum 
Boric acid Merck Millipore 
Bovine serum albumin Sigma-Aldrich 
Bromphenol blue Merck Millipore 
CaCl2 AppliChem 
DAPI Roche 
DMSO Roth 
DTT Biomol 
ECL Thermo Scientific 
ECL plus Thermo Scientific 
EDTA USB 
Ethanol Sigma Aldrich 
Ethidiumbromide Roth 
Fish gelatin Sigma-Aldrich 
Gelatin Sigma-Aldrich 
Glycerol USB 
Glycine Biomol 
I-Block Tropix 
IPTG Roth 
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Isopropanol Merck Millipore 
Kanamycin Roth 
KCl USB 
KH2PO4 Merck Millipore 
Methanol Merck Millipore 
MgCl2 Roth 
MgSO4 Sigma-Aldrich 
Na2[B4O5(OH)4] Sigma-Aldrich 
Na2HPO4 Merck Millipore 
NaCl Merck Millipore 
NaH2PO4 Sigma-Aldrich 
NaHCO3 Merck Millipore 
NaN3 Merck Millipore 
Paraformaldehyde SERVA 
Sodium borate decahydrate (Borax) Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Roth 
Staurosporine Sigma-Aldrich 
Suberic acid bis(3-sulfo-N- 
hydroxysuccinimide- ester) sodium salt (BS3) 
Sigma-Aldrich 
Sucrose Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) USB 
TO-PRO-3 Life technologies 
Tris base AppliChem 
Triton-X-100 Merck Millipore 
Tryptone BD Bioscience 
Yeast extract BD Bioscience 
ß-mercaptoethanol Roth 
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3.1.6. Kits 
Name Company 
Caspase 3/7 Glo Promega 
DNase digest Kit Qiagen 
Endofree Plasmid Maxi Kit Qiagen 
Gel and PCR clean-up Kit Marcherey-Nagel 
LDH assay Promega 
NucleoBond Xtra Midi EF Marcherey-Nagel 
Nucleospin Plasmid Kit Marcherey-Nagel 
Proteasome activity assay Promega 
RNeasy Mini Kit Qiagen 
RT-PCR Kit  
TaqMan MicroRNA Reverse Transcription Kit 
Applied Biosystems 
SsoFast
TM
 EvaGreen® Supermix Bio-Rad 
TUNEL assay Roche 
XTT assay Roche 
3.1.7. Reagents 
Name Company 
Benzonase Sigma-Aldrich 
Calf-intestinal alkaline phosphatase (CIP) NEB 
DNA ladder Life technologies 
DNA polymerase (Pfu) Agilent 
DNA Polymerase (Taq) Promega 
DNAse Sigma-Aldrich 
Deoxyribonucleotides (dNTPs) Roche 
Glutathione sepharose 4B GE Healthcare 
Lysozyme Merck Millipore 
Phosphatase inhibitor cocktail Sigma-Aldrich 
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Protein A Sepharose beads GE Healthcare 
Protein G Dynabeads Life technologies 
Proteinase inhibitor cocktail Sigma-Aldrich 
Restriction enzymes NEB 
RNA Later Ambion 
RNAse A Sigma Aldrich 
SeaBlue Prestained Protein Ladder Plus2 Life technologies 
T4-Ligase NEB 
3.1.8. Antibodies 
Name Company 
ß-Actin, clone AC-15 Sigma-Aldrich 
Alexa secondary antibodies Life technologies 
Poly-AP, clone 14E12 Elisabeth Kremmer 
Anti-mouse-HRP Promega 
Anti-rabbit-HRP Promega 
Anti-rat-HRP Santa-cruz 
Calnexin Proteintech 
Poly-GA, clone 1A12 Elisabeth Kremmer 
GFP, clone N86/8 Neuromab 
GFP, clone N38/8 Neuromab 
GFP Clonetech 
HA Sigma-Aldrich 
HA, clone R001 Elisabeth Kremmer 
Myc, clone 9E10 Elisabeth Kremmer 
MAP2, clone AP-20 Sigma-Aldrich 
Myc, clone A-14 Santa-cruz 
P62 Cell signaling 
P62 MBL 
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PSD-95, clone K28/43 Neuromab 
PSMC2 Bethyl laboratories 
PSMC4 Bethyl laboratories 
pTDP-43, Ser409/410 clone 1D3 Elisabeth Kremmer 
TDP-43 Cosmo 
TDP-43 Sigma-Aldrich 
Unc119#1 Eurogentec 
Unc119#2 Thermo Scientific 
V5 Life technologies 
3.1.9. Cloning vectors and oligonucleotides 
3.1.9.1. Cloning vectors 
Name Company 
Fu3a Dieter Edbauer 
FhSynW2 Dieter Edbauer 
FUW2 lentivirus vector Dieter Edbauer 
pEF6/V5-His Life technologies 
pCS2-Q102-GFP Betina Schmid 
pEGFP-N1 Clonetech 
pSPAX (Salmon and Trono, 2007) 
pVSVg (Kuhn et al., 2010) 
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3.1.9.2. Oligonucleotides for shRNA cloning 
Oligonucleotides were cloned into Fu3a vector. 
Name Species Sequence sense Sequence antisense 
shUnc mr gatccccGAGAGGCACTACTTT
CGAAttcaagagaTTCGAAAGT
AGTGCCTCTCtttttggaaa 
agcttttccaaaaaGAGAGGCACTACTTTC
GAAtctcttgaaTTCGAAAGTAGTGCCT
CTCggg 
shLuc ff gatccccCGTACGCGGAATACT
TCGAttcaagagaTCGAAGTATT
CCGCGTACGtttttggaaa 
agcttttccaaaaaCGTACGCGGAATACTT
CGAtctcttgaaTCGAAGTATTCCGCGT
ACGggg 
h= human, m= mouse, r= rat, ff= firefly 
3.1.9.3. Cloning primers 
cDNA was cloned AscI/EcoRI or AscI/NotI into FUW2 vector.  
Name Species Sense Antisense 
Bag6 r ataggcgcgcctATGGAGCCG
AGTGATAGTACCAGTAC
CGCT 
tatgcggccgcCTAGGGGTCATCAGCAA
ATGCCCGGTGGGC 
Ctbp1 h aGGCGCGCCTatgggcagctcg
cacttgctca 
ataGCGGCCGCCTACAACTGGTCAC
TGGCGTGGT 
Epdr1 r ataggcgcgcctATGCTCACA
CGCGCTCCCCGCCG 
tatgcggccgcTCACAGGGAGCAGTTCT
CTTTCATCTTCTCTG 
Fabp5 h ataggcgcgcctATGGCCAGC
CTTAAGGACCTGGAAGG 
actgaatTCATTGTACCTTCTCATAGAC
CCGAGTACAGATG 
Hsd17b4 r ataggcgcgcctATGGCTTCGC
CTCTGAGGTTCGACGGG
C 
tatgcggccgcTCAGAGCTTGGCATAGT
CTTTCAGAATCATCTGT 
Mapre2 h aGGCGCGCCTatgcctgggccg
acccaaacc 
ataGCGGCCGCTCAGTACTCTTCCTG
CTGCGGGG 
Rpl31 r ataggcgcgcctATGGCTCCC
GCAAAGAAGGGTGGCG
AG 
actgaattcTTAGTTCTCATCCACATTG
ACTGTCTGTAGATTT 
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Rps5 r ataggcgcgcctATGACTGAA
TGGGAAACAGCCACACC
CGCG 
actgaattcTCAGCGGTTAGACTTGGCC
ACACGCTCCAG 
Tmem160 r ataggcgcgcctATGGGAGGC
GGCTGGTGGTGGGCTC 
actgaattcTTACTCGGGGGGTGGCCGG
CCCGCTTC 
Unc119 h aGGCGCGCCTATGAAGG
TGAAGAAGGGCGGCG 
ataGCGGCCGCtcagggtgtcccgctgtaggaat
a 
Unc119 r aaaggcgcgcctATGAGCGGG
TCGAACCCGAAGGCTAC
G 
atagaattcGCTTACTGGCCTCCGTTAT
AGGCATAGTCGG 
3.1.9.4. qPCR primers 
Name Species Sense Antisense 
C9orf72 
intron 
h AAGAGGCGCGGGTAGAA
G 
AGTCGCTAGAGGCGAAAGC 
C9orf72 
exon 1b-2 
h CTGCGGTTGCGGTGCCTG
C 
AGCTGGAGATGGCGGTGGGC 
C9orf72 
exon 2-3 
h ACTGGAATGGGGATCGC
AGCA 
ACCCTGATCTTCCATTCTCTCTGT
GCC 
C9orf72 
specific RT 
h CAATTCCACCAGTCGCT
AGA 
CTGCGGTTGCGGTGCCTGC 
Unc119 r GCGCTTTGTTCGATACCA
GT 
TGTTCTTGCTGCTGGGAATG 
YHWAZ h TGAACAAAAGACGGAAG
GTGCTG 
TCTGATAGGATGTGTTGGTTGCA 
GAPDH r CCGCATCTTCTTGTGCAG
TGCC 
AGACTCCACGACATACTCAGCA
CC 
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3.1.10. Cell culture 
3.1.10.1. Reagents 
Name Company 
B27 supplement Life technologies 
Bovine serum albumin (BSA) Sigma-Aldrich 
DMEM glutamax-I Life technologies 
Fetal bovine serum Life technologies 
Laminin Roche 
L-glutamate Sigma-Aldrich 
L-glutamine Sigma-Aldrich 
Lipofectamine 2000 Life technologies 
Neurobasal Life technologies 
Non-essential amino acids (NEAA) Life technologies 
OptiMEM Life technologies 
Penicillin/Streptomycin (P/S) Life technologies 
Poly-D-lysine (PDL) Sigma-Aldrich 
Trypsin (2.5 %) Life technologies 
Trypsin EDTA Life technologies 
3.1.10.2. Cell lines and bacteria strains 
Name Company 
DH5α E. coli competent cells Life technologies 
HEK293-FT Life technologies 
Stble 3 E. coli competent cells Life technologies 
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3.1.11. Patient material 
Case number GGGGCC 
expansion 
Gender Clinical and neuropathological 
diagnosis 
Age of death 
Ctrl-1 - female control, no neurological or 
 psychiatric disease 
47 
Ctrl-2 - male control, no neurological or 
 psychiatric disease 
60 
Ctrl-3 - female control, no neurological or 
 psychiatric disease 
60 
Ctrl-4 - male control, no neurological or  
psychiatric disease 
70 
Ctrl-5 - male ALS 65 
Ctrl-6 - male ALS/FTLD 61 
Ctrl-7 - male FTLD-(MND) 55 
C9-1 + female FTLD-MND 65 
C9-2 + female FTLD-MND 59 
C9-3 + female ALS/beginning FTLD 47 
C9-4 + male FTLD/Parkinson 65 
C9-5 + female ALS 63 
3.1.12. Buffers and Media 
All buffers were prepared with MilliQ water unless specified otherwise  
3.1.12.1. Antibody purification 
Name Composition 
100x lysozyme stock 20 mg/ml lysozyme stock in STE buffer 
100x NaN3 for antibody dilutions 10 % NaN3 
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Acid elution buffer 0.1 M Glycine-HCl 
150 mM NaCl 
adjust to pH 2.5 
BS3 stock solution (25 mM) 25 mg BS3 in 1.75 ml 20 mM sodium- 
phosphate buffer 
adjust to pH 7.4 
 
Column wash buffer 0.1 M Tris-HCl 
0.5 M NaCl 
Adjust to pH 8 
Conjugation buffer 20 mM sodium phosphate Na2HPO4 
0.15 M NaCl 
adjust to pH 7 to 9 
Neutralization buffer 1 M Tris 
adjust to pH 9.5 
Quenching buffer for antibody purification 1 M Tris 
adjust to pH 7.5 
STE 10 mM Tris-HCl 
150 mM NaCl 
1 mM EDTA 
adjust pH 8 
3.1.12.2. Biochemistry 
Name Composition 
20x SB agarose gel buffer (100 mM) 38.17 g sodium borate decahydrate (Borax) 
33 g boric acid 
1L dH2O 
adjust to pH 8.0 
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4x Laemmli buffer 4 % SDS 
20 % glycerol 
5 % ß-mercaptoethanol 
200 mM Na2HPO4 
bromophenol blue 
adjust to pH 7.4 
4x SDS PAGE running buffer 1.5 M Tris base 
0.4 % (w/v) SDS 
adjust to pH 8.8 
4x SDS PAGE stacking buffer 0.5 M Tris base 
0.4 % (w/v) SDS 
adjust to pH 6.8 
5x DNA loading buffer 50 % glycerol 
50 mM Na2EDTA 
0.05 % bromophenol blue 
adjust to pH 8.0 
Acrylamide-Schägger buffer 49.5 % acrylamide 
3 % bisacrylamide 
Anode buffer 0.2 M Tris-HCl 
adjust to pH 8.9 
Basic buffer 150 mM NaCl 
50 mM Tris pH 7.5 
5 % Glycerol 
Blotting buffer 25 mM Tris 
0.2 M Glycine 
Cathode buffer 0.1 M Tris-HCl 
0.1 M Tricine 
0.1 % SDS 
I-Block buffer 0.2 % I-Block in TBSTx 
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RIPA buffer 137 mM NaCl 
20 mM Tris, pH 7.5 
0.1 % SDS 
10 % glycerol 
1 % Triton-X-100 
0.5 % sodium deoxycholate 
2 mM EDTA 
SDS PAGE running buffer 1x with SDS 25 mM Tris 
0.2 M glycine 
0.1 % SDS 
SDS filter trap cell culture 2 % SDS 
100 mM Tris 
adjust to pH 7 
SDS filter trap brain 1 % SDS 
100 mM Tris 
adjust to pH 7 
Seperating gel buffer 1.5 M Tris 
0.4 % (w/v) SDS 
adjust to pH 8.8 
Stacking gel buffer 0.5 M Tris 
0.4 % (w/v) SDS 
adjust to pH 6.8 
TBSTx 20 mM Tris 
0.14 M NaCl 
0.2 % Triton-X-100 
adjust to pH 7.6 
Tricine-Schägger gel buffer 3 M Tris-HCl 
0.3 % SDS 
adjust to pH 8.45 
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Triton filter trap  1 % Triton-X-100 
50 mM MgCl2 
0.2 mg/ml DNAse I 
3.1.12.3. Cell and bacterial culture 
Name Composition 
Borate buffer 40 mM boric acid 
10 mM sodium tetra borate Na2B4O7•10H2O 
adjust to pH 8.5 
 
Coating solution for cover glasses 1.5 % PDL 
0.5 % laminin 
dissolve in borate buffer 
Coating solution for plastic culture plates 1.5 % PDL 
dissolve in borat buffer 
Cortical primary neuron medium 0.25 % L-glutamine (200 mM stock) 
2 % B27 
1 % penicillin/streptomycin 
in Neurobasal medium 
HBSS 0.14 M NaCl 
5.4 mM KCl 
0.25 mM Na2HPO4 
5.6 mM glucose 
0.44 mM KH2PO4 
1.3 mM CaCl2 
1.0 mM MgSO4 
4.2 mM NaHCO3 
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HEK293 cell medium 1 % penicillin/streptomycin 
1 % NEAA 
10 % FCS 
in DMEM Glutamax 
High BSA HEK293 medium 6.4 % high BSA stock in HEK293 cell 
medium 
prepare fresh 
High BSA stock 20 % BSA in DMEM medium 
filter through 0.2 µm sterile filter 
Hippocampal primary neuron medium 2 % B27 
0.25 % L-glutamine (200 mM stock) 
0.125 % L-glutamate (10 mM stock) 
1 % penicillin/streptomycin 
in Neurobasal medium 
LB agar 1.5 % agar 
dissolve in LB medium 
LB medium 1 % tryptone 
0.5 % yeast extract 
86 mM NaCl 
Phosphate-buffered saline (PBS) 0.14 M NaCl 
10 mM Na2HPO4 
2.8 mM KH2PO4 
2.7 mM KCl 
adjust to pH 7.4 
Poly-D-lysine stock 10 g/ml in borate buffer 
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3.1.12.4. Immunofluorescence 
Name Composition 
2x GDB 0.2 % gelatin powder 
0.33 M Na2HPO4 
0.9 M NaCl 
0.6 % Triton-X-100 
adjust to pH 7.4 
Immunofluorescence blocking buffer 2 % fetal bovine serum 
2 % bovine serum albumin 
0.2 % fish gelatin 
dissolve in PBS 
Permeabilisation/quenching buffer 0.2 % Triton-X-100 
50 mM NH4Cl 
dissolve in PBS 
PFA-fix 4 % PFA 
0.15 mM NaOH 
0.13 mM NaH2PO4 
0.12 mM sucrose 
adjust to pH 7.5 
3.1.12.5. Mass spectrometry 
Name Composition 
Resuspension buffer 1 8 M Urea 
10 mM HEPES 
adjust to pH 8.0 
Resuspension buffer 2 6 M Urea 
2 M Thiourea 
10 mM HEPES 
adjust to pH 8.0 
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3.2. Methods 
3.2.1. Molecular Biology 
3.2.1.1. Molecular Cloning 
Subcloning 
The insert fragment of interest was cut from the plasmid using two restrictions 
enzymes. 3 µg plasmid were digested in optimal buffer and temperature conditions 
for the respective enzymes for 1 h. Afterwards, enzyme activity was terminated via 
heat inactivation ( 65 °C/20 min) and the insert was isolated on a 1 % agarose gel 
containing 1 µg/ml Ethidiumbromide. After excising the band containing the insert 
fragment, the DNA was purified with the NucleoBond Gel Extraction kit  and eluted 
in 50 µl H2O. The backbone of choice was cut with the same restriction enzymes 
and additionally dephosphorylated with 1 µl calf intestinal phosphatase (CIP) for 1 
h at 37 °C to prevent religation. The following purification steps were performed as 
described for the insert. Following, 9 µl insert and 3 µl backbone were ligated with 
1 µl T4 ligase and 2 µl ligase buffer and 5 µl MilliQ water for 1 h at room 
temperature. The ligation mix was then transformed in competent bacteria as 
described below. 
Oligonucleotide cloning 
To design shRNAs with a unique seed region for a target of interest, the iScore 
designer (http://www.med.nagoya-u.ac.jp/neurogenetics/i_Score/i_score.html) and 
the NCBI Blast web tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were used. Final 
Oligonucleotides with restriction sites flanking sense and antisense pairs were made 
to order at Sigma Aldrich. Oligonucleotides were dissolved to 100 µM with MilliQ 
water. Annealing was carried out by mixing 1 µl of sense and antisense 
oligonucleotides with 2 µl NEB buffer 4 and 16 µl MilliQ wa ter and heating the 
reaction mix to 95 °C for 4 min. The backbone was prepared as described above in 
“subcloning” but without CIP dephosphorylation. 2 µl annealed Oligonucleotides 
were ligated with 2 µl backbone, 2 µl ligase buffer, 13 µl MilliQ water and 1 µl T4 
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Ligase at room temperature for 1 h. Transformation was performed as described 
below. 
PCR Product cloning 
Primers for PCR product cloning were designed manually with similar annealing 
temperatures for forward and reverse primer and restriction sites  flanking both 
ends. The PCR reaction-mix was prepared as follows:  
Component Amount 
DNA template 100 ng 
Forward primer (20 µM) 1 µl 
Reverse primer (20 µM) 1 µl 
dNTPs (10 mM each) 1 µl 
10x Pfu buffer 5 µl 
Pfu DNA Polymerase 1 µl 
MilliQ water ad 50 µl 
 
For a standard PCR the following program was applied:  
Step Temperature 
[°C] 
Time # of cycles 
Initial 
denaturation 
95 2 min 1 
Denaturation 95 20 s  
30 Annealing Tm(primer)-5 20 s 
Extension 72 1 min/1 kb 
Final extension 72 8 min 1 
 
Following PCR, the samples were loaded on a 0.7 -2 % Agarose, supplemented with 
1 µg/ml Ethidiumbromide, depending on the PCR product length. The gel was run in 
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SB buffer at 250 V for 15 min. Afterwards, the band on the correct height was cut 
from the gel and DNA was isolated with the Nucleobond Gel extraction kit. To 
obtain the restriction site sticky ends for ligation, the PCR product DNA was 
digested overnight with the respective enzymes at optimal buffer and temperature 
conditions. On the next day a heat  kill was performed and ligation was carried out  
as described above in “subcloning”. 
Transformation 
Chemical competent DH5α or Stable3 (for recombination prone inserts) E. coli  
bacteria were freshly thawed on ice. 100 µl were added to the ligation mixture and 
incubated on ice for 30 min. Afterwards, bacteria were heat shocked at 42 °C for 1 
min to facilitate DNA uptake. For recovery bacteria were shortly incubated on ice 
for 2 min and 400 µl LB media were added. The DH5α mix was incubated at 300 
rpm and 37 °C for 1 h, whereas Stable3 bacteria were incubated at 30 °C for 2 h. 
Following, the whole sample was plated on a LB agar plate containing selection 
antibiotics. For re-transformation of a construct only 200 µl of the mixture were 
plated on LB plates with antibiotics. DH5α bacteria plates were incubated at 37 °C 
overnight, whereas Stable3 bacteria plates were incubated at 30 °C for 24 h.  On the 
following day, clones were picked and grown in LB media with respective 
antibiotics at 37 °C (DH5α) or 30 °C (Stabl3) overnight.  
DNA preparation 
Bacteria cultures were centrifuged at 3000 g for 10 min at 4 °C. The supernatant 
was discarded and DNA was purified from the pellet with the NucleoBond Plasmid 
kit (miniprep.) or the NucleoBond Xtra Midi EF kit (midiprep.) ac cording to the 
manufacturer’s instructions. The DNA was eluted in 50 µl MilliQ water.  
Control digest 
A control digest with respective restriction enzymes was carried out to verify the 
cloning success. Therefore, restriction enzymes were chosen to achieve a  specific 
digest pattern. 2 µl of the purified DNA were added to 0.5 µl of each enzyme. The 
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digest was carried out in the optimal buffer and temperature conditions for the 
respective enzymes for 1 h. Loading dye was added 1:5 to each sample and 
depending on the length of the DNA fragments, samples were loaded on a 0.7 -2 % 
agarose gel supplemented with 1 µg/ml Ethidiumbromide. The gel was run in SB 
buffer at 250 V for 15 min. Afterwards, the restriction pattern was detected with an 
UV-lamp. 
Sequencing 
To assess the final construct for small deletions, insertions or point mutations, 100 
ng of the purified plasmid were sequenced forward and/or reverse with appropriate 
primers at the GATC Biotech AG (Konstanz).  
3.2.1.2. Real time quantitative PCR (qRT-PCR) 
Quantitative PCR primer design 
For primer design the cDNA sequence of the gene of interest provided by Ensembl 
was used as a template. Primers were designed using the Primer3 web tool 
(http://bioinfo.ut.ee/primer3/) around exon-intron boarders spanning large introns 
(>1000 bp) to avoid the amplification of genomic DNA. Primers were chosen to 
yield a product size of 200-300 bp and an optimal annealing temperature of 60 °C. 
RNA isolation 
To isolate RNA from primary neurons and HEK293 cells the Qiagen RNAeasy Mini 
kit was used according to the manufacturer’s instructions. For patient samples the 
same kit was used with an additional DNAse digestion step as recommended in the 
manufacturer’s instructions to avoid interference of residual genomic DNA. RNA 
samples were stored at -80 °C.  
Reverse transcription RT-PCR 
Depending on the experiment conditions the isolated RNA was diluted with RNAse -
free H2O prior to RT-PCR. The RT-PCR to generate complementary DNA (cDNA) 
was carried out with the TaqMan MicroRNA Reverse Transcription kit with random 
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hexamer primers (N6) according to the manufacturer’s instructions. For C9orf72 
patient experiments, specific RT-PCR primers were used to specifically amplify the 
sense and antisense repeat pre-mRNA/mRNA (see 3.1.9.4). A standard was 
generated by pooling equal amounts from all RNA samples and a dilution series was 
produced by diluting the pool 1:2 and three subsequent 1:10 dilutions. The exact 
composition of the final reaction mix for one RNA sample is depicted in the table 
below. 
Component Amount 
100 mM dNTPs 0.45 µl 
MultiScribeTM Reverse Transcriptase (50 U/µl) 3 µl 
RNase inhibitor 0.56 µl 
10x RT buffer 4.5 µl 
N6 primer (50 ng/µl) 4.5 µl 
diluted RNA 15 µl 
nuclease-free H2O ad 45 µl 
 
The final mix was incubated on ice for 5 min and the standard RT -PCR program 
was set as follows: 
Temperature Time 
16 °C 30 min 
42 °C 30 min 
85 °C 5 min 
4 °C hold 
 
Quantitative PCR 
The qPCR was performed with the SsoFastTM EvaGreen reagent according to the 
manufacturer’s instructions. After RT -PCR the cDNA was diluted 1:5 in nuclease 
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free H2O and 2 µl of each sample were pipetted in triplicates as technical replicates 
to a 384-well plate. Gene specific qPCR primers were added to the SsoFast TM Eva 
Green reagent to a final concentration of 400 nM. 3 µl of the primer mix were 
added per sample. The final reaction mixture for one sample is described below.  
Component Amount 
SsoFast
TM
 EvaGreen 2.5 µl 
Forward primer (400 nM) 0.05 µl 
Reverse primer (400 nM) 0.05 µl 
cDNA template 2 µl 
Nuclease free H2O ad 5 µl 
 
The standard qPCR program was set to a total of 50 cycles as follows:  
Step Temperature Time # of cycles 
Initial denaturation 95 °C 30 s 1 
Denaturation 95 °C 5 s  
50 Annealing + 
extension 
60 °C 5 s 
Extension 95 °C 10 s 
Melt curve 65-95 °C 5 s 1 
 
The relative mRNA expression was calculated with the BioRad CFX manager 
software using the Δ-Δ-Ct method with Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta (YWHAZ or Y1) as a housekeeping gene.  
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3.2.2. Cell culture and lentivirus production 
3.2.2.1. HEK293-FT culture 
Cultivation 
Human embryonic kidney cells (HEK293 cells) were cultivated in DMEM Glutamax 
medium supplemented with 10 % FCS, 1 % P/S and 1 % MEM NEAA (HEK 293 
culture medium) at 37 °C and 5 % CO2. Cells were splitted at 80 % confluency. 
Medium was removed and cells were washed with PBS once. Afterwards the cells 
were detached with 0.05 % Trypsin/EDTA for 1 min at 37 °C. Following, the cells 
were carefully resuspended in fresh medium and plated at the desired amount in cell 
culture dishes or splitted 1:10 for further cultivation.  
Transfection 
For transfection 200,000 cells were seeded in 1 ml HEK293 culture medium per 12-
well. On the next day cells were transfected with lipofectamine 2000 according to 
the manufacturer’s instructions.  
Component Amount per well  
Total DNA 1 µg 
in OptiMEM 0.125 µl 
After 5 min combine with:  
Lipofectamin 2000 2.5 µl 
in OptiMEM 0.125 µl 
 
The final transfection mixture was incubated for 30 min at room temperature. 
Following the incubation, the transfection mixture was added to the cells and cells 
were incubated at 37 °C and 5 % CO2. After 48 h cells were harvested for further 
experiments. 
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Lentivirus production 
To produce lentivirus, a new HEK293 cell batch was freshly thawed and expanded. 
Full confluency was avoided to increase virus titer. One day prior to seeding, cells 
were splitted 1:2. Cells were seeded with a density of 5.5 million cells per 10 cm 
dish. On the following day HEK293 cells were transfected with Lipofectamine 2000 
with three constructs as described below:  
Component Amount per 10cm dish 
LTR vector 18.6 µg 
pSPAX2 11 µg 
pVSVg 6.4 µg 
Total DNA 36 µg 
in OptiMEM 4.5 ml 
After 5 min combine with:  
Lipofectamin 2000 108 µl 
in OptiMEM 4.5 ml 
 
Whereas pVSVg and pSPAX allow for the formation of the virus particle, the LTR 
vector contains the construct of interest. After preparation, the transfection mixture 
was incubated for 20 min at room temperature. In the meantime, medium was  
exchanged to 5 ml prewarmed OptiMEM supplemented with 10 % FCS. Following 
incubation, 3 ml of the transfection mixture were slowly added to each 10 cm dish. 
On the next day medium was exchanged to 10 ml High BSA packaging medium and 
cells were further incubated for 24 h. The virus containing medium was collected 
subsequently and centrifuged at 600 g for 10 min at room temperature. The 
supernatant was filtered through a sterile 0.45 µm PES membrane filter and the 
filtrate was centrifuged at 66,000 g for 2.5  h at 4 °C. Afterwards the supernatant 
was discarded and the virus pellet was resuspended in 120 µl NB medium. The virus 
was stored in aliquots at -80 °C. 
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3.2.2.2. Primary neuron culture 
Preparation of cover slips and cell culture dishes 
Prior to the preparation of primary neuron cover slips and culture dishes were 
pretreated to improve culture conditions. Therefore, 18 mm cover slips were treated 
with 65 % nitric acid for two days to remove lipids. Afterwards they were washed 
four times with MilliQ water and steril ized in an oven at 200 °C for 6 h. Following, 
cover slips were transferred into 12-well culture plates and coated with 1.5  % PDL 
and 0.625 % laminin in 0.1 M borate buffer for at least 4 h. Culture dishes and 
plates without cover slips were coated with 1.5  % PDL in 0.1 M borate buffer for 
the same amount of time. After coating, the culture dishes and plates were washed 
three times with sterile MilliQ water and in a final step fresh NB medium was 
added. Cell culture dishes and plates were kept at 37 °C in 5 % CO2 until plating of 
neurons. 
Preparation of primary neurons 
To prepare primary cortical and hippocampal neurons an embryonic day 18/19 
(E18/19) pregnant Sprague-Dawly rat was sacrificed with CO2 treatment and 
subsequent cervical dislocation. The embryos  were collected from the mother’s 
body and decapitated. Following, the brain was prepared from the embryo heads and 
transferred into a 10 cm cell culture dish containing ice cold HBSS. Afterwards the 
hippocampi and cortices were prepared by microdissection  and collected separately 
in a 10 ml tube with ice cold HBSS. The hippocampi and cortices were washed three 
times with cold HBSS and afterwards hippocampi were incubated in 5 ml HBSS 
containing 150 µl of 2.5 % trypsin for 15 min at 37 °C. Cortices were inc ubated in 5 
ml HBSS containing 500 µl of 2.5 % trypsin and 350 µl DNAse (2,000 U/mg). 
Afterwards, the hippocampi and cortices were washed three times with prewarmed 
HBSS and neurons were dissociated gently by carefully pipetting up and down. The 
cell number was counted with a Neubauer cell counting chamber and 85,000 
hippocampal neurons were seeded in 1 ml NB medium supplemented with 2 % B27, 
1 % penicillin/streptomycin, 0.25 % glutamine, 0.125 % glutamate per 12 -well. For 
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cortical neurons 400,000 cells were seeded in 1 ml NB medium supplemented with  
2 % B27, 1 % penicillin/streptomycin, 0.25 % glutamine per 12 -well. Other cell 
culture dishes were seeded with adapted cell numbers according to the 12 -well 
standard plates. 
Cultivation of primary neurons 
Primary cortical neurons were cultivated in NB medium supplemented with 2 % 
B27, 1 % penicillin/streptomycin, 0.25 % glutamine (cortical neuron medium) and 
hippocampal neurons were cultured in the same medium with additional 0.125 % 
glutamate (hippocampal neuron medium) at 37 °C and 5 % CO2. After 7 days in 
culture or 1 day after transduction 1 ml fresh NB medium with 2 % B27, 1 % 
penicillin/streptomycin, 0.25 % glutamine was added to a 12 -well to feed the cells. 
For other plate formats the volume was adjusted accordingly. 
Transfection of primary neurons 
Prior to the transfection, NB medium containing 1 % penicillin/streptomycin and 
0.25 % glutamine was prepared and prewarmed in a new 12-well plate. The 
transfection mixture was prepared as noted below and incubat ed for 20 min at room 
temperature: 
Component Amount 
Total DNA 1.8 µg 
in NB medium 100 µl 
After 5 min combine with:  
Lipofectamin 2000 3.2 µl 
in NB medium 100 µl 
 
At the end of the incubation period the hippocampal neurons on the glass cover 
slips were dipped once in prewarmed NB medium and transferred into the prepared 
12-well plate. Afterwards, the transfection mixture was added drop wise and the 
neurons were incubated for 45 min at 37 °C and 5 % CO 2. Following the incubation, 
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cover slips were dipped in warm NB medium twice and transferred back into the 
original plate. Neurons were analyzed 3 or 5 days after transfection.  
Transduction of primary neurons 
Primary neurons were transduced on day 6 in vitro (DIV 6). Therefore, 1 µl virus 
was added to a 12-well plate. On the following day 1 ml cortical neuron medium 
was added and cells were incubated for 10 to 17 days until analysis. A 10 cm dish 
cortical neurons was transduced with 10 µl virus and  5 ml cortical neuron medium 
were added the following day. Cells were harvested for IP-Mass spectrometry 
experiments 17 days after transduction.  
3.2.3. Cellular assays 
3.2.3.1. Toxicity assays  
Caspase 3/7 assay 
Caspase-3 activation plays a crucial role in the execution phase of apoptosis and 
therefore measuring Caspase-3 activity with a luminescence based assay can be 
used to determine cell viability in cultured cells. Thus, primary cortical neurons 
were cultured in a white 96-well plate to support maximum luminescence output. 
The assay was performed according to the manufacturer’s instructions. Medium was 
exchanged to 50 µl freshly prepared cortical neuron medium and 50 µl caspase 
activity reagent were added. The plate was shortly mixed at room temperature (400 
rpm, 1 min), followed by an incubation at room temperature for 1 h. Luminescence 
was directly measured using the Microlumat plus 96 V. Relative Caspase 3/7 
activity was calculated through normalization to a  respective control. 1 µM 
Staurosporine treatment for 4 h was used as a positive control.  
LDH activity assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme. Its presence in the cell culture 
media is a marker for cytotoxicity. The LDH toxicity assay detects extracellular 
LDH through an enzymatic reaction producing a red formazan dye that can be 
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measured spectrophotometrically. For detection of cytotoxicity primary cortical 
neurons or HEK293 cells were cultured in 96-well plates. The complete supernatant 
was collected and transferred to a new 96-well plate. Afterwards, the cells were 
frozen at -80 °C for 30 min for cell lysis. 100 µl of fresh culture media were added 
and the cells were thawed at 37 °C for 15 min. After cell resuspension the plate was 
centrifuged at 4 °C and 250 g for 4 min. 50 µl of both supernatants were transferred 
into a new 96-well plate and 50 µl substrate mix were added. Following, the plates 
were incubated for 30 min at room temperature in the dark. To stop the enzymatic 
reaction 50 µl stop solution were added and the emission was measured at 490 nm 
with a plate reader. Subsequent the relative toxicity was calculated by substracting 
the background and then following the formula % toxicity = experimental LDH 
release/maximum LDH release.  The results were normalized to the respective 
control. Staurosporine treatment (1 µM, 4 h) was used as a positive control.  
SRB assay 
Sulforhodamine B (SRB) is a protein binding dye that can be used to determine cell 
density. The assay was set up according to (Vichai and Kirtikara, 2006). Primary 
cortical neurons or HEK293 cells were cultured in a 96 -well plate. For fixation cell 
culture medium was removed and 50 µl of 10 % Trichloricacid (TCA) were added 
followed by incubation on ice for 30 min. Fixed samples were washed with MilliQ 
water three times and dried at room temperature overnight. On the following day, 
cells were stained with 75 µl 0.4 % SRB in 1 % acetic acid for 15 min at room 
temperature. To remove unbound SRB dye, cells were washed repeatedly with 1 % 
acetic acid and the washed plate was dried at room temperature overnight. 200 µl of 
10 mM Tris in MilliQ water were added and the plate was incubated at 200 rpm at 
room temperature until the SRB dye was dissolved completely. Afterwards, the 
absorption was measures with a plate reader at 510 nm. Relative cell viability was 
calculated by normalizing to the respective control. Staurosporine was used as a 
positive control (1 µM, 4 h).  
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TUNEL assay 
Terminal deoxynucleotidyl nick end labeling (TUNEL) is used to detect DNA 
fragmentation that occurs during apoptosis. For the detection of apoptosis, primary 
cortical neurons were cultured in a black 96-well plate and fixed with 50 µl PFA-fix 
solution (15 min, room temperature). Afterwards cells were washed three times with 
PBS and subsequently permeabilized with 50 µl permeabilization/quenching buffer 
on ice for two minutes. Enzyme solution and labeling solution were mixed 1:10 and 
25 µl of the mixture were added per well. The plate was incubated at 37 °C in the 
dark for 1 h. Afterwards, cells were washed again three times with PBS and stained 
with DAPI as a nuclear marker (0.2 mg/ml PBS) for 15 min. After a final washing 
step with PBS, images were acquired automatically in tile scans with the Zeiss LSM 
710 confocal microscope. Image analysis was performed manually with the ImageJ 
cell counter plugin, blinded to the experimental conditions. At least 400 cells were 
counted per condition. Staurosporine was used as a positive control (1 µM, 4 h).  
XTT assay 
The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) assay is used to assess cell viability through the colorimetric reduction of the 
tetrazolium salt XTT by cellular enzymes. For this purpose cortical neurons were 
cultivated in a 96-well plate. According to the manufacturer’s instructions, freshly 
thawed XTT labeling reagent and Electron-coupling reagent were mixed 50:1. 
Following, 50 µl of the mix were added per well and the plate was incubated for 24 
h at 37°C and 5 % CO2. The absorption was measured spectrophotometrically with a 
plate reader at 480 nm and a reference wavelength of 650 nm. Relative cell viability 
was calculated by substraction of A650 from A480 and subsequent normalization to 
the respective control. 1 µM Staurosporine treatment for 4 h was used as a positive 
control. 
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3.2.3.2. Other assays 
Proteasome activity assay 
Proteasome activity was measured by evaluating all three major proteolytic 
activities (Trypsin-like, Chymotrapsin-like and Caspase-like) independently with a 
Luciferase based detection system. HEK293 cells were cultivated in a white 96-well 
plate (PerkinElmer). Prior to cultivation, cells were washed with medium twice 
after trypsination to get rid of remaining trypsin before measuring proteasome. Two 
days after transfection, medium was exchanged to 50 µl medium-reagent mixture 
containing 25 µl fresh medium and 25 µl of the respective Proteasome -Glo cell 
based reagent equilibrated to room temperature. Additionally, a no cell containing 
medium control was prepared. Afterwards, the plate was sealed and incubated at 
room temperature while shaking at 400 rpm for 4 min. The plate was further 
incubated for 30 min at room temperature and luminescence was measured directly 
following incubation using the Microlumat plus 96 V.  Proteasome activity was 
determined via subtraction of the medium control and subsequent sample 
normalization to the experiment control. Epoxomycin (8 µM, 2 h) was used as a 
positive control for impaired proteasome activity.  
3.2.4. Protein biochemistry 
3.2.4.1. Generation and purification of Unc119 rabbit polyclonal antibody  
Antigen purification 
For affinity purification with the corresponding Gluthatione-S-Transferase (GST)-
fusion protein, E.coli  bacteria were transformed with GST-hUnc119 coding vectors 
and bacteria were expanded in 800 ml LB media. Upon an OD600 of 0.6 the culture 
was induced with 1 mM IPTG at 30 °C. Following centrifugation at 600 g for 10 
min at 4 °C the resulting pellet was resuspended in STE buffer. To disrupt the cells 
and extract the antigen, 100 µg/ml lysozyme were added and incubated on ice for 15 
min. Afterwards, 5 mM DTT was added and the lysate was sonicated for 1 min. The 
samples were centrifuged at  10,000  g for 10 min at 4 °C. Following, the supernatant 
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was incubated with 4 ml maltose beads under vigorous shaking for 30 min. The 
beads were washed three times in STE buffer and the antigen was eluted with 
glutathione elution buffer and collected in 1 ml fractions. The protein concentration 
was measured using OD280. Samples from all steps of the purification protocol were 
taken to check purity of the antigen by SDS-PAGE and subsequent Coomassie 
staining. Protease and phosphatase inhibitor were present in all steps of the 
purification. 
Antibody production 
Polyclonal antibodies were generated at Eurogentec SA, Belgium through the 
immunization of rabbits with the GST-tagged antigens. The serum of several large 
bleeds and the final bleed of immunized rabbits was collected and stored at -20°C 
until affinity purification of the antibodies.  
Antibody purification 
For affinity purification of the antibodies glutathione-S-transferase (GST)-fusion 
proteins with the corresponding antigen or GST alone, generated as described 
above, were incubated with 4 ml glutathione beads while shaking for 30 min. 
Afterwards the beads were washed with 0.5 % Triton-X-100 in STE buffer three 
times. Washed beads were transferred into a column and washed another four times 
with conjugation buffer. Subsequent, the beads were  crosslinked to the antigen with 
5 mM BS3. Protease and phosphatase inhibitor were present throughout all steps.  
For negative selection the serum from immunized rabbits was diluted 1:1 with PBS 
and passed over the GST-only column three times. The flow through was collected 
and subsequently passed over the GST-Unc119 fusion protein column thrice.  
Following, beads were washed with column buffer  thrice. Finally, the antibody was 
eluted with glycine elution buffer and collected in 1 ml fractions. Fractions were 
neutralized with 100 µl 1M Tris pH 9.5 and the protein concentration was measured 
using OD280. Samples from all steps of the purification protocol were taken to check 
purity of the antibody by western blotting.  
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3.2.4.2. Immunoblotting 
HEK293 lysate preparation 
HEK293 cells were washed once with PBS and 300 µl RIPA buffer  substituted with 
Protease inhibitor cocktail (1:500) was added to a 12 -well. Following, cells were 
incubated on ice for 20 min. Cells were detached from the well bottom with a 
pipette and transferred into a 1.5 ml tube. Afterwards, cells were incubated ag ain 
for 20 min on ice and subsequent centrifuged at 1,000 g for 10 min. 4x Laem mli 
was added to the lysate to obtain a 1x solution and samples were boiled at 95 °C for 
10 min. Samples were used immediately or stored at -20 °C until further use.  
Neuron lysate preparation 
Primary neuron lysates were prepared by adding 150 µl 2x Laem mli directly to each 
well after washing the cells with PBS once. The lysate was transferred to 1.5 ml 
tubes and boiled at 95 °C for 10 min. Samples were used immediately or stored at -
20 °C until further use.  
SDS-polyacrylamid gel electrophoresis (SDS PAGE) 
To separate proteins according to their molecular weight, lysates were run under 
denaturizing conditions on a discontinuous SDS polyacrylamide gel electrophoresis 
system. Polyacryamide gels consisted of a 12.5 % acrylamide separating gel and a 4 
% stacking gel. The detailed composition is described below. 
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Gel type Composition of a 12.5 % gel  
Stacking gel 6.5 ml H2O  
2.5 ml stacking gel buffer  
1 ml acrylamide 
added for polymerization: 
100 µl 10% APS 
10 µl TEMED 
Separating gel 8.75 ml H2O  
5 ml separating gel buffer  
6.25 ml acrylamide  
added for polymerization:  
200 µl 10% APS 
20 µl TEMED 
 
Gels were loaded with 25 µl lysate and 5 µl of the Seeblue Protein 2 marker and r un 
at 80 V in running buffer for the first 20 min and 130 V afterwards until the dye 
front began running out of the gel.  
Tricine-SDS-Schägger gels 
Ready to use 10-20% Tricine gels were loaded with 20 µl lysate and 5 µl Seeblue 
Protein 2 marker and run at 80 V in cathode buffer for approximately 3 h.  
Immunoblotting and immunodetection of proteins 
Proteins were blotted on an isopropanol activated polyvinylidene difluoride (PVDF) 
membrane in blotting buffer at 400 mA for 75 min. After blotting, membranes were 
blocked in 0.2 % I-Block in TBSTx to saturate all unspecific binding sites for at 
least 1 h. Primary antibody diluted in 0.2 % I-Block in TBSTx was added and the 
membranes were incubated at 200 rpm and 4 °C overnight. On the following day, 
membranes were washed in TBSTx every ten minutes for approximately 1 h. 
Afterwards, a HRP coupled secondary antibody diluted 1:1000 in 0.2 % I-Block in 
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TBSTx was added and the membrane was incubated at 200 rpm and room 
temperature for 1 h.  
3.2.4.3. Filter trap 
Cultured cells 
For filter trap assays primary cortical neurons or HEK293 cells were cultured in 12 -
well plates. Medium was removed and cells were washed with PBS once. Following 
cells were harvested in 600 µl 1 % Triton-X-100 in PBS substituted with DNAse 
(0.2 mg/ml) and 50 mM MgCl2. The lysate was centrifuged at 18,000 g for 30 min  
(4 °C). Afterwards, the supernatant was discarded and the pellet was dissolved in 
200 µl 2 % SDS in 100 mM Tris pH 7 and incubated for 1 h at room temperature. 
After incubation, the mixture was diluted 1:5 three times and filtered through a 0.2 
µm cellulose acetate membrane. The membrane was blocked in 0.2 % I-Block in 
TBSTx for 1 h. Following, primary antibody was added and the membrane was 
incubated at 4 °C and 200 rpm overnight. The following steps were performed as 
described in immunodetection of proteins.  
Patient material 
The brain samples were homogenized in RIPA buffer containing 0.2 mg/ml DNAse. 
After centrifugation at 4 °C and 186,000 g for 30 min, the pellet was resuspended in 
1 % SDS in 100 mM Tris pH 7. The following steps were performed as described 
above for cultured cells.  
3.2.4.4. Immunoprecipitation of poly-GA aggregates 
IP from HEK293 cells 
HEK293 cells were harvested two days after transfection from a 10 cm dish in 1 ml 
RIPA buffer substituted with 0.2 mg/ml DNAse I and 10 µl Protease Inhibitor 
cocktail. Afterwards, samples were rotated at 4 °C for 30 min and centrifuged at 
1,000 g for 15 min. Meanwhile, 5 µg GFP antibody (Neuromab) were pre-incubated 
with 25 µl Protein G Dynabeads for 1 h at 4 °C. After centrifugation 2 % of the 
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supernatant were kept as input control and the rest was mixed with the beads and 
rotated at 4 °C for 3 h. Following, the beads were washed with basic buffer thrice. 
Protein was released from the beads by boiling in  25 µl 4x Laemmli at 95 °C for 10 
min. The Laemmli-mix was then diluted 1:1 with MilliQ water and 25 µl of each 
sample were used for immunoblotting.  
Neuron IP for Mass spectrometry 
Primary cortical neurons were harvested from 10 cm dishes after 17 days in vitro in 
1 ml RIPA buffer substituted with 67 U/ml Benzonase and 10 µl Protease Inhibitor 
cocktail. Following, samples were rotated at 4 °C for 30 min and centrifuged at 
1,000 g for 15 min. In the meantime, 50 µl Protein G Dynabeads were incubated 
with 10 µg GFP antibody for 1 h at 4 °C. 2 % of the sample supernatant were kept 
as input control and the rest was added to the pre-incubated dynabeads. The mix 
was rotated at 4 °C for 3 h. Afterwards, the beads were washed with 1 ml basic 
buffer thrice. 1/5 of the beads was kept for immunoblotting and protein was 
released from the beads by boiling at 95 °C in 20 µl 4x Laemmli for 10 min. The 
rest of the sample was further processed for mass spectrometry analysis.  
3.2.4.5. Mass spectrometry (in collaboration with Daniel Hornburg) 
Sample preparation 
The bead-mix from the neuron-IP was resuspended in 50 μl 8 M Urea, 10 mM Hepes 
pH 8.0. The protein cysteines were reduced with DTT and alkylated with 
iodoacetamide (IAA), followed by quenching of IAA with thiourea. Proteins were 
digested with LysC for 4 h and the bead-mix was centrifuged for 5 min at 16,000g. 
The supernatant was removed and diluted with 4 volumes of 50 mM ammonium 
bicarbonate. The pellet was resuspended in 1 volume 6 M urea, 2 M thiourea, 10 
mM Hepes pH 8.0, 4 volumes 50 mM ammonium bicarbonate. For overnight 
digestion LysC and Trypsin were added and the digest was carried out for 16 h. The 
resulting peptide mix was desalted on C18 StageTips and analyzed in single shots.  
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LC-MS/MS 
Peptides were separated on a Thermo Scientific EASY-nLC 1000 HPLC system with 
in-house packed columns (75 μm inner diameter, 20 cm length, 1.9 μm C18 
particles) in a 100 min gradient from 2 % acetonitrile, 0.5 % formic acid to 80 % 
acetonitrile, 0.5 % formic acid at 400 nl/min. The column temperature was set to 50 
°C. An Orbitrap mass spectrometer was directly coupled to the LC thr ough a nano 
electrospray source. The Orbitrap Elite was operated in a data -dependent mode. The 
survey scan range was set from 300 to 1,650 m/z, with a resolution of 120,000. Up 
to five of the most abundant isotope patterns with a charge ≥2 were subjected to 
collision-induced dissociation fragmentation at a normalized collision energy of 35, 
an isolation window of 2 Th and a resolution of 15,000 at m/z 200. Data was 
acquired with the Xcalibur software.  
Data analysis 
The MS raw files, were processed with the MaxQuant software (v 1.4.0.4) and 
Andromeda search engine ,  against the UniProtKB Rat FASTA database (06/2012) 
using default settings. Enzyme specificity was set to trypsin allowing cleavage N -
terminally to proline and up to 2 miscleavages. Carbamidomethylation was set as 
fixed modification. Acetylation (N-terminus) and methionine oxidation were set as 
variable modifications. A false discovery rate (FDR) cutoff of 1 % was applied at 
the peptide and protein level. ‘Match between runs’, allowing the transfer of 
peptide identifications in the absence of sequencing, was enabled with a maximum 
retention time window of 1 min. For protein identification at least one razor peptide 
was required and data were filtered for common contaminants ( n = 247). Peptides 
only identified by site modification were excluded from further a nalysis. A 
minimum of two valid quantifications was required in either GA 149-GFP or GFP 
quadruplicates. The PERSEUS environment (Maxquant/R-framework) was used for 
bioinformatics analysis and visualization. Imputation of missing values was 
performed with a normal distribution (width = 0.3; shift = 1.8). For pairwise 
comparison of proteomes and determination of significant differences in protein 
abundances, t-test statistics were applied with a permutation -based FDR of 2 % and 
Materials and Methods 
 
 
86 
 
S0 of 2. For poly-GA-aggregate interacting proteins 1D annotation enrichment on 
the Welch-test difference using Uniprot Keywords with a Benjamini–Hochberg 
corrected FDR of 2 % was applied.  
3.2.5. Immunofluorescence 
Standard Immunostaining 
Cells on cover slips were fixed with 500 µl PFA-fix for 15 min at room 
temperature. Cells in black 96-well plates were fixed with 50 µl PFA-fix and also 
incubated for 15 min at room temperature. Afterwards cells were washed with PBS 
three times. Meanwhile the primary antibody solution was prepared. Therefore 2 x 
GDB buffer was mixed with equal amounts of MilliQ water and the primary 
antibodies were added. For each cover slip, 50 µl of the solution were placed on a 
parafilm in a wetchamber. The cover slips were dipped in MilliQ water once and 
carefully placed onto the antibody solution with the cell side down. Following , the 
cover slips were incubated overnight at 4 °C in the dark. On the next day cover 
slips were transferred back into a 12-well plate and washed with PBS thrice. The 
secondary antibody dilution was prepared by mixing 2x GDB buffer with Mil liQ 
water as described above and the Alexa-tagged secondary antibodies were added 
1:400 to the mix. 50 µl of the final mix were again placed on a parafilm in a 
wetchamber and the coverslip was placed on top. Incuba tion was carried out in the 
dark for 1 h at room temperature. Following the incubation , the cover slips were 
again transferred into a 12-well plate and washed once. Afterwards 1 ml PBS 
containing the nuclear marker DAPI (1:5000) was added and cells were in cubated in 
the dark at room temperature for 15 min. Following, cells were washed with PBS 
twice and mounted on a glass slide with a drop of vectashield mounting medium. 
Finally, cover slips were fixated on the glass slide with clear nail polish.  
Immunostaining of TDP-43 
For TDP-43 immunostaining, cells grown on cover slips were fixed with 500 µl 
PFA-fix at room temperature for 15 minutes. Afterwards cells were washed with 
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PBS twice. To permeabilize the nucleus, cells were incubated in 500 µl 
permeabilisation/quenching buffer (0.2 % Triton-X-100, 50 mM NH4Cl in PBS) on 
ice for 2 min. Next, cells were washed with PBS twice and incubated in 50 µl 
blocking buffer in a wetchamber on a parafilm at room temperature for 1 h in the 
dark. Cover slips were transferred to a fresh parafilm with 50 µl primary antibody 
dilution (blocking buffer diluted 1:10 in MilliQ water containing primary antibody , 
(Cosmo TDP-43)) and incubated at room temperature for 1 h in a wetchamber in the 
dark. Subsequently, cover slips were transferred back into the 12-well plate and 
washed with PBS thrice. The secondary antibody dilution was prepared adding 
Alexa-tagged antibodies 1:400 to the 1:10 dilution of blocking buffer in MilliQ 
water. 50 µl of the mix were pipetted on a parafilm and the cover slips were added 
on top and incubated in a wetchamber for 1 h at room temperature. The following 
steps were conducted as described in standard immunostaining.  
Immunostaining of patient material (in collaboration with Martin Schludi) 
Before staining, patient tissue slides were deparafinized. Therefore slides were 
quickly rinsed with xylol 10x. Afterwards 10x rinsing was repeated with 100 % 
ethanol twice, followed by 96 % ethanol once and 70 % ethanol washing steps twice 
and kept in MilliQ water afterwards. For antigen retrieval slides were incubated in 
citrate buffer in the microwave at 750 W for 4 min. This procedure was repeated 4 
times. Afterwards, slides were washed with Brij washing buffer for 5 min twice. 
Slides were blocked with 2 % FCS in PBS for 5 min. Primary antibodies  were 
diluted in blocking buffer (Anti -GA and Unc119 #1 1:1000) and slides were 
incubated at 4 °C overnight. Following, the slides were washed with Brij washing 
buffer twice. Secondary antibody solutions with Alexa antibodies were prepared 
1:500 in blocking buffer and slides were incubated for one hour in the dark.  Slides 
were washed in Brij washing buffer twice and subsequent stained with DAPI, 
diluted 1:5000 in Brij washing buffer, for 20 min in the dark. To reduce background 
and autofluorescence slides were also briefly incubated with Sudan black for 30 sec. 
Slides were washed again twice. Afterwards, a third washing step was conducted 
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with MilliQ water for 5 minutes. Slides were mounted with mounting media and 
fixed with clear nail polish. 
Image acquisition 
Images were acquired using the Zeiss LSM 710 confocal microscope and the Zeiss 
ZEN 2010 software. Depending on the experiment, either the 20x, 40x, or 63x 
objectives, as specified in the material sections, were used. The pinh ole was set to 1 
Airy unit for the longest wavelength and maintained for all others. For the filter 
setting and excitation/emission spectra the preset software adjustments for the 
specific dyes were used. To be in a linear range and to avoid oversaturation  of 
pixels, laser intensity and detector gain were set accordingly. To achieve an optimal 
resolution in z-direction, the distance between two adjacent confocal planes of a z -
stack was set that every pixel was covered by two confocal planes. Images were 
acquired in a x-y-resolution of at least 1024x1024 pixels and the scanning speed 
was chosen according to the experiment purpose. For quantitative and semi 
quantitative measurements all settings were maintained for every image of the 
respective experiment. 
Image analysis 
All images were analyzed blinded to the experimental conditions. For cell 
countings, images were analyzed with the Fiji cell counter plugin and at least 200 
cells were counted per conditions. For exact numbers see corresponding figure 
legends. For neuron morphology analysis, maximum intensity projections Sholl 
analysis was performed with the MetaMorph software.  
3.2.6. Statistical analysis 
All statistical analyzes were performed with the GraphPad Prism software. 
Depending on the data set, t-test, one-Way-ANOVA or two-way-ANOVA with 
appropriate post-tests was conducted. All morphological analyzes and 
quantifications were performed blinded to the experimental conditions. Statistical 
significance was set as follows. * p < 0.05; ** p < 0.01; *** p < 0.001  
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4. Results 
4.1. Expanded repeat RNA is stabilized in C9orf72 mutation carriers  
The initial discovery of non-ATG translation of the intronic C9orf72 hexanucleotide 
repeat expansion mutation raised questions about the inter-connection and relative 
role of the proposed pathomechanisms. For instance, how can the expanded repeat 
be translated, if the expression of the mutant allele is reduced? To what extend is 
the transcript of the repeat-containing intron expressed, compared to non-repeat 
carriers? Is the antisense strand also transcribed and translated into the additional 
DPR species poly-PA, poly-PR and more poly-GP in patients?  
To address these questions, I performed RT-qPCR analysis from the cerebellum of 
three C9orf72 mutation carriers aged 41 to 65 and 6 aged matched controls that 
showed ALS or FTD pathology, but did not carry a C9orf72 mutation. In the RT-
qPCR, I used specific primer sets for both sense and antisense transcripts and 
intron-spanning primers amplifying exon 2 to 3 of C9orf72 to detect all isoforms as 
well as primers spanning intron 1b to 2 amplifying only transcripts lacking the 
repeat (Figure 7A and compare Figure 5).  
The total expression of C9orf72, normalized to the housekeeping gene YWHAZ, is 
downregulated by about 50 % in mutation carriers, compared to controls (Figure 
7B). This observation is in line with the findings of other groups, investigating the 
expression of C9orf72 in mutation carriers (DeJesus-Hernandez et al., 2011; Renton 
et al., 2011). Using strand-specific reverse transcription with either sense or 
antisense primers followed by qPCR analysis (Figure 7A), I investigated the 
expression of both transcripts. The expression levels were normalized to sense 
transcripts levels in control patients and PCR products were sequence verified. 
Strikingly, the expression of the repeat expansion transcripts, sense as well as  
antisense, is increased about 8-fold compared to control patients (Figure 7C), 
suggesting a stabilization of the containing repeat RNA species and first 
establishing the presence of the antisense transcript in C9orf72 mutation carriers.  
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This data may reconcile C9orf72 haploinsufficiency with RNA and protein toxicity 
and was the first step in the discovery of antisense derived DPR species (Mori et 
al., 2013c). 
 
Figure 7: C9orf72 transcripts are differentially expressed in mutation carriers. 
(A) C9orf72 genomic structure and primer settings for the RT/qPCR experiment. (B) Mature C9orf72 mRNA levels 
are downregulated in the cerebellum of mutation carriers compared to control. Intron-spanning primers amplifying 
exon 2 to 3 detect all isoforms, whereas primers amplifying exon 1b to 2 detect the isoform lacking the repeat 
sequence. Data represent mean ± SEM; # = p < 0,058. (C) C9orf72 sense and antisense transcript of the C9orf72 are 
transcribed to a higher extend in mutation carriers compared to controls. Mean ± SEM; * = p < 0,05 One-way-
ANOVA with Bonferoni correction; N=3 for cerebellum from C9orf72 mutation carriers and N=6 for cerebellum 
from controls. 
4.2. A cell culture model for DPR protein expression 
4.2.1. DPR expression system  
To address the role of DPR proteins in C9orf72  FTD/ALS, I established a cell 
culture expression system. Even though the existence of DPR proteins in C9orf72  
mutation carriers is now widely accepted (Ash et al., 2013; Mori et al., 2013c; Zu et 
al., 2013), the contribution of DPR proteins to the development of C9orf72  FTD and 
ALS is still an open question. Thus, one of my major aims was to decipher the 
individual characteristics of the different DPR species and their contri bution to 
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disease development. Here, I used ATG-initiated epitope-tagged expression 
constructs for all possible reading frames of the G 4C2 hexanucleotide repeat (Figure 
8). The synthetic constructs encode 149 to 175 repeats of the distinct dipeptides. A 
mixture of alternative codons helped to prevent genomic repeat instability in E. coli 
observed with the GGGGCC repeats and a good expression in mammalian cell 
culture systems was achieved. Furthermore, the lack of a GGGGCC repeat allows to 
largely exclude RNA based toxicity and to focus on protein-based toxicity in my 
experiments. The poly-GP construct gene synthesis, however, failed repeatedly. 
Therefore, an ATG-initiated construct from the endogenous repeat sequence with 
about 80 GP repeats was designed (Figure 8).  
 
Figure 8: Schematic illustration of the DPR constructs used in this thesis. 
For all possible reading frames almost GGGGCC-free synthetic genes were designed with an ATG start codon. For 
the poly-GR constructs, the GFP-Tag position had to be changed because GR149-GFP was not expressed, whereas 
GFP-GR149 could be expressed nicely. The poly-GP synthetic gene construct could not be synthesized despite 
several attempts, therefore the original GGGGCC repeat was used for the construct design. For analysis of repeat 
sequence toxicity apart from protein toxicity non-ATG versions with the original repeat sequence from 7-145 
repeats were designed. To further exclude toxicity of the synthetic gene RNA, a TAG-GA149 construct was prepared. 
To additionally analyze, if the original repeat sequence induces RNA toxicity in a 
cell culture system, I used constructs containing 7 to 145 repeats of the original 
repeat sequence without an ATG start codon (Figure 8). A GFP or empty vector was 
used as a control in all experiments (Figure 8).  
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In summary, I could establish an expression system for all DPR proteins to further 
analyze their characteristics in cell culture systems.  
4.2.2. Poly-GA forms p62-positive inclusions in HEK293 cells 
All five DPR species co-aggregate into mainly cytosolic and p62-positive star-
shaped inclusions in patients (Mori et al., 2013a; Mori et al., 2013c) . To analyze the 
expression of the individual DPR proteins and their aggregation pattern in cell 
culture, HEK293 cells were transfected with GA175-GFP, GFP-GR149, GP80-V5, 
PA175-myc, PR175-GFP or GFP as a control.  
 
Figure 9: DPR proteins aggregate differently in HEK293 cells. 
HEK293 cells were transfected with GA175-GFP, GFP-GR149, GP80-V5, PR175-GFP, PA175-myc as well as a GFP, V5 
tag or myc-control. Two days after transfection, cells were analyzed by GFP fluorescence, V5 or myc antibody in 
the case of GP80-V5 and PA175-myc. DAPI was used as a nuclear marker. Only GA175-GFP transfected cells show 
cytosolic aggregates that are p62-positive. GFP-GR149 mainly shows nuclear aggregates and no aggregation could be 
detected for GP80-V5. Since the AP175-GFP construct also produced free GFP, the tag had to be changed to a myc-
tag for proper analysis. PR175-GFP mainly showed nuclear aggregates, whereas no aggregation could be detected for 
PA175-myc. White arrows indicate cytosolic aggregates and magenta arrows nuclear aggregates. Bottom panels 
show close-ups indicated in the merge column. Scale bars depict 15 µm in overviews and 5 µm in close-ups. 
Immunofluorescence of GFP was analyzed 2 days after transfection. Whereas poly-
GA forms cytosolic inclusions, positive for the proteasomal marker p62, poly-GR 
and poly-PR mainly show large nuclear aggregates and no co-staining with p62 
Results 
 
 
93 
 
(Figure 9). Poly-GP and poly-PA were distributed throughout the whole cell and  no 
aggregates could be detected. Moreover, no p62 co-localization could be observed 
for poly-PA and only a few poly-GP expressing cells showed co-localization with 
p62 (Figure 9).  
In addition to p62-positive cytosolic inclusions, small nuclear aggregates of poly-
GA are present in patients (Mackenzie et al., 2013). In my HEK293 cell culture 
model, these aggregates could also be seen in a low frequency. However, not all 
nuclear aggregates were found to be p62-positive (Figure 10). 
Thus, poly-GA is the only of the five DPR proteins that shows a typical aggregation 
pattern comparable to patients in HEK293 cells.  
 
Figure 10: Poly-GA additionally forms less common nuclear aggregates. 
HEK293 cells transfected with GA175-GFP for three days. A part of nuclear poly-GA aggregates is p62-positive. 
Magenta arrows mark p62-positive and white arrows p62-negative nuclear aggregates. Scale bar = 5 µm  
4.2.3. Biochemical properties of DPR proteins differ in HEK293 cells 
Following, immunostaining of the DPR proteins, running behavior and expression 
levels of the different proteins were evaluated. GA175-GFP, GFP-GR149 and PR175-
GFP could be detected at the top of the gel, whereas PA175-myc ran on a higher 
molecular weight than expected, suggesting the formation of higher molecular 
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weight species. Only GP80-V5 could be detected at the expected height of 20 kDa 
(Figure 11A).  
 
Figure 11: DPR proteins show differential biochemical properties. 
HEK293 cells were transfected with GA175-GFP, GFP-GR149, GP80-V5, PA175-myc, PR175-GFP or GFP as a control. 
After 2 days cells were harvested for immunoblotting or filter trap analysis. (A) Immunoblotting with indicated 
antibodies shows expression of DPR proteins and GFP control. GA175-GFP, GFP-GR149, PA175-myc and PR175-GFP 
are detected at the top of the gel (arrow), whereas GP80-V5 runs at its expected height of 20 kDa. P62 levels are only 
elevated in GA175-GFP transfected cells. (B) Filter trap assay for insoluble proteins. Only GA175-GFP and GFP-
GR149 form insoluble aggregates. Immunoblotting was carried out with a GFP antibody. Immunoblotting with anti-
V5 for poly-GP or anti-myc for poly-PA showed no insoluble aggregates (Data not shown). 
To analyze the solubility of the different proteins, a filter trap assay was performed. 
Only GA175-GFP and GFP-GR149 were insoluble in 2 % SDS and could be detected 
on the filter, thereby exhibiting the same features as the patient aggregates ( Figure 
11B). 
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4.3. DPR proteins are not toxic in HEK293 cells 
The key question is, if and how the DPR proteins contribute to disease 
pathophysiology in C9orf72  cases. Therefore, the next step was to analyze toxicity 
of all five DPR proteins in the HEK293 cell culture system. For detecting dead 
cells, I performed an LDH assay. LDH is an intracellular enzyme that is only 
released upon cell death. The amount of LDH in the media is measured through the 
conversion of a colorimetric substrate. After three days of transfection with the 
different DPR proteins no toxicity was observed (Figure 12A). Staurosporine, which 
was used as a positive control, however, showed a marked reduction in cell viability 
of 20 % after 4 h treatment with 1 µM Staurosporine and a 95 % reduction after 24 
h treatment. 
 
Figure 12: DPR proteins and RNA are not toxic in HEK293 cells. 
HEK293 cells were transfected with the DPR protein constructs (GA175-GFP, GFP-GR149, GP80-V5, PR175-GFP, 
PA175-myc) or GGGGCC-repeat expressing constructs in various length for 3 days. (A) LDH release assay detects 
no significant toxic effect upon DPR expression compared to GFP control in HEK293 cells. Treatment with 1 μM 
Staurosporine was used as a positive control. n=3 experiments with 10 replicates each; mean ± SD, *** p<0.001 in 
one-way ANOVA with Dunett’s post-test. (B) Cell viability of HEK293 cells transfected with GGGGCC-repeat 
expressing constructs of increasing length (lacking an ATG start codon) was measured by XTT assay on day 3. No 
significant toxicity compared to an empty vector control (Ctrl) was observed (one-way ANOVA, Dunett’s post-test). 
Since the synthetic constructs showed no toxicity, I checked whether  constructs 
with the original repeat sequence of C9orf72 in various lengths without an ATG 
start codon show toxicity(Figure 8). However, no toxicity could be detected in the 
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tetrazolium dye based XTT assay measuring mitochondrial activity after 3 days of 
transfection in the HEK293 cell culture system (Figure 12B). 
4.4. Poly-GR and poly-PR decrease proliferation of HEK293 cells 
During my previous experiments I noticed, that although poly-GR and poly-PR did 
not show an effect on cell viability, there appeared to be fewer cells than in control 
conditions. Therefore, I used a XTT assay to investigate if poly-GR and poly-PR 
influence proliferation. Notably, after three days of transfection, poly-GR 
significantly reduced the number of cells to 80 % and poly-PR to 87 % compared to 
the GFP control (Figure 13A). 
 
Figure 13: Poly-GR and poly-PR decrease proliferation in HEK293 cells. 
HEK283 cells were transfected with GA175-GFP, GFP-GR149, GP80-V5, PR175-GFP, PA175-myc or GFP as a control 
for three days. (A) XTT proliferation assay detects a significant decreased in proliferation in poly-GR and poly-PR 
expressing cells. N=3 with 10 replicates each. Mean ± SD are depicted. *p<0,05; ***p<0.001 in a one-way ANOVA 
with Dunetts post test. (B) Growth curves of DPR protein expressing HEK293 cells measured by SRB assay. 
Compared to GFP control poly-GR and poly-PR expressing cells grow significantly slower over time. Timepoints 
depicted are 0 h, 4 h, 8 h, 12 h, 24 h, 48 h, 72 h. N=3 with 10 replicates each. Mean ± SD are depicted. **p<0,01; 
***p<0.001 in a two-way ANOVA. 
To further corroborate, if the effect is really based on decreased proliferation and 
not on additional toxicity, I conducted a time-course series in a Sulforhodamine B 
(SRB) assay, analyzing cell number 0, 8, 12, 24, 48 and 72 hours after transfection 
with all five DPR proteins and GFP as a control. The SRB assay is based on total 
protein content and therefore is an additional approach to investigate cell number 
after DPR construct transfection. The proliferation over  time clearly showed that 
cells transfected with poly-GR and poly-PR did not proliferate as fast as GFP 
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control cells and the other DPR expressing cells. 72 h after transfection 50 % less 
poly-GR expressing cells and 40 % less poly-PR expressing cells were present, 
compared to GFP control cells (Figure 13B). The other DPR proteins poly-GA, 
poly-GP and poly-PA had no significant effect on HEK293 cell proliferation.  
In summary, HEK293 cells recapitulate some important features of the patient 
situation, however, cell death cannot be observed in this model. Since DPR proteins 
in patients are mostly expressed in quiescent neurons that probably cannot be 
compared with immortalized cell lines , I established a lentiviral DPR expression 
system in primary rat neurons for further investigations. 
4.5. Lentiviral poly-GA expression system in primary neurons 
4.5.1. Lentiviral poly-GA expression in primary neurons is comparable to 
patient levels 
As poly-GA expression in HEK293 cells  resembled the patient situation most, I first 
focused my investigations on poly-GA in primary neurons. To verify if the 
lentiviral expression system is comparable to the aggregate load detected in 
patients, I used primary cortical neurons, transduced with GA149-myc (DIV 6+15) 
and a thin smear of frontal cortex tissue from a C9orf72 patient (Figure 14A) to 
allow identical fixation and staining conditions .  
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Figure 14: Expression levels of lentiviral poly-GA in neuronal culture are comparable to levels in C9orf72 
patients. 
Primary cortical neurons (DIV 6+15) transduced with GA149-myc or a thin smear of cortical tissue from a C9orf72 
patient were immunostained under identical conditions with poly-GA antibody. DAPI was used as a nuclear marker. 
(A) Scale bar depicts 20 µM. The in vitro system shows more poly-GA-positive cells compared to the patient 
sample. (B) The size of the individual poly-GA aggregates is comparable in patient sample and lentiviral system, 
whereas the intensity of the poly-GA staining is over two-fold higher in patient material. Poly-GA area and intensity 
was manually quantified with the imageJ software for 50 inclusions in each condition. Mean ± SD; student-t-test; 
***p<0,001. 
Following poly-GA immunostaining, I compared fluorescence intensity and 
inclusion size. Whereas transduced primary neurons, showed more cells with poly-
GA aggregates, aggregate size was comparable with the patient material ( Figure 
14B). In contrast, the poly-GA fluorescence intensity was 2.5-fold higher in patient 
material compared to neurons (Figure 14C). 
Thus, the lentiviral expression model may even slightly underestimate the patient 
situation and therefore is a valid tool to investigate the effect of poly-GA 
expression in neurons. 
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4.5.2. Poly-GA forms insoluble p62-positive aggregates in primary neurons 
Subsequently, I analyzed whether poly-GA also forms the typical p62-positive 
aggregates seen in patients in the neuron system. Therefore, GA149-GFP  was 
expressed lentivirally in primary hippocampal neurons (DIV 6+15). 
Immunofluorescence depicted compact p62-positive inclusions that were most 
common in the cell soma, but were also present in the dendrites (Figure 15). 
 
Figure 15: Poly-GA forms p62-positive aggregates in primary neuron culture. 
Primary hippocampal neurons were transduced at day 6 in vitro with GA149-GFP or GFP as a control. After 15 days 
in culture, immunostaining for p62 and MAP2 was performed. DAPI was used as a nuclear marker. P62-positive 
inclusions are formed in cytosol and dendrites (white arrow). Scale bar = 15 µM. 
In western blots of lentivirally transduced primary cortical rat neurons with GA 149-
myc or GFP as a control, all poly-GA was detected at the top of the gel, indicating 
higher molecular weight aggregates (Figure 16A). Consistent with the HEK293 cell 
results, p62 levels were increased in neurons infected with poly-GA lentivirus 
compared to control cells (Figure 16A). Protein levels of the synaptic marker PSD-
95 and the housekeeping protein β -actin remained unchanged (Figure 16A). 
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Figure 16: Neuronal p62-positive poly-GA aggregates are insoluble. 
Primary cortical neurons transduced with GA149-myc or GFP as a control on day 6 were incubated for 17 days. (A) 
Immunoblotting with indicated antibodies. Poly-GA is detected at the top of the Gel and p62 levels are increased in 
GA149-myc expressing neurons. PSD-95 and β-Actin levels remain unchanged. (B) Insoluble aggregates of poly-GA 
can be detected in the filter trap assay with 2 % SDS concentration. 
To further elucidate solubility of poly-GA aggregates in neurons a filter trap assay 
was performed, indicating the formation of 2 % SDS-resistant poly-GA aggregates 
(Figure 16B). 
4.6. Poly-GA aggregates cause dendrite loss and toxicity in primary 
neurons 
4.6.1. Neuron morphology is impaired in poly-GA expressing cells 
Upon poly-GA transduction, I noticed a reduced density of surviving neurons and 
neurites, visualized by MAP2 staining, seemed to be less complex (Figure 15). To 
quantify the effect of poly-GA on neuron morphology, I used Sholl analysis which 
measures neuron complexity by counting the number of dendrites crossing 
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concentric circles around the cell . Upon transfection of primary cortical neurons 
(DIV 7+4) with GA149-myc or an empty vector control, together with GFP to 
visualize neuron morphology, poly-GA expressing neurons showed less and shorter 
dendrites than the control (Figure 17A).  
 
Figure 17: Poly-GA causes dendrite loss in primary neurons. 
Cortical neurons were transfected with empty vector or GA149-myc and GFP to visualize the morphology of the 
neurons (DIV 7+4). (A) Poly-GA neurons show reduced dendrite number and branching. Scale bar = 40 µm (B) 
Sholl analysis was performed to measure dendrite complexity by manually counting the number of dendrites 
crossing concentric circles around the cell body. Poly-GA expression leads to decreased dendrite complexity. N = 3 
with 40 neurons counted in each experiment. Mean ± SEM, p<0.001 for 12.5 µm radius, p<0.0001 for 25 to 50 µm 
radius, p<0.001 for 62.5 µm radius, p<0.01 for 75 µm radius and p<0.05 from 87.5 to 112.5 µm radius (two-way 
ANOVA). 
Sholl analysis revealed a dramatic loss of neuron complexity in poly-GA expressing 
neurons based on Two-way ANOVA (Figure 17B). These results raised the 
question, if poly-GA not only influences morphology but is in general toxic to 
neurons. 
4.6.2. Poly-GA induces apoptosis in primary neurons 
To comprehensively investigate, if poly-GA induces toxicity in primary rat neurons, 
I carried out four different toxicity assays, based on different cellular features. 
Whereas TUNEL and Caspase 3/7 activity assay both measure the induction of 
apoptosis, XTT and SRB assay are a general measure for cell density. TUNEL 
staining detects DNA double strand breaks, occurring in  apoptotic cells. Compared 
to empty vector transduced control cells (DIV 6+17), primary rat hippocampal 
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neurons transduced with GA149-myc show an increased number of apoptotic cells 
(Figure 18A).  
 
Figure 18: Poly-GA expression induces apoptosis in neurons. 
Primary cortical neurons were infected with GA149-myc or a control (DIV 6+17). (A) TUNEL assay reveals 
apoptotic DNA fragmentation. Co-staining for poly-GA and nuclei. GA149-myc transduces neurons show ~2.5 fold 
increased apoptosis (arrow). (B) Apoptosis in transduced neurons was analyzed using a fluorogenic assay to detect 
caspase 3/7 activation and a TUNEL assay to detect apoptotic DNA fragmentation (DIV 6+17). Caspase 3/7 activity 
was increased 2.0-fold in GA149-myc transduced cortical neurons. TUNEL-positive apoptotic cells (manually 
counted using the Fiji cell count plug-in) were increased by 2.5-fold in GA149-myc transduced hippocampal neurons 
compared to control cells. n = 3 experiments with 6 replicates each; mean ± SD, Student’s t-test ***p<0,001. (C) 
XTT assay provides additional evidence for toxicity of GA149-myc. Cell viability is significantly decreased by 25 %. 
N=3 with 6 replicates each; mean ± SD, Student’s t-test ***p<0,001. (D) SRB whole protein assay detects a 20 % 
reduced cell viability of poly-GA expressing cells compared to GFP control cells. N=3 with 6 replicates each; mean 
± SD, Student’s t-test ***p<0,001.  
The quantification showed a 2.5-fold increase in apoptotic neurons, compared to 
control cells (Figure 18B). The additional Caspase-3/7 activity assay further 
confirmed this finding after lentivirus transduction of primary rat cortical neurons 
with either GA149-myc or GFP control. Here, a 2-fold increase in Caspase 3/7 
activity, two crucial enzymes in the apoptosis cascade, could be measured. As a 
further proof for poly-GA toxicity, I could detect a significant decrease in cell 
viability by an XTT assay. Upon infection of primary cortical rat neurons with 
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GA149-myc or GFP control lentivirus (DIV 6+17), I measured a reduction in cell 
viability of 20 % in poly-GA expressing neurons, compared to control neurons  
(Figure 18C). Additionally, a SRB assay, performed with primary cortical neurons 
transduced with either GA149-myc or GFP (DIV 6+17), confirmed this result as 
poly-GA expression decreased viability to 82 % (Figure 18C). 
Thus, poly-GA expression induces apoptosis in primary rat neurons . 
4.6.3. Toxicity of poly-GA expression in primary rat neurons is protein 
dependent 
Following the discovery of the toxicity in neurons, I was interested in whether the 
occurring toxicity is indeed an effect of the poly-GA protein alone or if the RNA, 
although not the original GGGGCC repeat sequence, may contribute to toxicity. To 
this end, I used a construct, where the poly-GA start codon was replaced with a stop 
codon (TAG-GA149) to abolish translation of poly-GA (Figure 8). 
To demonstrate that the TAG-GA149 does not produce any poly-GA protein, I 
lentivirally transduced primary cortical neurons with TAG -GA149, ATG-GA149 or 
GFP as a control.  
 
Figure 19: Poly-GA toxicity is protein dependent. 
Primary cortical neurons transduced with ATG-GA149-myc, TAG-GA149-myc or GFP as a control. (A) 
Immunoblots of cortical neurons transduced with GA149-myc constructs with or without start codon (DIV 8+10). 
Replacing the ATG start codon in the synthetic GA149-myc gene with a TAG stop codon prevents poly-GA 
expression and aggregation. Arrow indicates top of the gel. (B) LDH release assay detected neurotoxicity of GA149-
myc only in the presence of an ATG start codon in transduced cortical neurons (DIV 8+14). Mean ± SD; One-way 
ANOVA with Tukey’s post-test. ***p < 0.001, n = 3 with six replicates in each experiment. 
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Immunoblotting with a poly-GA antibody detected only poly-GA aggregates in 
ATG-GA149 transduced neurons but not in TAG-GA149 or GFP control transduced 
neurons (Figure 19A), suggesting that the synthetic gene sequence does not support 
RAN translation. Thus, the TAG-GA149 construct can be used to discriminate if the 
toxicity in poly-GA expressing neurons is exclusively protein dependent.  Toxicity 
in primary cortical rat neurons was assessed with an LDH assay 14 days after 
transduction. Whereas ATG-GA149 expressing neurons showed a 2-fold increase in 
LDH activity, confirming poly-GA toxicity, no change in LDH activity could be 
detected for the TAG-GA149 expressing neurons, compared to GFP control neurons  
(Figure 19B). These results demonstrate that, the toxicity observed in primary 
neuron culture is only dependent on the expression of the poly-GA protein and not 
the ATG-GA149 RNA. 
4.7. Other DPR proteins in neurons 
4.7.1. No DPR protein apart from poly-GA shows typical insoluble 
cytoplasmic inclusions 
Since I could detect toxicity of poly-GA in neurons, the question arose, if the other 
four DPR proteins could also affect neuron viability and if their expression in 
neurons better resembles the patient situation, compared to the observations in the 
HEK293 cell system. Therefore, primary hippocampal neurons (DIV  8) were 
transduced with GA175-GFP, GFP-GR149, GP80-V5, PA175-GFP, PR175-GFP or GFP 
control lentivirus. Immunostaining was performed after 5 days in culture. However, 
neither poly-GR nor poly-GP, poly-PA or poly-PR showed the patient typical 
cytoplasmic inclusions, which were seen for pol y-GA. As in HEK293 cells poly-GP 
and poly-PA are distributed diffusely throughout the cytosol and some dendrites and 
poly-PR shows mainly nuclear inclusions (Figure 20). 
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Figure 20: DPR proteins aggregate differently in primary neurons. 
Primary hippocampal neurons were infected with GA175-GFP, GFP-GR149, GP80-V5, PR175-GFP, PA175-GFP as well 
as a GFP as a control. 5 days after transduction cells were analyzed by GFP fluorescence or V5 antibody in the case 
of GP80 . TOPRO was used as a nuclear marker. Only GA175-GFP transfected cells show cytosolic aggregates. GFP-
GR149 mainly shows a cytosolic halo around the nucleus and some nuclear aggregates. No aggregation could be 
detected for GP80-V5. PR175-GFP mainly showed nuclear aggregates, whereas no aggregation could be detected for 
PA175-myc. White arrows indicate cytosolic aggregates and magenta arrows nuclear aggregates. Scale bar 15 µm. 
Poly-GR, however, rather forms a halo around the nucleus and very few cells show 
intranuclear aggregates (Figure 20). 
Moreover, immunoblotting of primary cortical  neurons infected with GA175-GFP, 
GFP-GR149, GP80-V5, PA175-GFP, PR175-GFP or GFP control lentivirus (DIV 8+5) 
reveals similar results compared to the HEK293 cell system. Whereas poly-GA, 
poly-GR and poly-PR are detected at the top of the gel, poly-PA runs higher than its 
expected height, suggesting higher molecular weight species. In contrast to HEK293 
results, poly-GP runs higher than its expected height of 20 kDa (Figure 21A). 
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Figure 21: DPR proteins show differential biochemical properties and toxicity in primary neurons. 
Primary cortical neurons were transduced with with GA175-GFP, GFP-GR149, GP80-V5, PA175-GFP, PR175-GFP or 
GFP as a control. After 5 days, cells were harvested for analysis. (A) Immunoblotting with indicated antibodies 
shows expression of DPR proteins and GFP control. GA175-GFP, GFP-GR149, PA175-GFP and PR175-GFP are 
detected at the top of the gel (arrow), whereas GP80-V5 runs higher than the expected height of 20 kDa. P62 levels 
are only elevated in GA175-GFP transfected cells. (B) Filter trap assay for insoluble proteins. GA175-GFP, GFP-
GR149, PA-GFP and PR175-GFP form insoluble aggregates. Immunoblotting was carried out with respective 
antibodies. Immunoblotting with anti-V5 for poly-GP showed no insoluble aggregates (Data not shown). (C) LDH 
release assay in primary cortical neurons (DIV 8+14) detects 1.6-fold increase in toxicity in poly-GA expressing 
cells and 2-fold increase in poly-PR expressing cells. All other DPR proteins did not show toxicity. Mean ± SD, 
one-way ANOVA with Tukey’s posttest. N=3 with 6 replicates each, ***p<0,001. 
To further elucidate the solubility of the different DPR proteins, a filter trap assay 
was performed. Thus, primary cortical neurons (DIV 8) were transduced with the 
above mentioned lentiviruses and the filter trap assay was conducted 10 days after 
transduction. As can be seen in Figure 21B, poly-GA, poly-GR, Poly-PR and poly-
AP could be detected in the filter. Poly-GP could not be detected (data not shown), 
leading to the conclusion that it does not form 2 % SDS resistant aggregates.  
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4.7.2. Poly-PR is toxic to neurons 
To analyze, whether the remaining four DPR proteins might also contribute to 
neurotoxicity, I transduced primary cortical neurons on DIV  6 with GA175-GFP, 
GFP-GR149, GP80-V5, PA-175-GFP, PR175-GFP or GFP alone as a control. An LDH 
assay was performed 14 days after transduction. Apart from poly-GA expressing 
neurons, showing an increase in toxicity of 1.6 fold, only poly-PR resulted in a 
significant increase of 2-fold (Figure 21C). For the other DPR proteins poly-GR, 
poly-GP and poly-PA no significant effect could be detected compared to GFP 
expressing cells (Figure 21C).  
Although the majority of the other DPR species form insoluble aggregates and poly -
PR even confers toxicity to the neurons, the detected inclusions do not resemble t he 
inclusions seen in patients.  
Thus, the poly-GA model is the most comparable to the patient situation and was 
focus for my further experiments.  
4.8. Identification of the poly-GA interactome 
4.8.1. Proteasome components are enriched in the poly-GA interactome 
To assess the mechanisms of toxicity of this unusual protein, I wanted to analyze 
whether important neuronal proteins are sequestered in the aggregates. A first 
approach to understand how poly-GA is causing neurotoxicity was to identify poly-
GA interacting proteins that could contribute to a better understanding of the 
underlying mechanism. In this approach, I collaborated with Daniel Hornburg and 
Felix Meissner from the Lab of Matthias Mann at the MPI for Neurobiology in 
Martinsried. We set up a label-free quantitative proteomics approach using a LC-
MS/MS based experiment with immunoprecipitation of the GFP tagged poly-GA 
from primary cortical neuron culture, transduced with either GA 149-GFP or GFP 
alone (DIV 6+17) and identified proteins attached to the poly-GA aggregates. 
Immunoblotting of 1 % input and the final Immunoprecipitation  sample showed that 
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poly-GA could be enriched in the IP sample (Figure 22A) used for LC-MS/MS 
analysis.  
 
Figure 22: The poly-GA interactome is enriched for the ubiquitin-proteasome system and Unc119. 
Primary cortical neurons (DIV 6+17) transduced with either GFP or GA149-GFP lentivirus and subjected to anti-GFP 
immunoprecipitation. Samples were used for quantitative mass spectrometry analysis (A) Immunoblotting with anti-
GFP confirms immunoprecipitation of GFP and GA149-GFP (arrowheads). Asterisks indicate immunoglobulin heavy 
and light chain. Arrow indicates top of gel. (B) Quantitative proteomics of GFP immunoprecipitations. p62/Sqstm1 
shows highest enrichment and statistical significance. Unc119 was identified by two unique peptides 
(GGGGTGPGAEPVPGASNR and LGPLQGK) and one peptide (YQFTPAFLR) shared with its homolog Unc119b. 
Full protein names are listed in Table 1. Upper panel illustrates distribution of quantified protein abundances binned 
for enrichment factors (x-axis below). Enrichment of ubiquitin-related and proteasomal proteins in the poly-GA 
interactome is highlighted in green. Lower panel depicts volcano plot showing poly-GA interacting proteins. False 
discovery rate (FDR) controlled statistical analysis identified 20 poly-GA interacting proteins compared to control 
(red dots). Dotted line depicts threshold for statistical significance. 
We could quantify the relative protein abundances  of 450 proteins in the GA149-GFP 
and the GFP samples, 20 proteins were significantly enriched in IPs from poly-GA 
expressing neurons (Figure 22B and Table 1). Strikingly, p62 showed the highest 
enrichment and thus confirmed the validity of affinity purification and the neuron  
culture system (Figure 15 and Figure 16). Furthermore, proteasomal subunits (e.g. 
PSMB6) and ubiquitin-related proteins (e.g. Ubiquilin 1 and 2) were 5.7 -fold 
enriched in the IPs of the poly-GA expressing cells (p = 8.7 x 10
-11
) (Figure 22B 
and Table 1), suggesting that poly-GA might interfere with proteasome activity and 
consequently causes toxicity.  
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Table 1: Proteins interacting with poly-GA identified by mass spectrometry.  
Enrichement of proteins in GA149-GFP immunoprecipitates compared to GFP control measured by LC-MS/MS. 
NCBI gene names, Uniprot identifier, logarithmic p-value and enrichment are listed. Statistical analysis was 
performed using a t-test with a false discovery rate of 2 % and S0 of 2 (Tusher et al., 2001). 
Gene names Protein IDs -log10(p) log2(GA/ctrl) Protein names 
Sqstm1 O08623-2; O08623; 
O08623-3 
3.37 7.25 p62/Sequestosome-1 
Rad23a; 
Rad23b 
Q4KMA2; Q5XFX7 1.79 5.47 UV excision repair protein RAD23 
homolog A and B 
Ubqln2; 
Ubqln4 
D4AA63; D4A3P1 2.77 4.57 Ubiquilin 2; Ubiquilin 4 
Sdcbp Q9JI92 2.43 4.52 Syntenin-1 
Ubb; Ubc; 
Uba52; 
Rps27a; 
LOC100360645 
G3V9Z2; P0CG51; 
Q63429; F1LML2; 
Q6P7R7; P62986; 
Q6PED0; P62982; 
F1M516 
3.04 4.51 Polyubiquitin-B; Ubiquitin; 
Polyubiquitin-C; Ubiquitin; 
Ubiquitin-related; Ubiquitin-60S 
ribosomal protein L40; Ubiquitin; 60S 
ribosomal protein L40; Ubiquitin-40S 
ribosomal protein S27a; Ubiquitin; 
40S ribosomal protein S27a 
Klhdc10 Q5U3Y0; D3ZUK9 2.10 4.46 Kelch domain-containing protein 10 
Bag6 Q6MG49; 
Q6MG49-2 
2.81 3.71 Large proline-rich protein BAG6 
Psmb6 P28073 2.95 3.65 Proteasome subunit beta type-6 
Ubqln1 F1M971; Q9JJP9 1.42 3.47 Ubiquilin 1 
Dbn1 Q07266; Q07266-2; 
C6L8E0 
1.91 3.36 Drebrin 
Myh10; Myh14 Q9JLT0; G3V9Y1; 
F1LNF0 
1.70 3.28 Myosin-10; Myosin-14 
Efhd1; Efhd2 Q4FZY0; D4A9T5 1.56 3.25 EF-hand domain-containing protein 
D1; EF-hand domain-containing 
protein D1 
Acat2 Q5XI22; F1LS48 1.34 3.21 Acetyl-CoA acetyltransferase, 
cytosolic 
Mlf2 D3ZPN3 2.32 3.13 Myeloid leukemia factor 2  
Psmc6 G3V6W6 1.70 3.12 Proteasome (prosome, macropain) 
26S subunit, ATPase, 6 
Psmb4 D4A640; P34067; 
G3V8U9 
3.44 3.10 Proteasome subunit beta type-4 
Psmb5 G3V7Q6; P28075 1.97 2.98 proteasome (prosome, macropain) 
subunit, beta type, 5 
Unc119; 
Unc119b 
Q62885; F1LZN2; 
D3ZY58 
1.97 2.90 Protein unc-119 homolog A and B 
Myo5b; Myo5c F1M111; F1M3R4; 
P70569 
1.68 2.85 Myosin VB/C 
Psmd13 B0BN93 3.01 2.68 26S proteasome non-ATPase 
regulatory subunit 13 
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Trypsin-like, Chymotrypsin-like and Caspase-like proteasome activity, however, 
was not affected in poly-GA expressing HEK293 cells, whereas proteasome 
inhibitor epoxomycin (8 µM, 2 h) abolished proteasome activity (Figure 23A).  
 
Figure 23: Proteasome activity is unaffected by poly-GA expression in HEK293 cells. 
(A) Expression of poly-GA did not affect chymotrypsin-like, trypsin-like and caspase-like protease activity of the 
proteasome in HEK293 cells compared to GFP control (n=3 experiments with 6 replicates each, mean ± SD, no 
significant change in one-way ANOVA). The proteasome inhibitor epoxomycine (8 μM, 2 h) significantly blocks 
proteasome activity in GFP transfected cells (one-way ANOVA with Tukey’s post-test, *** p<0.001; ** p<0.01). 
(B) Expression of proteasomal subunits (PSMC2, PSMC4) was not affected by expression of DPRs in HEK293 cells 
(GA175-GFP, GFP-GR149, GP80-V5, PA175-myc and PR175-GFP). (C) Expression of proteasomal subunits (PSMC2; 
PSMC4) was unchanged in GA149-myc transduced cortical neurons compared to GFP transduced controls. Three 
separate transductions are shown (DIV 6+17). 
Additionally, poly-GA expression did not affect protein levels of the proteasomal 
subunits PSMC2 and PSMC4 both in HEK293 cells, upon three days of transfection 
with GA175-GFP, (Figure 23B) and primary cortical neurons after transduction of 
GA175-GFP lentivirus (DIV 6+17) (Figure 23C). Concluding that changes in the 
proteasome are presumably not responsible for the poly-GA toxicity seen in 
neurons. 
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4.8.2. Poly-GA co-aggregates with the cargo adapter Unc119 
Since the proteasome was unaffected in primary neurons, I focused on proteins 
apart from the proteasome that were significantly enriched in poly-GA expressing 
neurons. Interestingly, Uncoordinated 119 (Unc119), a cargo adapter of 
myristoylated proteins (Constantine et al., 2012), was 7.5-fold enriched in poly-GA 
expressing neurons, compared to control conditions (Figure 22B and Table 1). 
Unc119 has previously been found in a C. elegans  screen to impair locomotion and 
is required for axon development and maintenance in t he worm (Knobel et al., 2001; 
Maduro and Pilgrim, 1995; Maduro et al., 2000) , thus being a promising target in 
the context of ALS and FTD. Furthermore, Unc119 was fo und to bind to the 
myristoylated GAGASA motif of Transducin α (GNAT1), which strongly resembles 
the poly-GA sequence (Zhang et al., 2011). 
To validate co-aggregation of Unc119 in cell culture, HEK293 cells were 
transfected with a HA-Unc119 construct and GA175-GFP for three days. 
Immunostaining for the HA-tag was performed and immunofluorescence was 
analyzed revealing profound co-aggregation of poly-GA and Unc119. Additionally, 
Unc119 partially loses its cytosolic location and is sequestered into poly-GA 
aggregates (Figure 24). GFP transfected as a control had no effect on Unc119 
localization (Figure 24). 
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Figure 24: Unc119 co-aggregates with poly-GA in HEK293 cells. 
Immunofluorescence of HEK293 cells co-transfected with GFP or GA175-GFP and HA-Unc119 or empty vector. 
GFP fluorescence, anti-HA immunostaining and DAPI as nuclear marker. Compare the HA-Unc119 localization in 
column 2 and 4. Many GA175-GFP inclusions show co-aggregation of HA-Unc119 (examples marked with arrows). 
Scale bar 30 µm. 
To further validate Unc119 binding to poly-GA, I performed a co-
immunoprecipitation with two different poly-GA constructs, GA175-GFP and GA149-
myc, to exclude effects based on the respective tag, and HA -Unc119. HEK293 cells 
were transfected with the poly-GA constructs or a GFP or myc control and HA-
Unc119 for three days. The immunoprecipitation was either performed with a GFP 
or a myc antibody. In both experiments Unc119 could be detected in the poly -GA IP 
but not in control conditions, concluding that Unc119 indeed binds to poly-GA 
(Figure 25). 
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Figure 25: Unc119 directly binds to poly-GA. 
Co-immunoprecipitation of Unc119 and poly-GA. HEK293 cells co-transfected with HA-Unc119 and GA175-GFP or 
GA149-myc for three days. The poly-GA proteins were immunoprecipitated with GFP or myc antibodies. Note that in 
freshly prepared protein extracts monomeric poly-GA can be resolved when directly loaded (asterisks). Aggregated 
poly-GA is stuck at the top of the gel (arrow). 
4.8.3. Further poly-GA interactors could be confirmed in HEK293 cells 
To additionally validate more candidates of the mass spectrometry interactome list , 
apart from Unc119, the Microtubule-associated Protein RP/EB Family Member 2 
(Mapre2) and C-terminal Binding Protein 1 (Ctbp1) were analyzed for co-
aggregation in the HEK293 cell expression system via immunostaining. 
Interestingly, Mapre2 and Ctbp1, although not co -aggregating with poly-GA had an 
effect on the amount of poly-GA aggregates (Figure 26). Mapre2 expression 
increased poly-GA aggregate number, whereas expression of Ctbp1 decreased poly-
GA aggregate number in HEK293 cells after three days transfection (Figure 26). 
However, both proteins have no reported link to neurodegeneration so far.  
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Figure 26: Mapre2 and Ctbp1 influence poly-GA aggregation in HEK293 cells. 
HEK293 cells were transfected with GA175-GFP or GFP as a control as well as Ctbp1-HA, Mapre2-HA or an empty 
vector as control. GFP immunofluorescence and HA antibody immunostaining was analyzed three days after 
transfection. DAPI was used as a nuclear marker. Although neither Ctbp1 nor Mapre2 co-aggregate with poly-GA 
they influence poly-GA expression. Ctbp1 decreases the amount of aggregates compared to GFP control whereas 
Mapre2 increases aggregate number. Scale bar depicts 30 µm.  
After these promising results , I validated further candidates of the target list. 
Ribosomal Protein S5 (Rps5), Fatty Acid Binding Protein 5 (Fabp5), Ribosomal 
Protein L31 (RPL31), Bcl-2 Associated Athanogene 6 (Bag6), Ependymrelated 
Protein 1 (Epdr1), Hydroxysteroid-17-beta-dehydrogenase 4 (Hsd17b4) and 
Transmembraneprotein 160 (Tmem160)  were analyzed regarding co-aggregation 
with poly-GA. Immunofluorescence analysis of these proteins via their HA-tag 
revealed no co-aggregation or change in localization upon poly-GA co-expression 
in HEK293 cells for Rps5, Fabp5 or L31 (Figure 27A). However, Bag6, Epdr1, 
Hsd17b4 and TMEM160 showed profound co-localization with poly-GA aggregates 
and thus, validate the proteomic poly-GA interactome analysis (Figure 27B).  
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Figure 27: Bag6, Epdr1, Hsd17b4 and Tmem160 co-aggregate with poly-GA in HEK293 cells. 
HEK293 cells were transfected with GA175-GFP or GFP as well as the above mentioned GA interactors identified in 
the mass-spectrometry screen. After three days of transfection, GFP immnuofluorescence was analyzed as well as 
HA antibody staining.  Bag6, Epdr1, Hsd17b4 and Tmem160 show profound co-aggregation with poly-GA, whereas 
the other potential targets do not. Scale bar 15 µm. 
To confirm specific binding of Bag6, Epdr1, Hsd17b4 and TMEM160, I performed a 
co-immunoprecipitation of GA175-GFP with the aforementioned potential 
interactors. As can be seen in Figure 28, I was able to confirm the binding of 
Hsd17b4 and Bag6 to poly-GA. In contrast, no binding was observed for TMEM160 
and Epdr1. This might either suggest no binding to poly-GA at all or a technical 
problem due to low expression of the proteins , since they were also not detectable 
in the input (Figure 28). Hsd17b4 and Bag6 are interesting candidates to follow up 
on and to investigate, if and how they contribute to neurotoxicity. Hsd17b4 is 
involved in the peroxisomal fatty acid beta-oxidation. Notably, mutations in 
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Hsd17b4 have been linked to the Perrault syndrome, an autosomal recessive disease 
leading to sensorineural hearing loss with an early childhood onset and in some 
females developmental delay or intellectual disability, cerebellar ataxia, and motor 
and sensory peripheral neuropathy (Möller et al., 1999). Bag6 is an anti-apoptotic 
protein that has been linked to autophagy and various other cellular pr ocesses (Sebti 
et al., 2014). It may also play a role in autoimmunity though a connection to 
neurodegeneration has not yet been made (Binici and Koch, 2014). 
 
Figure 28: Bag6 and Hsd17b4 bind poly-GA. 
Coimmunoprecipitation of novel poly-GA interactors and poly-GA. HEK293 cells cotransfected with HA-Bag6, 
HA-Epdr1, HA-Hsd17b4, HA-Tmem160 as well as GA175-GFP for three days. The poly-GA proteins were 
immunoprecipitated with GFP. Aggregated poly-GA is stuck at the top of the gel (arrow). 
In summary, I could validate co-aggregation of Bag6, Hsd17b4, Epdr1, and 
Tmem160, found in the mass spectrometry interactome analysis of poly-GA. 
Furthermore, I identified Bag6, Hsd17b4, Mapre2 and Ctbp1 as additional targets 
apart from Unc119 that might play a role in the  mechanisms of poly-GA toxicity. 
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4.9. Unc119 co-aggregates with poly-GA in rat neurons and the co-
aggregation is poly-GA specific 
Due to the initial results in HEK293 cells, I investigated, if Unc119 also co-
aggregates with poly-GA in neurons. Therefore, I transduced primary rat cortical 
neurons (DIV 6+15) with GA149-GFP or GFP as a control and HA-Unc119. 
Immunostaining with HA antibody showed co-localization of poly-GA aggregates 
with Unc119 (Figure 29). 
 
Figure 29: Unc119 co-aggregates with poly-GA  in primary neurons. 
Immunofluorescence of primary hippocampal neurons co-transduced with HA-Unc119 and either GFP or GA149-
GFP (DIV 6+17). Arrows indicate examples of poly-GA inclusions showing co-aggregation of HA-Unc119. Scale 
bar 15 μm. 
To clarify, if this interaction was poly-GA specific or rather an unspecific 
aggregate dependent effect, I transfected HEK293 cells with HA-Unc119 combined 
with GA175-GFP, GFP-GR149, GP80-V5, PA175-myc, PR175-GFP or Q102-GFP as an 
unrelated aggregate control. As seen in Figure 30, only poly-GA co-aggregates with 
Unc119 but none of the other DPR species or polyQ, suggesting that the interaction 
of Unc119 and poly-GA is specific.  
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Figure 30: Unc119 specifically co-aggregates with poly-GA. 
HEK293 cells were transfected with the five different poly-DPR constructs (GA175-GFP, GFP-GR149, PR175-GFP, 
PA175-myc and GP80-V5) or Q102-GFP and analyzed using GFP fluorescence and immunostaining of HA-Unc119, 
PA175-myc and GP80-V5 using specific antibodies 2 days later. HA-Unc119 co-aggregates only with GA175-GFP 
(white arrows). DAPI (in blue) was used as a nuclear marker. Scale bar 20 μm. 
4.10. Unc119 knockdown and antibody validation 
Understanding the underlying mechanisms of how poly-GA causes neurotoxicity 
will help to identify potential therapeutic strategies. Therefore, it is of utmost 
importance to clarify if and how Unc119 may contribute to poly-GA based 
neurotoxicity. In this regard, a shRNA based knockdown system specific for 
Unc119 was established. To test whether the designed shRNA is functional, primary 
cortical neurons (DIV 8+10) were lentivirally transduced to express either shUnc or 
a control shRNA. In cortical neurons, shUnc specifically downregulates Unc119 
mRNA levels to 7 %, compared to the control shRNA (Figure 31A), hence proving 
the efficient knockdown. 
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Figure 31: Unc119 antibodies #1 and #2 are specific for human and rat Unc119. 
(A) Primary cortical neurons were transduced with an shRNA targeting Unc119 and a control shRNA.  RT-qPCR 
shows efficient reduction of Unc119 mRNA normalized to the reference gene GAPDH. mean ± SEM. N=3. p<0.001 
in Student’s t-test (B) Unc119 antibodies #1 and #2 detect rat and human HA-Unc119 overexpressed in HEK293 
cells. Note that HEK293 cells show very little endogenous Unc119. (C-E) Primary cortical neurons were transduced 
with a shRNA targeting Unc119 or a control shRNA (DIV 7+10). (C) Two Unc119 antibodies (#1 and #2) show 
reduced Unc119 protein levels upon Unc119 shRNA transduction compared to controls in immunoblots. Two 
separate transductions are loaded. (D, E) Both antibodies detect reduced Unc119 protein levels by immunostaining. 
tagRFP co-expressed from the shRNA lentivirus shows high transduction efficiency. Scale bars represent 20 μm. 
To analyze the endogenous Unc119 levels, two antibodies were teste d; one self-
made (Unc119#1) and one commercial one (Unc119#2). HEK293 cells were 
transfected with HA-ratUnc119, HA-hUnc119 or an empty vector as a control. Both 
antibodies were able to specifically detect overexpressed human as well as rat 
Unc119 in western blot analysis (Figure 31B).  
Next, the antibodies were tested on endogenous levels of rat Unc119. Therefore, 
primary cortical neurons (DIV 7+10) were transduced with shUnc and shCtrl. Both 
antibodies detect Unc119 in cells expressing shCtrl (Figure 31C). As expected, the 
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Unc119 signal cannot be detected anymore upon shUnc expression , further 
confirming the knockdown quality and validating the antibod ies in immunoblotting 
(Figure 31C). Following, the antibodies were also validated in immunofluorescence 
by infecting primary cortical neurons (DIV 7+10) with shUnc and shCtrl  as control 
shRNA. Immunostainings were performed for both  antibodies (Figure 31D+E). 
Unc119#1, as well as Unc119#2, specifically detect Unc119 that is localized in t he 
cytosol of the primary neurons (Figure 31D+E). Thus, both antibodies can be used 
for further studies to elucidate the role of Unc119 in poly-GA induced neuronal 
toxicity and the relevance for FTD and ALS.  
4.11. Unc119 sequestration contributes to poly-GA toxicity in 
primary neurons 
To assess the effect of poly-GA on Unc119 in neuron culture I transduced cortical 
neurons at day 6 in culture with GA175-GFP or GFP as a control. Although Unc119 
has been found 7.5 fold enriched in the poly-GA interactome, Unc119 was 
undetectable at the expected size (27 kDa) by immunoblot (Figure 32A).  
 
Figure 32: Unc119 is sequestered in poly-GA aggregates in neurons. 
(A) Immunoblot with the indicated antibodies in GFP or GA149-myc transduced cortical neurons shows decreased 
levels of soluble Unc119 running at 27 kDa. Two separate transductions are shown (DIV 6+17). (B) qPCR analysis 
of neurons transduced as in (A) shows no significant changes in Unc119 mRNA levels (mean ± SD, Student’s t test, 
DIV 7+10) 
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However, the mRNA levels of Unc119 are unaffected (Figure 32B), indicating that 
Unc119 is translated normally but is then sequestered into insoluble p oly-GA 
aggregates, thus preventing western blot detection. This suggests a loss of function 
mechanism. To elucidate whether Unc119 loss of function contributes to poly-GA 
toxicity, I first compared phenotypes of poly-GA expression and Unc119 
knockdown. Thus, I analyzed dendrite morphology as I could previously show that 
GA expression diminishes dendrite outgrowth. For this purpose, primary 
hippocampal neurons were transfected with shUnc or shCtrl  as a control and GFP to 
visualize morphology. Unc119 knockdown leads to a loss in dendrite complexity 
similar to the defect seen in poly-GA expressing cells (Figure 33A+B).  
 
Figure 33: Unc119 loss of function contributes to poly-GA toxicity. 
(A, B) Hippocampal neurons transfected with shRNA targeting Unc119 (shUnc) or a non-targeting control (shCtrl) 
together with GFP to outline cell morphology (DIV 7+5). Dendritic branching was quantified by Sholl analysis. 
Unc119 knockdown reduced dendrite complexity significantly (p < 0.0001 for 12.5–62.5 μm radius and p < 0.001 
for 75 μm radius, two-way ANOVA, n = 40 neurons per condition). Scale bar depicts 40 μm. (C) LDH release assay 
from cortical neurons co-transduced with either GFP or GA149-GFP (GA) together with HA-Unc119 (Unc), shRNA 
targeting Unc119 (shUnc) or non-targeting shRNA (shCtrl) (DIV 6+17). Note that Unc119 knockdown causes 
toxicity in GFP-transduced neurons, but does not increase poly-GA toxicity further. HA-Unc119 expression rescues 
GA149-GFP toxicity. One-way ANOVA with Tukey’s post-test. **p < 0.01, ***p < 0.001, n = 3 with six replicates 
in each experiment 
Moreover, lentiviral knockdown of Unc119 in cortical neurons induced toxicity in 
an LDH-release assay 1.8-fold compared to the control shCtrl (Figure 33C). 
Overexpression of Unc119 alone showed no effect on cell viability . In contrast, the 
overexpression of Unc119 in GA149-myc expressing neurons could rescue the toxic 
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phenotype suggesting that Unc119 loss of function indeed contributes to the poly-
GA toxicity in neurons (Figure 33C). Additionally, knockdown of Unc119 in GA 149-
myc expressing cells did not deteriorate viability further, indicating that Unc119 
loss of function is important in the mechanisms of poly-GA induced toxicity.  
In summary, poly-GA aggregates may cause loss of Unc119 function by 
sequestration and could thereby contribute to poly-GA mediated neurotoxicity and 
finally to FTD/ALS pathogenesis.  
4.12. Unc119 is detected in C9orf72 patient poly-GA aggregates 
As the previous results suggested a participation of Unc119 in the pathomechanism 
of ALS and FTD, it was important to analyze whether Unc119 can be detected in 
C9orf72  patient aggregates. Before investigating this, both Unc119 antibodies were 
validated thoroughly in patient material. Therefore competition experiments with 
GST-Unc119 using immunoblotting (Figure 34A) and immunohistochemistry 
(Figure 34B) were performed. Upon pre-incubation with denatured as well as native 
GST-Unc119 the signal intensity of overexpressed human as well as rat Unc119 
protein was strongly reduced in immunoblots of HEK293 cells transfected with 
either HA-hUnc119 or HA-rUnc119 (Figure 34A). 
This is also true for pre-incubation with native-GST-Unc119 and Unc119#1 
antibody in immunohistochemistry of frontal cortex (SFG) region and dentate gyrus  
of a C9orf72 mutation carrier. Aggregate as well as cytosolic staining of Unc119 in 
both regions is almost completely abolished (Figure 34B) upon pre-incubation, thus 
validating both antibodies for use in human tissue.  
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Figure 34: Antigen pre-incubation confirms specificity of Unc119 staining in patient material. 
(A) Immunoblots of HEK293 cells transfected with rat and human HA-Unc119 using antibodies Unc119#1 and #2. 
To confirm specificity Unc119 antibodies were preincubated with 25 μg/ml native or denatured GST-Unc119 or 
denatured GST as a control. While specific Unc119#2 signal is best blocked with denatured GST-Unc119, the 
Unc119#1 antibody is best blocked with native GST-Unc119, which may explain the better sensitivity of Unc119#1 
for immunohistochemistry. (B) Using the Unc119#1 antibody preincubated with GST-Unc119 but not with GST 
alone abolishes the staining of cells and inclusions strongly indicating antibody specificity for 
immunohistochemistry as shown for the superior frontal gyrus (SFG) and the hippocampal dentate gyrus/cornu 
ammonis region 4 (DG/CA4) of a C9orf72 mutation carrier. Scale bars depict 10 μm for SFG and 30 μm for 
DG/CA4. 
To investigate if Unc119 forms intracellular inclusions in C9orf72  patients, 
immunohistochemistry staining of a C9orf72 mutation carrier and a healthy control 
in the CA3/4 region of the hippocampus was carried out by Martin Schludi. 
Intracellular Unc119 inclusions resembling poly-GA aggregates could only be 
detected in C9orf72 mutation carriers but not in healthy controls (Figure 35A). 
Furthermore, I performed a filter trap assay to confirm that Unc119 is sequestered 
into poly-GA aggregates and is therefore insoluble. In the frontal cortex of two 
C9orf72 patients but not in two aged matched healthy controls, insoluble Unc119 
could be detected in the filter (Figure 35B). 
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Figure 35: Unc119 forms neuronal cytoplasmic inclusions in C9orf72 patients. 
(A) Immnuohistochemistry analysis of Unc119 in the frontal cortex of a C9orf72 mutation carrier and a healthy 
control. C9orf72 mutation carriers, but not controls, show cytoplasmic inclusions resembling poly-GA inclusions in 
their shape. Scale bar 20 µm. (B) Filter trap assay detects insoluble Unc119 in 1 % SDS in C9orf72 mutation 
carriers but not healthy controls. 
To examine if Unc119 co-aggregates with poly-GA in C9orf72 patients I performed 
double immunofluorescence stainings together with Martin Schludi using both 
Unc119 antibodies. Co-localization of Unc119 and poly-GA could be confirmed in 
the cortex and cerebellum of C9orf72 cases (Figure 36A+B, Figure 37A). However, 
no aggregates could be detected in control cases (Figure 36C and Figure 37B). 
Importantly, in a fraction of neurons nearly all Unc119 was sequestered into 
aggregates and no residual cytosolic staining could be detected (Figure 36A). 
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Figure 36: Poly-GA but not TDP-43 co-aggregates with Unc119 in patients with C9orf72 mutation. 
Double immunofluorescence analysis of Unc119 with poly-GA or phosphorylated TDP-43 (p-TDP-43) in C9orf72 
mutation cases C9-1, C9-2 and C9-3. (A) In the superior frontal gyrus (SFG), a subset of poly-GA-positive neuronal 
cytoplasmic inclusions also contains Unc119. Redistribution of Unc119 compared to poly-GA-negative cells can be 
seen in a fraction of co-aggregating cells (white arrows). (B) In the cerebellar granular cell layer (CBL) abundant 
cytoplasmic poly-GA inclusions are only rarely positive for Unc119 (white arrows). (C) As shown for the superior 
frontal gyrus, Unc119 (white arrow) and p-TDP-43 (red arrow) are not co-localized in the same cytoplasmic 
inclusions. Scale bars represent 10 μm for overviews and 5 μm for the close-up in the second column of (A) 
Strikingly, all Unc119 inclusions were found to be poly-GA positive indicating that 
DPR proteins drive inclusion formation. Moreover, despite abundant poly-GA and 
phospho-TDP-43 (p-TDP-43) pathology in the frontal cortex, Unc119 only co-
localized with poly-GA but not p-TDP-43 inclusions. This further validates poly-
GA specific co-aggregation of Unc119 (Figure 36C and Figure 37B). 
Taken together, Unc119 specifically co-aggregates with poly-GA inclusions in 
C9orf72 patients. 
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Figure 37: Second antibody Unc119 #2 confirmes co-aggregation of Unc119 and poly-GA. 
Double immunofluorescence analysis of Unc119 with poly-GA or p-TDP-43 in C9orf72 mutation cases C9-1 and 
C9-3. (A) In the superior frontal gyrus (SFG), a subset of poly-GA positive NCI also contains Unc119. (B) There is 
no co-localization of poly-GA and p-TDP-43 in the frontal cortex. Scale bars represent 10 μm in overviews and 5 
μm in close ups. 
4.13.Poly-GA may induce TDP-43 pathology in primary neurons 
Although the data I have presented in this thesis strongly suggest an important 
contribution of DPR proteins to neurodegeneration in  C9orf72 mutation carriers, it 
is still unclear if and how DPR proteins can induce the p-TDP-43 pathology that is 
seen in most C9orf72  patients. It is still under discussion whether DPR pathology 
precedes TDP-43 pathology. Reports of a few patients with abundant DPR 
pathology but no detectable p-TDP-43 inclusions support this hypothesis (Proudfoot 
et al., 2014). 
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To investigate if poly-GA might be involved in the development of TDP-43 
pathology I transduced primary cortical rat neurons (DIV  6+15) with either GA149-
myc or GFP as a control. Immunoblotting for TDP-43 revealed no differences in 
TDP-43 expression on the expected height of 43 kDa and furthermore I could not 
detect any pTDP-43 (Figure 38A and data not shown). Upon longer exposure, 
however, I could detect TDP-43 at the top of the gel specifically in poly-GA 
expressing neurons (Figure 38A). As this alone does not implicate poly-GA in the 
development of TDP-43 pathology, I performed immunofluorescence analysis of 
GA149-myc transduced hippocampal neurons (DIV 6+15) and GFP control neurons. 
Whereas TDP-43 in control neurons was strictly restricted to the nucleus, a portion 
of poly-GA expressing neurons also showed TDP-43 outside of the nucleus. The 
distribution seemed to be diffuse with small aggregates in the cytosol (Figure 38B). 
A quantification of this phenotype in at least 250 cells per condition in three 
experiments revealed a significant shift of TDP-43 from the nucleus to cytosol in 
poly-GA expressing neurons.  
Whereas 95 % of control cells showed TDP-43 expression exclusively in the 
nucleus, in poly GA expressing neurons, more than 50 % of tranduced cells showed 
additional TDP-43 in the cytosol forming the aforementioned tiny aggregates 
(Figure 38C). Additionally, only 46 % of the neurons showed TDP -43 to be 
exclusively located in the nucleus. Moreover, 5 % of contro l and poly-GA cells 
showed a partial mislocalization of TDP-43 even though no poly-GA aggregate was 
present which is depicted in basal misloc.  
Thus, a first hint that poly-GA might be involved in the induction of TDP-43 
pathology is provided. However, more detailed analyzes are necessary to understand 
which type of aggregate is formed and if these initial aggregates can further develop 
into the pTDP-43 pathology seen in patients.  
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Figure 38: Poly-GA induces cytoplasmic mislocalization of TDP-43. 
(A) Cortical neurons infected with GFP or GA149-myc lentivirus (DIV 6+15). Immunoblots with the indicated 
antibodies. TDP-43* depicts TDP-43 found in the stacking gel with a longer exposure time. Arrows depict top of the 
gel. (B) Hippocampal neurons transduced with GFP or GA149-myc lentivirus. Immunostaining with TDP-43 and 
DAPI as nuclear marker (DIV 6+15). Arrows mark the formation of dot-like TDP-43 structures. Scale bar, 5 µm. 
(C) Quantification of TDP-43 mislocalization. 250 cells counted per condition and experiment. A significant 
increase in mislocalized TDP-43 of 52% compared to control cells could be detected (n=3; paired student t-test 
p<0.001) 
 
In summary, I could establish a cell culture system to investigate DPR protei n 
contribution to the pathogenesis of C9orf72 FTD/ALS. The cell culture system 
replicates important key features found in C9orf72  patients, such as p62-positive 
cytosolic inclusions as well as neurodegeneration. Strikingly, with my cell culture 
model I could detect Unc119 in the poly-GA interactome of primary neurons and 
identified this protein as a novel component of poly-GA aggregates in patients. 
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Moreover, I could demonstrate a direct role of Unc119 in the poly-GA mediated 
neurotoxicity.  
Finally and most importantly, I could establish a first link between DPR proteins 
and TDP-43, the protein whose aggregates correlate best with neurodegeneration in 
C9orf72 FTD/ALS.  
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5. Discussion 
5.1. Translation of the C9orf72 hexanucleotide repeat expansion 
The discovery of the hexanucleotide repeat expansion in C9orf72 as a major cause 
for FTD/ALS, 10 years after initial implication of this locus , has been an important 
breakthrough (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . Understanding 
how the mutation causes disease is crucial  in order to develop therapeutic 
approaches. Therefore, appropriate cell culture models are valuable tools to 
elucidate underlying molecular mechanisms. Three (not mutually exclusive) 
theories exist, how the C9orf72 repeat expansion could lead to neurodegeneration. 
First, loss of C9orf72 protein expression and thereby function. Second, RNA 
mediated toxicity through sequestration of important RNA-binding proteins and 
third, toxic protein gain of function through translation of the repeat into DPR 
proteins. All of these mechanisms need to be addressed to get a clear picture on 
their contribution to C9orf72 related FTD/ALS. 
In 2013, our lab and others could show that the intronic hexanucleotide repeat 
expansion is indeed translated and sense proteins poly-GA, poly-GR and poly-GP 
are detected in p62-positive star-shaped inclusions of C9orf72 patients. As part of 
this study, I was the first to show that the repeat RNA is stabilized and transcripts 
in sense and antisense direction are produced. Thus, I offered the first hint that 
antisense proteins might also be a part of the whole picture. A f ew months 
afterwards, this result was confirmed by the detection of antisense proteins poly-
PA, poly-PR and poly-GP in FTD/ALS patients (Gendron et al., 2013; Mori et al., 
2013a; Zu et al., 2013). 
To follow up on these initial results, my thesis focused on the contribution of all 
five DPR proteins to disease. For this purpose, I established a primary neuron cell 
culture system lacking the original repeat sequence to exclude RNA repeat based 
mechanisms. Poly-GA expression recapitulates the main features seen in patients 
such as p62 accumulation and neurotoxicity, thus directly links C9orf72 repeat 
translation to neurodegeneration. Furthermore , my model was able to predict new 
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pathologic features such as Unc119 co-aggregation, thus is a valuable tool to 
analyze underlying disease mechanisms. 
5.2. DPR aggregation and toxicity 
The approach in my thesis was to express all five DPR proteins from almost 
GGGGCC-free constructs containing an ATG start codon in a cell culture system to 
understand if and how DPR proteins contribute to the disease. Through that 
approach, I mainly excluded RNA-based toxicity and in comparison to previous 
GGGGCC-based constructs, my model showed higher expression levels of the DPR 
proteins. Furthermore, it was the first model to show aggregation of DPR proteins  
in vitro. Together, this presumably accelerates the disease mechanisms that take 
years to build up in patients.  
The sense and antisense DPR proteins surprisingly showed very different 
aggregation patterns in cell culture. Only poly-GA formed the typical compact p62-
positive inclusions, suggesting that it possibly is the main driving force for 
aggregation. This is consistent with the observation that poly-GA is present in 
nearly all TDP-43 negative inclusions, whereas the other DPR proteins are only 
detected in 10-50 % of these inclusions (Mori et al., 2013a; Mori et al., 2013c). 
Strikingly, the charged DPR proteins poly-GR and poly-PR showed mainly nuclear 
inclusions, similar to poly-GA aggregates rarely identified in patients (Mackenzie et 
al., 2013; Schludi et al., 2015). It is possible, that they are actively transported into 
the nucleus as positively charged arginines  are a typical feature of nuclear 
localization signals (Palmeri and Malim, 1999; Truant and Cullen, 1999) . The 
difference in aggregation pattern in my model , compared to patients, may be a 
result of the different length of the proteins, as the repeat number in my system is 
much shorter than in patients. Additionally, the lack of other DPR proteins may 
cause the differences, since in patients a combination of DPR proteins can often be 
found in one aggregate. Overall, my findings on DPR localization are in line with 
results from other groups also showing comparable aggregation patterns in primary 
neuron culture, drosophila and mice (Chew et al., 2015; Yamakawa et al., 2015; 
Yang et al., 2015; Zhang et al., 2014) . 
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Despite robust DPR expression in transfected HEK293 cells, I could not find 
evidence for cell death due to protein toxicity of the five DPR species .  Furthermore, 
I could not detect any toxicity of the GGGGCC expression constructs wit hout ATG 
start codon and the GGGGCC repeat based ATG-driven poly-GP construct,  
suggesting HEK293 cells are not susceptible to either C9orf72 repeat RNA or 
protein toxicity under these conditions, however, another study could detect toxicity 
of poly-PR and poly-GP in HEK293 cells in an LDH activity assay. This 
discrepancy may be a result of different expression levels or DPR protein length.  
In contrast to HEK293 cells, caspase activation, DNA fragmentation and increased 
LDH release in primary neurons suggest that p62-positive poly-GA inclusions lead 
to apoptosis in primary hippocampal and cortical neurons. Nuclear poly-PR 
inclusions also induce cell death in primary neurons in an LDH release assay. As 
the synthetic genes largely lack GGGGCC repeats and, as can be seen for the poly-
GA construct, require ATG-initiated protein expression to cause toxicity, DPR 
proteins themselves are neurotoxic. Nonetheless, my results do not rule out an 
additional or synergistic effect of GGGGCC repeat-RNA or C9orf72 
haploinsufficiency in the pathogenesis of C9orf72 FTLD/ALS.  
Apart from my work, a lot of studies accumulated during the last year showing 
toxicity for different DPR proteins in several culture models (Kwon et al., 2014; 
Mizielinska et al., 2014; Wen et al., 2014; Yamakawa et al., 2015; Zhang et al., 
2014), thus, of DPR proteins in the disease. All of these studies used almost 
GGGGCC-free expression constructs in various length (50 to 175 repeats) to focus 
on DPR protein effects.  However, in most studies only poly-GA showed an 
aggregation pattern and p62 co-aggregation comparable to what is seen in patients 
(May et al., 2014; Wen et al., 2014; Yamakawa et al., 2015; Zhang et al., 2014) . 
The arginine-rich proteins poly-GR and poly-PR formed aggregates in the nucleus 
and especially in the nucleolus that could not be detected in patients so far (Schludi 
et al., 2015). This, however, may be due to a rapid death of neurons harboring these 
toxic aggregates during the course of disease (Cooper-Knock et al., 2015). 
Therefore, it will be very hard to confirm or dismiss this hypothesis completely.  
Poly-GP and poly-PA did not show any aggregation and were mostly distributed 
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throughout the whole cell (May et al., 2014; Wen et al., 2014; Yamakawa et al., 
2015; Zhang et al., 2014). 
Overall, studies favor poly-GA, poly-PR and poly-GR as the potential toxic species. 
Whereas Zhang, Yamakawa and May mainly saw toxicity of poly-GA in primary 
neurons and N2a cells, Mizielinska, Wen and Kwon saw strong toxicity for poly -PR 
and poly-GR in Drosophila, primary neurons and other cell lines. However, 
Mizielinska and colleagues also saw mild toxicity for poly-GA in their study. The 
differences seen in toxicity of these three proteins in the individual studies may 
occur due to different construct design or cell culture models and further studies are 
needed to elucidate the individual contribution to neurodegeneration seen in 
patients. A detailed description of all available models on DPR protein toxicity can 
be found in Table 2 under 5.6 C9orf72 disease models. The toxic mechanisms of 
poly-PR and poly-GR are presumably due to unspecific RNA and DNA binding that 
may lead to transcriptional dysregulation and nucleolar stress  (Kwon et al., 2014; 
Mizielinska et al., 2014; Wen et al., 2014) . Yet, nucleolar stress could not be 
detected in patient samples (Schludi et al., 2015) and thus questions if these 
mechanisms are important in patients or rather a cell culture artefact . In contrast, 
poly-GA may interfere with cellular proteostasis by inhibiting protein degra dation 
(Yamakawa et al., 2015; Zhang et al., 2014) . Toxicity might also be mediated 
through sequestering important cellular proteins such as Unc119. Unfortunately, 
Unc119 function outside sensory neurons is so far poorly understood. Interestingly, 
I could identify p62, an important protein in the  ubiquitin-proteasome system and 
autophagy, as the top-hit in our mass spectrometry approach. Apart from p62 , 
proteins of the ubiquitin-proteasome system were found to be enriched, however, 
proteasome activity was not impaired in the assays I used. Interestingly, two other 
groups could show in their cell culture systems , show that poly-GA may indeed 
decrease proteasome activity and cause toxicity (Yamakawa et al., 2015; Zhang et 
al., 2014). This difference may occur due to different expression levels of the  poly-
GA protein, different cellular systems or the assays used to assess UPS activity. In 
contrast to the UPS activity assay I used that assessed the activity of chymotrypsin -
like, trypsin-like and caspase-like activity with specific substrates, Yamakawa and 
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colleagues used an Ub-G76V-GFP reporter to assess UPS activity and Zhang and 
colleagues focused only on chymotrypsin-like activity. Overall, the ubiquitin -
proteasome system is clearly linked to repeat expansion disorders such as C9orf72  
FTD/ALS or Huntington’s disease (Schipper-Krom et al., 2012), however, the 
contribution to neurodegeneration is still under discussion. Additionally, autophagy 
might also be altered, as p62 is an important protein in the autophagy mechanisms 
(Pankiv et al., 2007). 
After the discovery of DPR proteins in C9orf72 FTD/ALS, a debate arose whether 
these proteins contribute to disease progression or are just innocent bystanders. 
Studies by Mackenzie, Schludi and others showed that none of the DPR proteins 
correlate with neurodegeneration in the patient brain questioning their involvement 
(Davidson et al., 2014; Gomez-Deza et al., 2015; Mackenzie et al., 2013; Schludi et 
al., 2015). The only correlations found in patients so far , are all related to the 
repeat length of the hexanucleotide repeat expansion. Repeat length inversely 
correlates with disease duration in FTD patients and age of onset (Benussi et al., 
2013; Suh et al., 2015; van Blitterswijk et al., 2013) . 
Interestingly, living C9orf72 patients also show atrophy of the thalamus and 
cerebellum, areas with high DPR load, in imaging approaches, a phenotype that is 
highly associated with C9orf72 FTD/ALS (Mahoney et al., 2012b). furthermore 
cerebellar atrophy can be detected in an MRI 10 years before the expected onset , 
further strengthening the specific involvement of the cerebellum in C9orf72 
FTD/ALS (Rohrer et al., 2015b). 
Overall, multiple potential explanations exist, how DPR proteins contribute to 
ALS/FTD without showing a spatial correlation to neurodegeneration. For example, 
formation of cytosolic aggregates might be a protective mechanism and soluble 
species are the cause of neuronal loss. Additionally, a combination of DPR proteins 
and/or RNA toxicity might be responsible for neurodegeneration in the patients and 
therefore focusing on a specific DPR aggregate type might not yield a correlation.  
The recent publication of an AAV-mouse model by Chew and colleagues could 
show that a combination of DPR proteins and repeat RNA is toxic in this model.  
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Taken together, there is a lot of evidence from cellular and animal models for a 
crucial role of DPR proteins in C9orf72 FTD/ALS.  
5.3. Poly-GA interactome and its disease relevance 
To understand the underlying mechanism of poly-GA toxicity, it is important to 
identify its interacting partners. Interactomics have yielded interesting insights into 
aggregate toxicity mechanisms of other neurodegenerative diseases by identifying 
sequestered proteins that allow conclusions on cellular pathways involved and 
additionally have helped to discover new modulators of toxicity (Hipp et al., 2014; 
Olzscha et al., 2011; Ripaud et al., 2014) .  
Using a quantitative proteomics approach, I discovered several interacting proteins 
upon GA149-GFP transduction of primary cortical neurons.  
P62, the main component of DPR inclusions was identified as the top hit in this 
experiment and thus, also validated the experimental approach and the feasibility of 
mass spectrometry analysis in analyzing aggregate interactomics. Apart from p62 
and the ubiquitin-proteasome system mentioned above, the screen yielded some 
other interesting interacting partners  such as Unc119, a cargo adapter of 
myristoylated proteins, the cytosolic chaperone Bag6 or Hsd17b4, an important 
enzyme in the peroxisomal fatty acid beta-oxidation (Binici and Koch, 2014; 
Constantine et al., 2012; Möller et al., 1999). Co-aggregation of many interaction 
partners, found in the mass spectrometry analysis, could be also validated in 
immunofluorescence. I focused on Unc119, because it had been linked to 
neuromuscular function in C. elegans  previously (see below). Additional 
experiments are needed to elucidate if Bag6 and Hsd17b4 can also be found in 
patient aggregates and how their  loss of function through sequestration might 
contribute to neurotoxicity. Interestingly, Bag6 is an important modulator of 
autophagy and loss of Bag6 leads to inhibition of au tophagy, which would fit to the 
increase in p62 seen in poly-GA expressing cells and patients (Sebti et al., 2014). 
Additionally, it is also known that Bag6 is involved in the degradation  of 
mislocalized proteins, explaining why binding to poly-GA is occurring (Hessa et 
al., 2011).  
Discussion 
 
 
136 
 
Hsd17b4, also known as Mfp2, is a peroxisomal matrix protein in the 
mitochondrium. Strikingly, Mfp2 knockout mice show a neurodegenerative 
phenotype characterized through motor deficits such as poor balance and 
coordination, ataxia and cerebellar atrophy (Verheijden et al., 2014).  
In conclusion, the mass spectrometry results validated important key findings of 
C9orf72 FTD/ALS such as p62 co-aggregation and accumulation of the ubiquitin -
proteasome system. Additionally, it yielded an important and novel poly-GA 
interaction partner Unc119 that is potentially relevant for the pathogenesis . 
Furthermore, the other validated co-aggregation proteins, Bag6 and Hsd17b4 may 
provide further insights into poly-GA induced toxicity in patients. 
5.4. The role of Unc119 in neurodegeneration 
Up to this time, the novel poly-GA interacting protein Unc119, a cargo adapter of 
myristoylated proteins, has mainly been investigated in C. elegans and the 
mammalian retina. In my thesis, I discovered that it also has a function in cortical 
neurons, as knockdown lead to loss of dendrite complexity and toxicity in these 
neurons. Importantly, Unc119 knockout in C. elegans almost completely paralyzes 
the worms and disturbs axonal development and maintenance (Knobel et al., 2001; 
Maduro and Pilgrim, 1995; Maduro et al., 2000) . As Unc119 is sequestered into 
poly-GA aggregates in C9orf72 FTD/ALS, Unc119 loss of function may have an 
important role in underlying disease mechanisms. 
Unfortunately, not much is known about Unc119 function in mammals outside the 
retina. As a trafficking factor for myristoylated proteins it specifically binds 
myristate residues through a hydrophobic pocket composed of β-sheets (Constantine 
et al., 2012). Most intriguingly, the binding motif to Transducin α, a photoreceptor 
protein in the retina, has been mapped to the myristoylated N-terminal GAGASA 
sequence which strongly supports the interaction data with poly-GA (Zhang et al., 
2011). Apart from Transducin α, the only other known cargos in the nervous system 
are Gα proteins in the C. elegans olfactory system (Constantine et al., 2012). 
Unfortunately, none of those can directly explain the underlying disease 
mechanisms of C9orf72 FTD/ALS. Therefore it will be important to investigate how 
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Unc119 sequestration affects neuronal function in C9orf72 patients. It is possible, 
that poly-GA enters and clogs the hydrophobic cavity of Unc119 and thus , inhibits 
transport of so far unidentified myristoylated Unc119 cargos in cortical neurons. 
This may contribute to neurotoxicity observed upon Unc119 knockdown or poly -GA 
expression. Interestingly, an Unc119 nonsense mutation was found in a patient with 
cone rod dystrophy and Unc119 knockout, as well as truncation mutations, cause 
retinal degeneration in mice (Ishiba et al., 2007; Kobayashi et al., 2000; Mori et al., 
2006; Zhang et al., 2011). Thus, fitting perfectly to the observed toxicity upon 
Unc119 knockdown in cortical and hippocampal neurons.  Strikingly, Unc119 
overexpression partially rescues poly-GA toxicity in primary neurons, while 
Unc119 knockdown does not further increase poly-GA toxicity. Together, this 
indicates that Unc119 sequestration is a major contributor to poly-GA toxicity in 
C9orf72 FTD/ALS.  
5.5. The relationship between TDP-43 and DPR proteins 
A very important feature of C9orf72 FTD/ALS is accumulation of another protein, 
TDP-43, whose abundance correlates with neurodegeneration and disease 
progression, whereas DPR pathology does not (Mackenzie et al., 2013; Schludi et 
al., 2015). TDP-43 rarely co-aggregates with DPR proteins and the link between 
C9orf72 repeat expansion and TDP-43 pathology is not known so far. GGGGCC 
repeat expressing fly models and loss of function models in zebrafish failed to 
recapitulate TDP-43 pathology (Lee et al., 2013; Xu et al., 2013) seen in patients. 
Importantly, my poly-GA neuronal cell culture expression model induces 
cytoplasmic TDP-43 mislocalization into small aggregates suggesting a direct link 
between DPR and TDP-43 pathology. These small aggregates are already insoluble 
as they cannot enter the 4 % stacking gel and are retained  at the top of the gel. 
Thus, suggesting that they may be a precursor of p-TDP-43 inclusions seen in 
patients. However, I could not detect any p-TDP-43 in the neuronal expression 
system. Overall, these findings are  in contrast to the poor correlation of DPR and p-
TDP-43 inclusions in patient brains. Still, there is evidence that DPR inclusions 
occur earlier than TDP-43 pathology and may serve as a trigger. In patients for 
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example, p-TDP-43 occasionally surrounds a DPR core, but never vice versa  
(Mackenzie et al., 2013; Mori et al., 2013c). Additionally, there are patients that 
show FTD/ALS like symptoms and abundant DPR pathology, but lack TDP-43 
pathology (Proudfoot et al., 2014). This strongly suggests that  DPR pathology 
precedes TDP-43 pathology and may cause initial symptoms. This would be 
comparable to Alzheimer’s disease, where A pathology occurs 10-15 years earlier 
than Tau pathology in a distinct regional distribution (Musiek and Holtzman, 2015; 
Perrin et al., 2009). Apart from my initial experiments , there is also evidence for a 
connection from another group, showing that RNA and DPR expression triggers 
pronounced TDP-43 pathology in an AAV mouse model (Chew et al., 2015). 
However, they also did not identify the underlying mechanisms. There are several 
possibilities how these aggregates may occur. First, poly-GA aggregates may induce 
stress response in the cell leading to the formation of  stress granules and the 
recruitment of TDP-43 into those stress granules as can be seen after oxidative 
stress in primary neurons (Colombrita et al., 2009). Second, poly-GA may interfere 
with the proteasome and/or autophagy and dysfunction of these important cellular 
processes may causes TDP-43 mislocalization. This is in line with a conditional 
knockout mouse of the proteasome subunit Rpt3 showing mislocalization of TDP -43 
(Tashiro et al., 2012). Third, TDP-43 is a DNA/RNA binding protein which shuttles 
between cytosol and nucleus although its main function lies in the nucleus , poly-GA 
may interfere with this shuttling process and , for example, inhibit importin-
dependent transport into the nucleus and thus may keep TDP-43 in the cytosol 
(Ayala et al., 2008; Dormann and Haass, 2011; Miyamoto et al., 2004) . 
In general, multiple explanations for the discrepancy between TDP pathology 
occurring in model systems or in the patient are conceivable. These explanations 
need to be addressed in future studies, particularly in animal models. First, end -
stage pathology may not accurately depict the early steps of pathogenesis. Second, 
DPR proteins may trigger TDP-43 aggregation through non-cell autonomous effects, 
similar to spreading and seeding of a-syn and tau pathology (Holmes and Diamond, 
2012). Third, soluble DPR species may be more toxic than the inclusions itself as it 
has been observed for poly-Q and Tau (Ferreira et al., 2007; Takahashi et al., 2008) . 
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Nevertheless, the data presented here provide the first link between C9orf72 repeat 
expansion and TDP-43 pathology, which undoubtedly plays an important  role in the 
pathogenesis of FTD/ALS.  
5.6. C9orf72 disease models 
Over the last few years, a large amount of studies has accumulated trying to 
decipher the underlying mechanisms of C9orf72  FTD/ALS. In vitro and in vivo  
models have been designed to mimic the patient situation and to investigate the 
disease causing mechanisms. All models with brief description of the key results are 
listed in table 2 with the disease mechanisms investigated and the obtained findings.  
Table 2: Summary of C9orf72 in vitro and in vivo models to investigate underlying disease mechanisms 
mechanism targeted model organism effect citation 
C9orf72 loss of 
function 
knockdown in N2a 
cells and primary 
cortical neurons 
defects in endocytosis 
and autophagy 
(Farg et al., 2014) 
C9orf72 loss of 
function 
knockdown in 
zebrafish  
axonopathy and 
motordysfunction 
(Ciura et al., 2013) 
C9orf72 loss of 
function 
knockout in C. elegans  motor neuron 
degeneration and 
motordysfunction 
(Therrien et al., 2013) 
C9orf72 loss of 
function 
conditional knockout 
mice 
only weight loss 
without 
neuropathological 
abnormalities 
(Koppers et al., 2015) 
repeat RNA toxic gain 
of function 
C9orf72 loss of 
function 
iPS cells from ALS 
patients differentiated 
into motor neurons 
no reduced C9orf72 
levels, knockdown 
showed no toxicity 
RNA foci and 
sequestration of RNA-
binding proteins 
hnRNPA1 and Pur α 
(Sareen et al., 2013) 
repeat RNA toxic gain 
of function 
human patient 
fibroblasts 
RNA foci (Lagier-Tourenne et 
al., 2013) 
repeat RNA toxic gain 
of function 
intronic repeat 
sequence in drosophila 
RNA foci and 
neurodegeneration 
(Xu et al., 2013) 
repeat RNA toxic gain 
of function 
intronic repeat 
sequence in zebrafish 
and neuronal cell lines 
RNA foci, 
sequestration of RNA-
binding proteins 
(RBPs) SF2, SC35 and 
hnRNPH and 
neurodegeneration 
(Lee et al., 2013) 
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DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
HEK293 cell and 
primary neurons 
p62-positive 
cytoplasmic poly-GA 
inclusions 
neurotoxicity for poly-
GA  
dendrite loss for poly-
GA and sequestration 
of Unc119 
mislocalization of 
TDP-43 (unpublished) 
(May et al., 2014) 
DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
HEK293 cell and 
primary neurons 
ubiquitin-positive 
poly-GA cytoplasmic 
inclusions; 
neurotoxicity for poly-
GA; 
dendrite loss for poly-
GA and ER stress 
(Zhang et al., 2014) 
DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
primary neurons 
p62-positive 
cytoplasmic poly-GA 
inclusions  
inhibition of UPS 
function by poly-GA 
and poly-GR 
neurotoxicity of poly-
GA and poly-GR 
(Yamakawa et al., 
2015) 
DPR protein toxic gain 
of function 
addition of short 
peptides n=20 to U2OS 
cells 
toxicity of poly-GR 
and poly-PR 
nucleolar localization  
(Kwon et al., 2014) 
DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
NSC-34 and HEK293 
cells 
toxicity of poly-GR 
and poly-PR 
no aggregation seen for 
all DPR proteins  
(Tao et al., 2015) 
DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
drosophila 
toxicity of poly-GR 
and poly-PR, mild 
toxicity for poly-GA 
(Mizielinska et al., 
2014) 
DPR protein toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats in 
drosophila, Hela cells 
and iPS cell derived 
human neurons 
toxicity of poly-GR 
and poly-PR in 
drosophila 
recruitment of poly-GR 
into poly-GA 
cytoplasmic inclusions 
in cell lines 
(Yang et al., 2015) 
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DPR protein and RNA 
toxic gain of function 
intronic repeat 
sequence in HEK293 
and SY5Y cells 
RNA foci, toxicity in 
cell models of 
antisense RNA and 
protein (poly-GP and 
poly-PR) 
(Zu et al., 2013) 
DPR protein and RNA 
toxic gain of function 
human iPS cells from 2 
FTD patients 
differentiated into 
neurons 
RNA foci, poly-GP 
expression, increased 
p62 levels and 
increased sensitivity to 
cellular stress through 
inhibition of autophagy 
(Almeida et al., 2013) 
DPR proteins and 
repeat RNA toxic gain 
of function 
human fibroblasts from 
3 C9orf72 patients 
differentiated into 
neurons  
RNA foci 
DPR expression (poly-
GP) 
(Su et al., 2014) 
DPR proteins and 
repeat RNA toxic gain 
of function 
expression of DPR 
proteins from synthetic 
genes lacking 
GGGGCC repeats and 
repeat RNA in 
drosophila, Nsc-34 
cells and primary 
neurons 
poly-PR nuclear 
aggregates are toxic, 
combination of RNA 
and protein has 
synergistic effect on 
toxicity 
(Wen et al., 2014) 
DPR protein and RNA 
toxic gain of function 
AAV mouse model for 
sense repeat and 
proteins 
RNA foci, p62-positive 
cytoplasmic inclusions, 
neurodegeneration, 
TDP-43 
mislocalization 
(Chew et al., 2015) 
all three mechanisms human iPS cells from 
patients differentiated 
into neurons 
C9orf72 
downregulation, RNA 
foci, sequestration of 
RBP ADARB2, diffuse 
poly-GP expression 
and high sensitivity to 
glutamate-induced 
excitotoxicity 
(Donnelly et al., 2013) 
 
So far, few reports focused on C9orf72 loss of function. Although initially some 
results from C. elegans and zebrafish showed motor deficits and motor neuron 
degeneration (Ciura et al., 2013; Therrien et al., 2013)  thus, pointed to a role of 
C9orf72  loss of function in the disease, results in mice showing no obvious 
phenotype even after long periods of time (Koppers et al., 2015) question this 
involvement. Therefore, further work is needed to elucidate the exact contribution. 
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In contrast, a lot of evidence is accumulating for the toxic gain of function 
hypothesis for both RNA and protein toxicity. Patient -derived pluripotent stem cells 
(iPS cells) differentiated into motor neurons could recapitulate RNA foci and 
sequestration of RNA-binding proteins. In addition, transcriptomic analyses showed 
a similar gene regulation pattern as in C9orf72 patients (Donnelly et al., 2013; 
Sareen et al., 2013; Stepto et al., 2014; Zu et al., 2013) . However, neurotoxicity in 
these models needs to be further confirmed and results from iPS cells are highly 
variable at the moment. Additionally, several important features seen in patients 
such as TDP-43 mislocalization and aggregation as  well as p62-positive inclusions 
are missing in these models. As already mentioned above, DPR protein 
overexpression models and specifically poly-GA based models recapitulate several 
important features seen in patients such as p62-positive cytoplasmic inclusions, 
TDP-43 mislocalization (unpublished) and most importantly, neurodegeneration. 
Thus, models combining DPR protein and RNA expression such as the AAV mouse 
model by Chew and colleagues may have the biggest potential in  reproducing 
important key features of C9orf72 patients. However, in the future also mice 
expressing specific DPR proteins or only high levels of repeat RNA without DPR 
expression (intermitting stop codons) will be necessary to determine the relative 
role of these entities in C9orf72 ALS/FTD.  
5.7. Implications for FTD/ALS 
The C9orf72 hexanucleotide repeat expansion is the first autosomal dominant 
mutation that equally often causes ALS and FTD, which tightened the connection 
between these diseases even further .  
My work and the work of several other groups have demonstrated that DPR proteins 
may play an important role in C9orf72 FTD/ALS. Most notably, DPR proteins can 
cause toxicity in different cellular models by several mechanisms  (Chew et al.,  
2015; Mizielinska et al., 2014; Wen et al., 2014; Yamakawa et al., 2015; Yang et 
al., 2015; Zhang et al., 2014). If and how these mechanisms are connected and if 
one or the other is more important in the patient needs further investigations. It is 
also possible that a combination of several DPR species and sense and antisense 
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repeat RNA causes the massive neuronal loss seen in patients  (Yang et al., 2015). 
Furthermore, it is still unclear if aggregates, soluble or intermediate DPR protein 
species are responsible for the neuronal loss. Since the distri bution of DPR 
aggregates of neither species strongly correlates with neurodegeneration (Schludi et 
al., 2015), toxicity may not be caused by the prominent cytosolic aggregates. 
However, additional studies are needed for a reliable conclusion. Nonetheless, the 
discovery of the hexanucleotide repeat expansion leading to toxic RNA transcripts 
and protein aggregates may offer a highly specific treatment option for patients  
(including gene therapy), because the repeat stretch does not occur in a healthy 
individual and has no physiological function. Thus, a repeat directed therapy may 
have little side effects.  
5.8. Summary and future perspectives 
Taken together, I established a cell culture model to investigate the role of DPR 
proteins in C9orf72 FTD/ALS. This model reproduces important features seen in 
patients such as cytosolic p62-positive poly-GA inclusions. Poly-GA causes 
neurotoxicity and dendritic loss in primary neuronal culture. Additionally, I was 
able to identify the novel DPR co-aggregating protein Unc119 in vitro  that is 
partially sequestered in DPR aggregates in patients and may have an important role 
in poly-GA toxicity. Furthermore, I provided first evidence for a link between DPR 
and TDP-43 pathology in vitro. Thus, DPR proteins likely have an important 
function in C9orf72  FTD/ALS. 
 
Nonetheless, several questions remain that need further investigation:  
1. As Unc119 is a cargo adapter for myristoylated proteins the loss of function 
may influence the localization and function of several myristoylated target  
proteins. Thus, identifying the neuronal Unc119 cargos will be a crucial step 
to uncover underlying disease mechanisms.  
2. Another important question is how TDP-43 aggregate formation is connected 
to DPR pathology. As I could show, poly-GA leads to partial re-localization 
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of TDP-43. Since TDP-43 pathology is a common factor in most forms of 
FTD/ALS, there may be a common mechanism by which TDP-43 becomes 
mislocalized in genetic and sporadic cases. For example, deficits in nuclear 
transport may cause cytoplasmic TDP-43 accumulation. A second hypothesis 
could be dysfunctional autophagy as induction of autophagy enhances TDP-
43 turnover in an ALS mouse model (Barmada et al., 2014) and several 
ALS/FTD associated genes are known to be related to autophagy suggesting a 
general disease relevant mechanism (Ching and Weihl, 2013; Shen et al., 
2015). 
3. Transgenic animal models are crucial  for further mechanistic studies and 
preclinical tests. So far, the only published mouse model for C9orf72 gain of 
function mechanisms relies on AAV injection and although it does 
recapitulate important disease features, genetic mouse models to dissect the 
role of DPR and RNA-based mechanisms will be very important tools in the 
future. 
4. More studies are needed to dissect the contribution of DPR protein, RNA 
toxicity and haploinsufficiency. Do all three mechanisms contribute to the 
disease equally or is the gain of toxic RNA and/or protein function the main 
mechanism? Thus, cell culture models overexpressing repeat RNA and DPR 
proteins at the same time are needed to understand the individual 
contributions of both, sense and antisense RNA as well as all five different 
DPR proteins.  
5. In the end the most important question is  how to transform the knowledge 
acquired in cell culture and animal experiments into a valid therapeutic 
strategy to improve the life of patients. Based on the toxic -gain of function 
hypothesis, there is already a very interesting approach using antisense 
oligonucleotides (ASOs) that bind to mRNA or pre-mRNA and lead to their 
silencing or degradation. This approach would prevent both RNA and protein 
toxicity mechanisms. There are already ASO therapies in clinical trials for 
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other diseases (Fernandes et al., 2013) and a group of researchers lead by C. 
Lagier-Tourenne and D. Cleveland is already testing the potential in C9orf72 
FTD/ALS (Lagier-Tourenne et al., 2013). 
In the end, combining the data from animal models, cell culture and patients will 
help to decipher the specific role of DPR proteins  and the other proposed disease 
mechanisms, RNA-mediated toxicity and  C9orf72  loss function. Taking into 
account the progress that has been made over the past two years  alone, there is a 
unique potential to find a feasible therapy for these severe neurodegenerative 
diseases in the near future. 
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